Regulation of ribonucleotide reductase analyzed by simultaneous measurement of the four enzyme activities by Mathews, Christopher K. et al.
AN ABSTRACT OF THE THESIS OF
 
Stephen P. Hendricks for the degree of Doctor of Philosophy in Biochemistry and 
Biophysics presented on March 12. 1998. 
Title: Regulation of Ribonucleotide Reductase Analyzed by Simultaneous Measurement 
of the Four Enzyme Activities. 
Abstract approved: 
Christopher K. Mathews 
The first committed step in DNA biosynthesis occurs by direct reduction of 
ribonucleotides. This reduction is catalyzed by ribonucleotide reductase (RNR), an 
enzyme which uses a unique radical mechanism to facilitate the transformation. All four 
DNA precursors are synthesized by a single enzyme. Therefore, an intricate pattern of 
regulation has evolved to insure that RNR generates the proper quantity of each 
deoxyribonucleotide. It is this regulation, and conditions that influence this regulation, 
that are the central focal points of this dissertation. 
The studies described in this thesis have been aided by the development of a novel 
RNR assay. Unlike the traditional assay, this new procedure permits the simultaneous 
monitoring of all four RNR activities. This four-substrate assay was used to investigate 
whether the four enzyme activities of RNR were differentially sensitive to inhibition by the 
radical scavenger, hydroxyurea. The assay results, along with the results of a technique 
that measured enzyme inhibition as a function of radical decay, suggest that all activities of 
Redacted for PrivacyRNR are equally inhibited by hydroxyurea. Instead of differential inhibition, it appears 
that the activity level of RNR determines the relative sensitivity to hydroxyurea. 
The effects of nucleotide effectors and substrates on the relative turnover rates of the 
vaccinia virus and T4 phage RNR were also investigated by use of the four-substrate 
assay. When physiological concentrations of the allosteric effectors and substrates were 
added to the reaction mixtures, both enzyme forms produced dNDPs in ratios that 
approximate the nucleotide composition of their respective genomes.  Non-physiological 
nucleotide concentrations generated significantly different product profiles, indicating that 
RNR has evolved to function within a defined nucleotide environment.  Interestingly, the 
substrate component of the nucleotide environment proved to be as important as the 
allosteric effectors in modulating the reaction rates. Although the allosteric effects of 
nucleoside triphosphates have been known for some time, little attention has been given to 
the potential role that substrates play in the regulation of RNR. The results from my 
research suggest that the regulation of RNR in vivo results from a complex interplay 
between the enzyme and its substrates, products, and allosteric effectors. © Copyright by Stephen P. Hendricks
 
March 12, 1998
 
All Rights Reserved
 Regulation of Ribonucleotide Reductase Analyzed by Simultaneous Measurement 
of the Four Enzyme Activities
 
by
 
Stephen P. Hendricks
 
A THESIS
 
submitted to
 
Oregon State University
 
in partial fulfillment of 
the requirements for the 
degree of 
Doctor of Philosophy 
Completed March 12, 1998
 
Commencement June, 1998
 Doctor of Philosophy thesis of Stephen P. Hendricks presented on March 12, 1998 
APPROVED: 
Major Professor, representing Biochemistry and Biophysics 
Chair of Department of Biochemistry and Biophysics 
Dean of Graduate School 
I understand that my thesis will become part of the permanent collection of Oregon State 
University libraries. My signature below authorizes release of my thesis to any reader 
upon request. 
Stephen P. Hendricks, Author 
Redacted for Privacy
Redacted for Privacy
Redacted for Privacy
Redacted for PrivacyAcknowledgements 
I would like to thank my advisor, Dr. Christopher K. Mathews, for giving me the 
opportunity to work on such an exciting project. He has been a good friend and mentor. 
I would also like to thank my committee members, Drs. Pui Shing Ho, Victor L. Hsu, 
William H. Gerwick, and Russel H. Meints for the time and effort that they spent on my 
thesis. Special thanks go to Drs. Gary F. Merrill, Kevin Ahern, and Indira Rajagopal 
for their support, advice, and friendship during my time at Oregon State University. 
Of course, none of this would have been possible had it not been for my parents, 
Thomas P. and Maria M. Hendricks. I thank them with all my heart. I also want to 
acknowledge my brothers, Thomas P. and Mark P. Hendricks, for the support that they 
have given me through the years. Finally, I wish to thank Cynthia S. Du Puy for 
encouraging me to go back to school and supporting me throughout the process. Table of Contents
 
1. The Structure and Function of Ribonucleotide Reductase 
Introduction
 
Protein  R2
 
Protein  R1
 
References
 
2. Inactivation of Vaccinia Virus Ribonucleotide Reductase by 
Hydroxyurea 
Summary
 
Introduction
 
Materials and Methods
 
Results
 
Discussion
 
References
 
3. Regulation of T4 Phage Aerobic Ribonucleotide Reductase: 
Simultaneous Assay of the Four Activities 
Summary

Introduction
 
Materials and Methods
 
Results
 
Discussion
 
References
 
4. Allosteric Regulation of the Ribonucleoside Diphosphate Reductase 
from Vaccinia Virus 
Summary

Introduction
 
Materials and Methods
 
Results
 
Discussion
 
References
 
p 
2 
17 
34 
51 
57 
58 
62 
64 
78 
95 
98 
99 
100 
102 
109 
112 
114 
115 
115 
118 
133 
147 149 
Table of Contents (Continued) 
page 
Concluding Remarks 
Bibliography
 
Appendices
 
Appendix I
 
Appendix II
 
Appendix III
 
Appendix IV 
Appendix V 
153 
160 
RNR Four-Substrate Assay Procedure  161 
Preparation of 7-phosphate linked dATP-sepharose  163 
Procedure for dNDP & dNTP analysis of 
165 whole cell extracts 
Measurement of Escherichia coli RNR Activity 
by use of the Four-Substrate Assay: Application of 
the Method to the Measurement of Nucleoside 
Diphosphate Kinase Activity and Inhibition of ADP 
Reduction by 5'-adenylylimidodiphosphate  168 
Ribonucleotide Reductase Four-Substrate Assay 
Method Validation  173 List of Figures
 
Page Figure
 
4
 Overview of DNA precursor (dNTP) biosynthesis
 
2  The proposed reaction mechanism of RNR  16
 
3  Three-dimensional structure of E. coli R2  21
 
4  Electronic absorption spectrum of E. coli R2  25
 
5  Structure of the tyrosyl radical and binuclear iron-oxo center  28
 
6  Mechanism of the formation of the iron center and tyrosyl radical of R2  32
 
1
 
7  The organization of the W barrel of E. coli R1  36
 
8  The three-dimensional structure of E. coli R1  38
 
9  The electron transfer pathway from E. coli RNR  43
 
65 2.1	  Purification of the vaccinia R2 subunit 
2.2	  Purification summary gel of vaccinia R1  66
 
2.3	  Light absortion spectra of R2 from three different species  68
 
2.4	  Hydroxyurea-mediated decay of the vaccinia R2 tyrosyl radical
 
and iron-oxo chromophores  70
 
2.5	  Hydroxyurea-mediated radical decays of R2 in different states  71
 
2.6	  The tyrosyl radical is more sensitve to hydroxyurea during 
72 substrate  turnover 
2.7	  HPLC chomatograms showing the results of vaccinia RNR

assays ± HU  74
 
2.8	  Overview of dexoxyribonucleotide metabolism  83
 
2.9	  dNMP/deoxyribonucleoside substrate cycle  87
 
3.1	  Anion-exchange HPLC separation of dNDPs and dNTPs  102
 
3.2	  HPLC analysis of a mixture of deoxyribo- and ribonucleotides
 
before and after boronate column chromatography  103
 
3.3	  Linearity of CDP reduction with respect to enzyme concentration  104
 List of Figures (Continued) 
Page Figure 
3.4	  HPLC analysis of product formation followed over time  105
 
106
 3.5	  Relative rates of formation of deoxyribonucleoside diphosphates 
108 3.6	  dTTP inhibition of CDP reduction 
4.1	  ATP activation of the vaccinia RNR measured using the 
119 four-substrate  assay 
4.2	  Allosteric regulation of vaccinia virus ribonucleotide reductase
 
by individual dNTPs  120
 
4.3  Inhibition of the vaccinia RNR by dATP	  122
 
4.4	  Comparison of the four activities of the vaccinia RNR assayed 
126 under different allosteric environments 
4.5	  HPLC results from assays containing different volumes of a

bioproportional rNDP mix  129
 
4.6  Substrate inhibition of rADP reduction	  130
 
4.7  Substrate inhibition of rADP and rGDP reduction	  131
 
4.8  Results from an assay of a vaccinia Rl/mouse R2 chimera	  132
 
A4.1 Analysis of the E. coli RNR activity as analyzed by the
 
four-substrate  assay  169
 
A4.2 Activation of the E. coli RNR by AMP-PNP  171
 
A5.1 HPLC chromatogram of the deoxyribonucleotide authentic standards  174
 
A5.2 HPLC analysis of nucleotide mixture 1 prior to boronate
 
chromatography  176
 
A5.3 HPLC analysis of nucleotide mixture 1 following boronate
 
chromatography  177
 
A5.4 HPLC analysis of nucleotide mixture 2 prior to boronate
 
chromatography  179
 
A5.5 HPLC analysis of nucleotide mixture 2 following boronate
 
chromatography  180
 
A5.6 HPLC chromatogram showing partial resolution of ADP and dADP  181
 List of Tables
 
E Table 
Regulation of the activities of Class Ia RNR	  8 1 
2.1	  Effects of hydroxyurea on the activities of the vaccinia RNR when 
allosterically activated by ATP  76 
2.2	  Effects of hydroxyurea on the activities of the vaccinia RNR when 
allosterically activated by ATP + a single dNTP effector  76 
2.3	  Effects of hydroxyurea on the activities of the vaccinia RNR when 
allosterically activated by ATP, dTTP, dATP, and dGTP  77 
3.1	  Relative rates of product formation by the T4 RNR  107 
4.1	  Allosteric regulation of the vaccinia RNR by individual dNTPs  121 
4.2	  Ribonucleoside diphosphate concentrations in vaccinia-infected 
124 B SC40  cells 
4.3	  Relative rates of product formation by the vaccinia RNR under 
different allosteric environments  127 Regulation of Ribonucleotide Reductase Analyzed  by
 
Simultaneous Measurement of the Four Enzyme  Activities
 
Chapter 1
 
The Structure and Function of Ribonucleotide  Reductase
 
Stephen P. Hendricks 2 
Introduction
 
With the exception of the RNA-containing viruses, the genetic material ofall organisms 
on Earth is DNA. In the 1950s, Arthur Kornberg accurately predicted that, like other 
biosynthetic processes, DNA synthesis was driven energetically by the polymerization of 
activated substrates. These substrates were determined to be in the form of 2'-deoxyribo­
nucleoside 5'-triphosphates (dNTPs). Kornberg's laboratory later purified the enzyme 
responsible for the polymerization of DNA and made the observation that all four dNTPs 
were required in the process (Lehman et al., 1958). 
Since the time that the general properties of the enzymatic synthesis of DNA were first 
described, much has been learned about the process. One important aspect of DNA 
synthesis is the amazing fidelity with which the template is replicated, and much is now 
known about the factors that affect this fidelity. Indeed, for DNA to serve as an effective 
medium for encoding the genetic instructions of the cell, a nearly perfect copy must be 
produced every time cell division occurs. The error frequency for DNA replication is on 
the order of 10-6 to 10-10 per nucleotide replicated depending on the organism (Drake, 
1991). Much of the fidelity of DNA synthesis can be attributed to the enzymes which 
catalyze the polymerization of dNTPs. However, other factors also contribute to the 
replication accuracy of the cell. One such factor is proper maintenance of the supply of 
substrates to the replication enzyme. Not only are all four dNTPs required for the reaction 
to proceed, as Kornberg and coworkers demonstrated, we now know that the fidelity of 
DNA replication is highly dependent on the relative amounts of these precursors (Kunz et 
al., 1994). 
Many enzymes contribute to the synthesis of dNTPs, and a large portion of these are 
regulated in a way which assures that the synthesis rates of all four nucleotides reflect the 
quantities required by the polymerase. The first step in the de novo synthesis of dNTPs is 3 
catalyzed by one of these highly regulated enzymesribonucleotide reductase (RNR)and 
it is this enzyme which is the focus of this thesis. 
In 1958, Peter Reichard observed that the conversion of ribose to deoxyribose occurred 
at the nucleotide level (Reichard, 1958). Later work determined that the deoxyribo­
nucleotides that were used in the production of DNA were produced by the direct reduction 
of ribonucleoside 5'-diphosphates (rNDPs). Eventually it was determined that a single 
enzyme, RNR, was ultimately responsible for the de novo synthesis of all four of the 
deoxyribonucleotides needed for DNA replication. 
Figure 1 provides a general overview of the pathways for the de novo biosynthesis of 
the dNTPs in eukaryotes and many prokaryotes. Three of the four dNTPs, 2'-deoxy­
cytidine 5--triphosphate (dCTP), 2'-deoxyadenosine 5'-triphosphate (dATP), and 2'­
deoxyguanosine 5'-triphosphate (dGTP), are produced exactly as determined by Reichard, 
by reduction of the corresponding ribonucleoside diphosphates. In the first step shown in 
Figure 1, RNR produces the 2'-deoxyribonucleoside 5'- diphosphates (dNDPs) by 
reducing the 2'-carbon of the rNDP substrate. The dNDPs are subsequently 
phosphorylated to the triphosphate level by the enzyme nucleoside diphosphate kinase 
(NDPK). 
The production of thymidine 5'-triphosphate (dTTP) is slightly more complicated and 
proceeds through two distinct pathways. The primary source of d rIP comes from the 
deamination of 2'-deoxycytidine 5'-monophosphate (dCMP) produced by the 
dephosphorylation of deoxycytidine diphosphate (dCDP). Deamination of dCMP produces 
2'-deoxyuridine 5'-monophosphate (dUMP), which is the substrate for thymidylate 
synthase (TS). In a reaction which utilizes N5,N10- methylene tetrahydrofolate as the 
source of the one-carbon unit, TS converts dUMP to thymidine 5'-monophosphate 
(dTMP). dTMP is then phosphorylated to the deoxyribonucleoside triphosphate by two 
distinct nucleotide kinases. The other pathway leading to d I IP goes through 2'­
deoxyuridine 5--diphosphate (dUDP) produced by the RNR-catalyzed reduction of uridine 4 
5'-diphosphate (rUDP). As a result of reactions which culminate in the net loss of one 
phosphate, dUDP is converted to dUMP. The dUMP produced by this pathway is further 
metabolized to dTTP in the same manner that the dUMP produced from dCMP deamination 
is metabolized. 
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Figure 1 Overview of DNA precursor (dNTP) biosynthesis. The enzymes 
pertinent to this introduction are RNR, ribonucleotide reductase; NDPK, nucleoside 
diphosphate kinase; and TS, thymidylate synthase. 
A concept fundamental to the understanding of the role of RNR in dNTP biosynthesis 
is that the same protein produces all four deoxyribonucleotide products. Furthermore, the 
products of RNR are used exclusively for the production of dNTPsthe building blocks 
for DNA synthesis. Therefore, Nature has evolved a highly sophisticated pattern of 
regulation to control the reactions catalyzed by RNR. To insure that a proper balance of the 
four products is maintained, the substrate specificity of RNR is allosterically regulated. 
Maintaining a proper ratio of the products of RNR may be required to insure that all four of 
the dNTPs are efficiently supplied to DNA polymerase, at the time at which they are 
needed. In light of the evidence that indicates that dNTP pool imbalances can lead to 5 
mutagenesis (Kunz et al., 1994), the maintenance of the proper RNR product ratio may be 
of critical importance to the long-term survival of a species. In many forms of RNR, the 
overall activity of the enzyme is controlled as well. This may be accomplished 
allosterically, as in the case of substrate specificity, or may be mediated through synthesis 
or degradation of the protein itself. The control of overall RNR activity has probably 
evolved to limit the production of dNTPs to times when DNA is being replicated or 
repaired. 
Interestingly, in most mammalian cell lines and tissues that have been studied, the 
dNTP pools are not truly balanced. Instead, the relative amounts of the four common 
dNTPs are asymmetric in a way that doesn't necessarily reflect the genomic base 
composition. In general, the DNA precursor pools are heavily biased toward dTTP and 
dATP. The dGTP pool is normally underrepresented and in many cases may represent as 
little as 5-10% of the total dNTPs (Mathews and Ji, 1992; Traut, 1994). 
The cause of this natural imbalance, however, remains elusive. One obvious 
possibility for the source of this dNTP pool asymmetry is RNR. Because RNR reduces all 
four rNDPs in a highly regulated way, it is possible that this intricate control is responsible 
for the pool asymmetries. It is also possible that this asymmetry is created by the dNTP 
biosynthetic machinery downstream of RNR or by the salvage pathway enzymes. In order 
to address the possible role of RNR in the generation of the dNTP pool asymmetry in 
mammalian cells, I have performed experiments which will be described in later chapters. 
RNR is categorized into three primary classes. These classes vary considerably at all 
four levels of protein structure, require different cofactors for activity, and have substrate 
requirements which differ based on the level of phosphorylation (i.e. rNDPs vs. rNTPs). 
Despite these differences, a unique radical-dependent mechanism of catalysis appears to be 
common to all three classes of RNR. In addition, the pattern of allosteric regulation, 
specifically in terms of substrate specificity, is almost identical for all the classes. The 
similar catalytic mechanism and allosteric behavior have led to the belief that all of the 6 
classes of RNR have evolved from a common ancestor through divergent evolution. 
According to this belief, although the proteins have changed significantly in sequence, 
mutations which disrupt the regulation of substrate specificity or change the mode of 
catalysis have been selected against (Reichard, 1993). 
Class I 
The enzymes that form the Class I RNRs are characterized by having a stable tyrosyl 
radical and an oxygen-linked diferric iron center. The Class I RNRs are found in all higher 
organisms and most prokaryotes examined to date. The enzyme from Escherichia coli is 
the best characterized of all RNRs and serves as the prototype for the Class I enzymes. 
The active holoenzyme structure of the prototypical Class I enzyme is an a202 
heterotetramer (Brown and Reichard, 1969a). According to convention (Fontecave et aL, 
1992), the larger a2 homodimer is usually referred to as R1 and the smaller [32 homodimer 
is called R2. This nomenclature will be used from this point on when referring to the 
individual homodimers. 
The smaller 132 homodimer, R2, contains the stable tyrosyl radical, which is required 
for enzyme activity, and a closely associated dinuclear iron center. Each protomer of the 
R2 from E. coli is composed of 375 amino acids. The total molecular weight of the dimer 
is 86.7 kDa. Each functional dimer contains 4 atoms of iron (2 per protomer) and one 
tyrosyl radical, on average. The iron center participates together with molecular oxygen to 
generate and stabilize the tyrosyl radical (Fontecave et al., 1992; Bollinger et al.,  1991). 
This class of RNR is functional only under aerobic conditions due to the requirement for 
molecular oxygen. The presumed function of R2 is to provide the tyrosyl radical, which is 
used by the larger homodimer R1, for activation of the ribose ring of the substrate in the 
first step of ribonucleotide reduction. 7 
Each E. coli R1 protomer consists of 762 amino acids (85.7 l(Da) and contains three 
nucleotide binding sites. One of these sites functions as the active site where the 
ribonucleotide substrates bind (von Dobe ln and Reichard, 1976), which in the case of the 
Class I enzymes, are ribonucleoside diphosphates (rCDP, rUDP, rADP, and rGDP). The 
other two nucleotide binding sites are allosteric sites, both of which function through the 
binding of ATP or certain dNTPs (Brown and Reichard, 1969b). One of these allosteric 
sites controls the overall activity of the enzyme and is therefore called the activity site. 
Binding of ATP to this allosteric site results in general activation of the enzyme. Binding 
of dATP to this site results in general inhibition of the enzyme. Traditionally, this site was 
called the low-affinity site, since dATP was found to bind with less affinity to this site than 
the second allosteric site.  The second allosteric site, historically referred to as the high-
affinity site, controls the relative substrate specificity of the enzyme and is now generally 
referred to as the specificity site. Binding of nucleoside triphosphates to this site modifies 
the substrate preference of the enzyme. For example, when dGTP binds to the specificity 
site, the protein undergoes a conformational change to a conformer which prefers rADP as 
substrate. Binding of dTTP to the specificty site results in an enzyme conformer with a 
preference for rGDP reduction. Binding of either ATP or dATP to this site on R1 
stimulates reduction of rCDP and rUDP. Interestingly, dCTP does not act as an allosteric 
effector of RNR. 
Table 1 summarizes the general allosteric behavior for most forms of the Class I RNRs. 
Some evidence, both published (Chang and Cheng, 1979; Cory et al., 1985) and presented 
in Chapter 4 of this thesis, suggests that allosteric regulation may also occur by the binding 
of nucleoside diphosphates to one, or both, of these nucleotide binding sites. In addition to 
the stable tyrosyl radical of R2, the activity of the holoenzyme requires the participation of 
five highly conserved, cysteine residues found in the R1 subunit. These cysteines have 
been shown to act in concert to carry out the reduction process (Thelander, 1974; Mao et 8 
al., 1992a-c). Ribonucleotide reduction requires an input of two electrons per catalytic 
event. This supply of electrons, or reducing equivalents, is shuttled to the active site via 
Table 1 Regulation of the activities of Class la RNR 
Nucleotide  Nucleotide  Activates  Inhibits 
bound in  bound in  reduction  reduction 
activity site  specificity site  of  of 
ATP  dATP or ATP  rUDP and rCDP 
dGTP  rADP  rUDP and rCDP ATP 
ATP  dTTP  rGDP  rUDP and rCDP 
dATP  any one  all 
four of these five cysteine residues, which function in redox-active pairs. In the E. coli 
R1 protein, one of these cysteine pairs is located in the active site (C225 and C462) and 
participates directly in the reduction of substrate. The other pair (C754 and C759), 
functions to shuttle the reducing equivalents from the exogenous electron source to the 
cysteine pair at the active site. The fifth required cysteine, C439, has been implicated as the 
protein residue which forms a transient cysteinyl radical responsible for initiating catalysis 
(see mechanism below). 
In vivo, the ultimate source of electrons used to reduce ribonucleotides comes from 
NADPH. During substrate turnover the active site cysteines, C225 and C462, are oxidized 
to a disulfide. To enter another round of catalysis, this newly formed cystine must be 
reduced. The reducing equivalents for this reduction are shuttled via the second pair of 
cysteines, C754 and C759, to the active site cystine. Cysteine residues 754 and 759 
receive their electrons from either thioredoxin or glutaredoxin, two small multifunctional 
redox-active proteins, which interact with RNR (Holmgren, 1988). Thioredoxin is 9 
reduced by thioredoxin reductase, which in turn gets its electrons directly from NADPH. 
Glutaredoxin gets its electrons by oxidizing a pair of glutathiones. The oxidized 
glutathione is reduced by glutathione reductase which uses NADPH as its electron source. 
In vitro, the electrons can be supplied by small dithiol-containing molecules like 
dithiothreitol (DTT). These dithiol compounds, however, are not as effective in serving as 
reductants of RNR as the protein-based redox systems and therefore the rate of substrate 
turnover is generally much lower when they are used as the source of reducing equivalents. 
For example, when DTT is used, the rate of rCDP reduction by the T4 bacteriophage RNR 
is 10% of the rate obtained when glutaredoxin is present (Berglund, 1972). By comparing 
the enzyme activities of a series of cysteine-to-serine site-directed mutants, it was 
determined that DTT can bypass the redox-active cysteine pair, C754 and C759, and 
directly reduce the cysteines at the active site after each catalytic event (Mao et al., 1992). 
Glutaredoxin, on the other hand, was unable to supply electrons to C754S and C759S 
mutants, corroborating that glutaredoxin functions as an electron source for RNR through 
interactions with the C754 and C759 cysteine pair. 
Recently, the Class I enzymes have been further divided into two subclasses, Class Ia 
and lb (Jordan et al., 1996). The new subdivision, Class Ib, is made up of proteins with 
properties very similar to the Class Ia enzymes and are found in enterobacteriaceae 
including E. coli. Like the Class Ia proteins, the Class Ib enzymes reduce ribonucleoside 
diphosphates, the functional holoenzyme form is an oc2132 heterotetramer, and the 02 dimer 
contains an iron center and tyrosyl radical (Jordan et al., 1994). However, the Class lb 
enzymes do differ significantly from the Class Ia enzymes in theirregulation of overall 
activity: they are not inhibited by dATP (Eliasson et aL, 1996). In the case of the Class lb 
enzyme from Salmonella typhimurium, dATP stimulates reduction of rCDP at 
concentrations which completely inhibit the Class Ia enzymes. The regulation of substrate 
specificity, on the other hand, is essentially the same as for the Class Ia RNRs. 10 
All known Class lb R1 proteins lack the last 50 to 60 N-terminal amino acids which are 
present in the Class Ia R1 proteins. Since the Class lb enzymes also functionally lack the 
dATP inhibition, it has been proposed that the activity site may be located in this region of 
the Class Ia proteins. In support of this proposal is the finding that the Class Ib protein 
from S. typhimurium contains two, rather than three, nucleotide binding sites (Eliasson et 
al., 1996). One of these sites is the active site where the rNDP substrates bind, and the 
other is the Class lb equivalent of the specificity site which controls substrate specificity 
through the binding of dNTP effectors. The function of this subclass of RNR in 
organisms like E. coli which also encode and express the Class Ia enzyme is unknown. 
Class II 
The Class II enzymes are found only in microorganisms and are classified as the 
adenosylcobalamin-dependent RNRs. The first example of an RNR which required 
adenosylcobalamin for activity was found in the microorganism Lactobacillus leichmannii 
(Blakley and Barker, 1964). The enzyme is a functional monomer with a molecular weight 
(89.1 kDa) similar to the R1 protomer of E. coli. Unlike Class I, in this class of RNRs 
both the substrates and allosteric modulators are nucleoside triphosphates. The enzyme 
from L. leichmannii converts rNTPs to the corresponding dNTPs and is therefore referred 
to as a ribonucleoside triphosphate reductase. Like the Class I enzymes, the substrate 
specificity is regulated by the binding of dNTPs to a single allosteric site on the protein. 
Thus, two of the products of the Class II RNRs (dATP and dGTP) are immediately able to 
act as allosteric effectors for regulation of this enzyme. This class of RNR is not inhibited 
by dATP as the Class Ia enzymes are. Presumably, the lack of dATP-mediated inhibition 
is due to the absence of a second allosteric nucleotide binding site analogous to the activity 
site of the Class Ia enzymes (Chen et al., 1977). 11 
The function of adenosyl cobalamin in the Class II RNRs is similar to the function of 
the R2 homodimer in the Class I enzymesit is the coenzyme which generates the radical 
required for enzyme activity (Hamilton et al., 1972). Like the Class I enzymes, five 
cysteine residues have been implicated by site-directed mutagenesis to be involved in 
ribonucleotide reduction by the L. leichmannii RNR. Four of these cysteines shuttle 
electrons to the substrate and are maintained in the reduced state by transthiolation with 
either thioredoxin or glutaredoxin (Booker et al., 1994). The last cysteine of this group has 
recently been demonstrated to be the residue which forms a transient cysteinyl radical, a 
critical component of the catalytically-active enzyme (Licht et al., 1992). 
Class III 
The generation of the tyrosyl radical and iron-oxo center in the Class I RNRs is oxygen 
dependent and therefore Class I enzymes are inactive under conditions of anaerobiosis. 
The Class II enzymes utilize S-adenosylcobalamin as the cofactor for radical generation and 
are active under either aerobic or anaerobic conditions. The Class Ill RNRs are found in 
organisms which can grow anaerobically but do not encode the S-adenosylcobalamin­
dependent enzyme. Organisms which contain this form of RNR include E. coli 
(Fontecave et al., 1989) and the bacteriophage T4 (Young et al., 1994). 
Similar to the a2132 structure of the Class I enzymes, the Class III RNRs consist of two 
closely associated homodimeric proteins. The smaller homodimer, like the R2 dimer of the 
Class I enzymes, functions to generate the radical required for enzyme activity. However, 
this protein contains an iron-sulfur cluster instead of the oxygen-linked dinuclear iron 
center in R2 (011agnier et al., 1996). Activation of this enzyme occurs by an S-adenosyl­
methionine-dependent reaction resulting in formation of an oxygen-sensitive glycine radical 
in the large homodimer. In E. coli this radical forms at G1y681 and in T4 bacteriophage the 
glycine radical occurs at position 580 (Young et al., 1996). 12 
Like the Class II enzymes, the Class III anaerobic RNRs require rNTPs as  substrates. 
The allosteric regulation of this class is very similar to the Class Ia enzymes in that there are 
two allosteric sites which control specificity and overall activity. However, these sites 
cannot be distinguished as being either an activity site or a specificity site. Instead, one 
site is referred to as the purine site and one the pyrimidine site. Binding of ATP to the 
pyrimidine site activates the enzyme for reduction of rCTP and rUTP. At the purine site, 
dGTP binding stimulates ATP reduction and dTTP binding stimulates GTP reduction. 
Binding of dATP to either site results in inhibition (Eliasson et al., 1994). Although the 
function of these two allosteric sites differs from the function of the allosteric sites in the 
Class Ia enzymes, the final outcome is the same: dATP is a general inhibitor of enzyme 
activity, and the other allosteric effectors act to specifically enhance the reduction of a 
particular substrate. 
Unlike the other two classes, the source of reducing equivalents for the Class III 
enzyme from E. coli is not the cysteine thiols of glutaredoxin or thioredoxin. Instead, the 
E. coli Class Ill RNR uses formate as the source of electrons for the reduction of 
ribonucleotides (Mulliez et al., 1995). Thus, E. coli uses completely different enzymes and 
electron donors for the production of dNTPs during anaerobic and aerobic growth. This 
strengthens the speculation that the Class B1 enzymes arose early during evolution and may 
be the closest ancestor of the first enzyme used to reduce ribonucleotides. 
As mentioned previously, it has been proposed that the three classes of RNR have 
evolved through divergent evolution. According to this proposal, the common ancestor of 
the modem RNRs most closely resembled the Class III enzyme (Reichard, 1993). This 
proposal is based on the two assumptions. The first assumption is that ribonucleotide 
reduction requires a radical mechanism, and the second is that DNA evolved prior to 
photosynthesis and the advent of an oxygen-rich atmosphere. The Class III enzymes 
require adenosylmethionine and anaerobic conditions to generate the protein radical. The 
lack of oxygen in the primordial environment makes this mechanism of radical formation a 13 
logical choice for the original RNR. Such a radical-generating mechanism is also used by 
pyruvate formate lyase, a key enzyme in anaerobic energy metabolism. It is speculated that 
the glycyl radical mechanism may have arisen early during evolution as a means for 
anaerobic energy metabolism and the first RNR may have exploited it for the reduction of 
ribonucleotides. As the oxygen concentration in the atmosphere increased, the oxygen-
sensitive glycyl radical became inoperative. Therefore, new ways of generating a stable 
protein radical were required to compensate for the increasing oxygen. Thisrequirement 
led to major changes in protein structure and the evolution of the Class I and II enzymes. 
Probably the best evidence in support of divergent evolution is the similar allosteric 
behavior common to all three types of RNR. Specifically, the allostery which determines 
substrate specificity is highly conserved within all classes of RNR: ATP (and dATP when 
it is not inhibitory) always activates reduction of the pyrimidine substrates, dGTP activates 
reduction of the adenosine nucleotide substrates, and dTTP activates reduction of the 
guanosine nucleotide substrates. 
Reaction mechanism of ribonucleotide reduction 
All three classes of ribonucleotide reductase catalyze the reduction of ribonucleotides 
using a unique radical mechanisma fact which is consistent with the idea that the different 
forms of RNR have arisen through divergent evolution. In the early 1970s a mechanism 
for ribonucleotide reduction by the E. coli enzyme was proposed (Thelander, 1974). In 
this paper, it was demonstrated that the E. coli RNR holoenzyme catalyzed the reduction of 
ribonucleotides at the expense of sulfhydryls in R1. Using the in vivo reducing system, 
thioredoxin and thioredoxin reductase, the kinetics of RNR catalysis was shown to be 
consistent with a ping-pong mechanism. This meant that the enzyme alternated between 
two forms, a reduced catalytically active form and an oxidized inactive form. The 
mechanism which was proposed to explain these data is as follows. In the reduction of 14
 
ribonucleotides, thioredoxin binds to R1, reduces the catalytically active sulfhydryls, and 
then dissociates from the enzyme. A ribonucleotide substrate then binds to  the enzyme and 
is reduced at the expense of R1 oxidation in a radical-dependent reaction. Finally, the 
newly formed deoxyribonucleotide is released from the enzyme, completing the cycle. 
To probe the mechanism further, nucleoside analogs were prepared in which the 2' or 
3' position was substituted with various substituents. Two separate laboratories reported 
that incubation of RNR with one such analogue, [3' -3H] 2'- chloro- 2'deoxyuridine 5'­
diphosphate (C1dUDP), resulted in production of uracil, chloride ion, inorganic 
pyrophosphate, and substoichiometric quantities of 3H20, and was accompanied by 
inactivation of the enzyme (Thelander et al., 1976; Stubbe and Kozarich, 1980). Then, in 
one of the biggest breakthroughs in the understanding of ribonucleotide reduction, it was 
found that incubation of substrate containing tritium at the 3'-position, specifically  [3'-311] 
rUDP, resulted in a 1° isotope effect on conversion to dUDP (Stubbe and Ackles, 1980). 
A similar isotope effect was also observed when [3"-3H]rADP was converted to its 
deoxyribonucleotide product. The observation of an isotope effect during the reduction of 
these 3'-tritiated substrates indicates that the 3'-CH bond is cleaved in the reaction and that 
the breaking of this bond is the rate-determining step. But how does the cleavage of the 3"­
CH facilitate the reduction of the 2'-carbon? To answer this question, a working 
hypothesis was developed which included the results obtained using the chloro analogue 
(C1dUDP) and the observed isotope effect. In this hypothesis, cleavage of the 2--COH 
bond of the substrate is activated by prior cleavage of the 3--CH bond. In the case of 
C1dUDP, interaction with RNR results in cleavage of the 3'-hydrogen and conversion of 
the analogue to 3'-keto-2'-deoxyuridine diphosphate. The hydrogens of this intermediate 
which are alpha to the 3'-keto functionality are substantially more acidic than a normal CH 
bond. Dissociation of one of these protons results in a rearrangement of electrons within 
the molecule culminating in the elimination of uracil and inorganic pyrophosphate and 
generation of a highly reactive species which was later identified as 2-methylene-3­15 
furanone. Nucleophilic attack on this reactive furanone by a side chain in the active site 
would then result in inactivation of the protein. This hypothesis also explained the small 
amount of H2O released when this analogue was incubated with the enzyme.  Apparently, 3 
the tritium which is abstracted from the 3'-carbon of the analogue in the intial step of the 
reaction is occasionally accompanied by loss of label to solvent. 
In these experiments with C1dUDP, the amount of tritium which appeared in H2O was 
lowonly about 1%. Mechanistically, it is important to determine the location of the 
remainder of the label. To determine the fate of the 3'-hydrogen which was abstracted by 
RNR, rUDP deuterated at the 3'-carbon was prepared and the location of the deuterium 
before and after the reaction was determined by NMR (Stubbe et al., 1983a). Analysis of 
the NMR spectra of the deuterated substrate and purified product indicated that the 
deuterium at the 3' position of substrate was returned to the 3' position in the product. 
Evidence for 3'-CH bond cleavage and reformation was also found in the Class II enzyme 
from L. leichmannii using similar analogues and techniques (Stubbe et al., 1983b). Since 
that time, similar results have been seen using the enzyme from herpes simplex virus (Ator 
et al., 1986). 
Based on the available evidence, the reaction mechanism is thought to be initiated by 
formation of an oxidized cysteinyl radical at the active site (C439 in E. coli R1 and C408 in 
the L. leichmannii Class II enzyme). Just recently, direct evidence for the existence of this 
transient cysteinyl radical in the Class II enzyme from L leichmannii was demonstrated 
using electron paramagnetic resonance (Licht et al., 1996). This transient radical species is 
thought to be generated through hydrogen abstraction of the cysteinyl thiol by another 
radical in the enzyme. In E. coli, this is presumably the stable tyrosyl radical of R2. In the 
current model of the Class I holoenzyme complex from E. coli, the distance between the 
tyrosyl radical in R2 and the active site in R1 is 35-40 A (Sjoberg, 1994). The abstraction 
event is proposed to occur via long range electron transfer through a highly conserved 
hydrogen bonded network which spans the distance from the R2 radical to the active site 16 
(Nordlund et al., 1993). Once formed, this transient thiolyl radical abstracts the hydrogen 
from the 3' position of the ribose ring creating a protein-bound substrate radical (see Figure 
2). The 2'-hydroxyl of the ribose is then protonated by an active site residue. Protonation 
of the 2'-hydroxyl is followed by loss of H2O from this position resulting in the formation 
of a radical cation intermediate. A hydride equivalent (a proton + two electrons) is then 
transferred to the 2' position of the radical cation intermediate from active site cysteines. In 
the E. coli enzyme, the hydride is thought to be donated by the C225/C462 pair of redox­
active cysteines. The reaction is completed by the return of the originally abstracted 
hydrogen back to the 3' position of the substrate resulting in regeneration of the protein 
radical. 
OH  OH H 
Figure 2 The proposed reaction mechanism of RNR (adapted from Stubbe, 1990). 
The rest of this chapter, like my studies, will focus on the Class I RNRs. 17
 
Protein R2 
Primary sequence homology 
Although the E. coli R2 has served as a model for the protein in eukaryotes, there are a 
number of significant differences between the proteins from E. coli and higher organisms. 
The amino acid sequences of the E. coli and mouse proteins are only 25% identical 
(Thelander & Graslund, 1994). Sequence alignments of the Class I small subunits 
comprise three groups of homology, each consisting of at least 50% identical amino acids. 
The eukaryotic proteins, including the protein from vaccinia virus, make up one group, the 
herpes virus proteins the second, and the E.coli and bacteriophage T4 proteins form the 
third. The R2 sequences among the three groups are highly divergent with only 16 
residues being conserved for all species. Among these conserved residues in the three 
groups are the tyrosine residue which forms the stable radical and the iron ligands. 
The eukaryotic R2 proteins form a highly homologous group of sequences to which the 
vaccinia and African swine fever viruses belong. As an example of the conservation within 
this group, the vaccinia virus amino acid sequence is 80% homologous to the mouse R2 
while the vaccinia and herpesvirus proteins are only 27% homologous (Slabaugh et al., 
1988). The greatest divergence in similarity among this group of R2 proteins is in the 
length of the amino terminus. The amino acid sequences from mammals and yeast average 
about 50 residues longer than the sequences from plants and viruses. These extra N-
terminal residues are thought not to be involved in enzyme activity since they are missing 
from the R2 sequences in many species. Furthermore, N-terminal truncation of the mouse 
R2 does not significantly affect the activity of the holoenzyme (Mann et al., 1991). 
Instead, the N-terminus may be involved in some aspect of R2 protein activity or turnover. 
Ser20 in the mouse R2 was recently shown to be phosphorylated in a cell-cycle-dependent 18 
manner by a cdc2-related protein kinase (Chan et al., 1993). The role of this kinase in cell 
cycle progression and the fact the the mouse R2 was phosphorylated by this enzyme during 
S-phase is consistent with the notion that phosphorylation may play a role in the cell cycle 
regulation of ribonucleotide reduction and therefore DNA synthesis. 
The C-terminus of R2 is involved in protein-protein interactions with the larger R1 
subunit and is essential for formation of the active holoenzyme. The sequence of the C-
terminus is highly species-specific and in many cases the formation of the holoenzyme, and 
therefore enzyme activity, can be inhibited by peptides with a sequence corresponding to 
the R2 C-terminus. The ribonucleotide reductase from E. coli can be inhibited by the 
addition of a 20-mer corresponding to the terminal twenty residues of the R2 sequence, and 
a truncated version of the R2 protein lacking the last thirty C-terminal residues is unable to 
bind R1 (Sjoberg et al., 1987). An interesting example of the importance of the interaction 
between the R2 carboxy terminus and the R1 protein was found when the R1 protein was 
prepared for crystallographic studies. In order to obtain X-ray quality crystals of the R1 
subunit, researchers found that a 20-mer with the same sequence as the R2 carboxy­
terminus was a required component of the mother liquor (see discussion on R1 structure). 
Furthermore, the peptide co-crystalized with the E. coli R1 at the site of the proposed R2 
interaction surface (Uhlin & Eklund, 1994). 
As in E. coli , the herpes simplex viral RNR proteins provide another example of the 
importance of the C-terminal region of R2 structure in the interaction between the R1 and 
R2 dimers, which is required for holoenzyme formation. A potent peptidomimetic inhibitor 
has been derived from the herpes R2 C-terminal sequence which shows promising in vivo 
efficacy against the herpes virus (Liuzzi et al., 1994). By competing with the herpes 
simplex R2 for binding to R1, this peptide can inhibit holoenzyme assembly and thus 
inhibit viral RNR activity. 
In the mouse protein, the last seven C-terminal residues of R2 have been shown to be 
essential for dimer-dimer interaction. Nuclear magnetic resonance (NMR) has been used to 19 
study the mobility and conformation of the C-terminus of the mouse R2 in the presence and 
absence of R1 (Lycksell et al., 1994). In the 1H NMR spectrum of mouse R2, a number 
of sharp proton resonances were observed with significantly narrower line widths than the 
majority of resonances in the spectrum. By the use of two-dimensional NMR techniques, 
these resonances were assigned to the carboxy-terminal residues of R2 by comparison with 
the cross-peak patterns of peptides of the same sequence as the R2 carboxy-terminus, and 
lack of those resonances in a C-terminal truncated version of R2. One interpretation of 
these data is that this segment of R2 is highly mobile and essentially unstructured in 
solution. Upon addition of the mouse R1 protein to the R2 solution, these sharp 
resonances become significantly broadened, suggesting that the mobility of this portion of 
R2 becomes severely restricted by the heterodimer interactions responsible for holoenzyme 
assembly. Presumably, the flexible C-terminal tail recognizes a particular surface on the 
large subunit, promoting holoenzyme formation and concomitant structuring of the R2 C-
terminus. It is suggested that this form of protein-protein recognition may fit into the 
model in which unstructured domains give rise to increased rates of specific 
macromolecular associations (Pontius, 1993). It has also been reported that the NMR 
spectrum of the small subunit of herpes simplex virus contains a number of resolved 
resonances corresponding to the C-terminus (La Plante et al., 1993). 
In Chapter 4 of this thesis I shall provide evidence indicating that similar R2 carboxy­
terminal sequences can allow for interspecies RNR activity, specifically in the case of the 
vaccinia virus and mouse proteins. 
Structure of the R2 protein 
The crystal structure of the small subunit from E. coli has been determined to 2.2 A 
resolution (Nordlund et al., 1990). The three-dimensional structure not only demonstrated 
what a beautiful job Nature has done in creating a protein environment which can produce, 20 
capture, and subsequently harbour a normally highly reactive and unstable free electron, it 
also provided new insight into the mechanics of the reaction mechanism. The generally 
accepted view prior to publication of the structure was that the tyrosyl radical directly 
abstracted the hydrogen from the substrate, activating the ribose ring for the subsequent 
steps in the reaction. From the crystal structure it was obvious that this tyrosyl radical 
could not directly abstract the hydrogen from the substrate since this particular tyrosine 
residue is buried deep in the protein, 10 A from the closest surface. Instead, it was 
postulated that electron transfer from the substrate to the stable tyrosyl radical occurs via a 
hydrogen-bonded array of highly conserved residues. These conserved residues, along 
with one of the irons in the iron center, provides a route for the electron to be transferred 
back and forth between the storage site and the active site where catalysis occurs. The 
proposed electron transport chain is described in greater detail in a later section. 
Helices make up about 70% of the R2 protein from E. coli. The protein has only one 
f3-sheet region, which forms an antiparallel hairpin turn. The main structural motif of the 
protein is a unique eight-helix bundle. The center of the bundle consists of a long 
hydrophobic helix which is surrounded by the other helices. The helices in the bundle are 
all relatively long, four of which comprising 30 residues or more. 
The functional dimer is formed by homologous interactions between three surface 
helices of each subunit around the molecular two-fold axis. The helices at the subunit-
subunit interface cross at an angle of approximately 140° to each other. The ellipsoidal 
shape of the individual subunits and the tilted interaction formed between them gives the 
molecule a heart shape. The tip at the bottom of the heart-shaped dimer is formed by a 
four-stranded sheet composed of the antiparallel 13- hairpins from both subunits. Figure 3 
shows the crystal structure of the R2 dimer from E. coli viewed from a position that 
emphasizes the heart-like shape of the protein. 
The top lobes of the R2 dimer are believed to make up the R1 interaction surface. As 
discussed, it is well established that the carboxy terminus of R2 is essential for holoenzyme 21
 
Figure 3 Three-dimensional structure of E. coil R2. The crystal structure of E. 
coli R2, shown above, was determined by Nordlund et al., 1990.  Indicated in the structure 
are the iron atoms (shown as red spheres) and the bridging oxygen atom (shown in 
yellow). Also highlighted in the structure is closely associated tyrosine side chain of Y122, 
which forms the stable phenoxy radical (shown in red). 22
 
assembly and enzyme activity. The structure of the C-terminus of R2 is not yet defined, 
since the last 32 residues of the protein are disordered and invisible in the crystal. 
However, the last resolvable C-terminal residue is located in the middle of the lobed region 
at the top of the R2 dimer. Thus, the carboxy terminus is located in a region consistent 
with the proposed R1-R2 interface. Characterization of the tertiary structure of the carboxy 
terminus of R2 may have to await the determination of the crystal structure of the RNR 
holoenzyme. 
Recently, the three dimensional structure of the mammalian small subunit from mouse 
was determined (Kauppi et al., 1996).  The overall tertiary structure of the mouse protein is 
similar to the prokaryotic form from E. coli, having as its main structural motif an eight 
helix bundle. Like the E. coli structure, the mouse R2 carboxy terminus is disordered and 
not visible in the electron density maps. Also missing from the mouse structure are the 
amino terminus residues which, as discussed earlier, are not required for enzyme activity 
but instead may play a role in protein-protein interactions with proteins other than R1 
(Mann et al., 1991). The dimer interface of the mouse R2 is formed primarily by 
hydrophobic interactions and the residues involved in these interactions are highly 
conserved among the eukaryotes. 
Although the overall structure is similar, there are several distinct differences between 
the mouse and E. coli R2 structures. The mouse R2 crystal structure totally lacks the (3­
strand motif seen in the E. coli protein. Thus, the tip structure seen in the E. coli protein is 
missing from the mouse protein giving it less of a heart-shaped appearance. 
Relevant to this thesis, one of the more significant structural differences between the 
eukaryotic and prokaryotic proteins is a narrow channel, about 10 A deep, in the mouse R2 
which leads from the surface of the protein to a region within the protein interior where the 
tyrosyl radical and iron-oxo center are located. The channel is about 15 A wide and lined 
primarily by hydrophobic amino acids. The E. coli R2 has a similar channel. However, in 
this latter case, the channel is about half the width of the channel in the mouse R2 and the 23
 
opening to the channel is blocked by the side chain of a tyrosine residue. The mouse and 
vaccinia virus, as well as most of the other eukaryotic proteins have a serine at this 
position, resulting in a larger channel opening and presumably a more accessible radical 
and iron center. The channel dimensions of these proteins are directly correlated with the 
relative ease at which radical scavenging drugs, like hydroxyurea, can inactivate the tyrosyl 
radical of these enzymes (Pasch et al., 1995). 
Based on the high sequence homology among the eukaryotic R2 proteins, the three-
dimensional structures of the other eukaryotic proteins, including the vaccinia virus R2, are 
expected to be very similar to the mouse protein. 
The tyrosyl radical 
The tyrosyl radical of the E. coli enzyme was the first example of a stable protein-
derived free radical to be reported. EPR was used to quantitate the amount of radical, and 
from this measurement, a correlation between the radical content and enzyme activity was 
made (Ehrenberg & Reichard, 1972). The amazing stability of this protein-derived radical, 
when compared to model organic radicals that had been described at that time (Land et al., 
1961), was quite surprising. In vitro, the E. coli tyrosyl radical is stable for more than a 
week at 4° C. Even at 25° C, the half-life of the radical is on the order of days (Atkin et al., 
1973). 
The surprising stability of the tyrosyl radical is no longer such an enigma since the 
three-dimensional structure of R2 was determined. From the structure it was obvious that 
the tyrosyl residue which harbours the radical is buried inside the protein and is therefore 
fairly inaccessible to solvent. The environment around the tyrosyl radical is primarily 
hydrophobic with no oxidizable residues within van der Waals contact of the radical 
(Nordlund et al., 1992). 24 
The stable radical is formed by a one-electron oxidation of the phenoxy ring of a 
specific tyrosine residue (Y122 in E. coli and Y177 in mouse) in a reaction between R2, 
iron and molecular oxygen (Atkin et al., 1973; Petersson et al., 1980; Bollinger et al., 
1991). Inactivation involves a gradual reduction of the phenoxy radical, presumably by 
solvent-derived reductants, resulting in formation of a normal tyrosine.  In the case of the 
E. coli enzyme, the intial reduction of the radical does not change the oxidation state of the 
iron-oxo center and the coordination of the iron atoms is probably also unchanged (Backes 
et al., 1989). This form of R2 is called metR2. 
The iron-oxo center of R2 
By the early 1970s, it was known that protein R2 was EPR-active.  The R2 EPR signal 
was assigned to an organic radical housed in the protein and was shown to be directly 
correlated with enzyme activity. In addition, this organically-derived free radical was 
dependent on the presence of iron in the protein (Ehrenberg and Reichard, 1972). 
However, at that time not much was known about the chemical nature of either the organic 
radical or the protein-bound iron. 
The initial characterization of the iron center was done using Mossbauer spectroscopy 
(Atkin et al., 1973). The Mossbauer spectrum of E. coli R2 contained four lines of 
approximately equal intensity. The spectrum was interpreted as arising from two pairs of 
split absorptions which were indicative of the presence of two nonequivalent iron sites.  As 
further evidence for this assignment, the Mossbauer spectrum of hemerythrin, a marine 
invertebrate oxygen-carrying protein containing a well-characterized binuclear iron center 
(Garbett et al., 1969), was compared with the spectrum from R2. The Mossbauer spectra 
of the two proteins strongly resembled each other both in the number of lines and the 
quadrupole splitting. To further explore the nature of the iron center as it related to the 
radical, E. coli R2 was stripped of iron and then regenerated in the presence of57Fe+2. 25 
Mossbauer and EPR spectroscopy of the 57Fe-containing R2 established that the iron nuclei 
were diamagnetic and therefore distinct from the paramagnetic species which gave rise to 
the EPR signal. Resonance Raman spectroscopy was later used to determine that the non­
protein ligand which bridges the two irons is an oxygen ion, specifically 02- (Sjoberg et 
al., 1982). 
The positions and molar extinction coefficients of the absorbance bands in the electronic 
spectra of hemerythrin and R2 are also very similar. Figure 4 shows the characteristic 
electronic absorption spectrum of E. coli R2. The specific peaks of interest in the spectrum 
are the relatively sharp peak at 410 nm, due primarily to the tyrosyl radical, and a broad 
band centered at 370 nm, arising mainly from the iron center. The band centered at -390 
nm is a composite absorption due primarily to the tyrosyl radical with some overlapping 
absorbance from the iron-oxo center. 
O
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Figure 4 Electronic absorption spectrum of E. coli R2. Spectrum was recorded 
on a Beckman DU-64 spectrophotometer. Protein concentration was -50 gM. The E. coli 
R2 was a gift from the laboratory of Britt-Marie Sjoberg. 26
 
The UV-vis absorption spectrum of oxyhemerythrin displays very similar iron 
absorption bands to the bands seen in the spectrum of E. coli R2. The only significant 
spectroscopic difference determined in this comparison was the lack of the sharp peak at 
410 nm and band at 390 nm in the spectrum of hemerythrin. This was not surprising since 
these absorbances had already been assigned to the protein-bound radical chromophore 
which we know today to be the tyrosyl radical. 
From these intial studies it was concluded that the iron in R2 was associated with, but 
not the source of, the paramagnetic entity. Instead, the paramagnetic species was assigned 
to a stable organic free radical (Ehrenberg and Reichard, 1972). Furthermore, it was 
known that destruction of the radical by treatment with NH2OH or hydroxyurea resulted in 
no change in the Mossbauer or iron-associated electronic spectra, indicating that the iron 
center remained intact even though the protein was inactivated by this treatment (Atkin et 
al., 1973; Ehrenberg and Reichard, 1972). What then is the function of the iron? 
The electronic spectrum of R2 was not affected by the addition of reducing agents used 
as electron sources (thioredoxin or dithiothreitol) during enzyme catalysis. This was 
interpreted as meaning that the iron in R2 was not participating as an electron carrier during 
the catalytic cycle (Atkin et al., 1973). Furthermore, other studies argued against a 
structural role for the iron. The apoprotein and native protein have identical electrophoretic 
and ultracentrifugal properties and both form 1:1 complexes with R1 (Thelander, 1973). 
Instead, based on the data available at that time, it was hypothesized that the function of 
the iron was to generate an organic radical from a protein-bound group concomitant with 
binding to the apoprotein. Once the iron was bound and the radical formed, the protein-
bound iron further functioned to stabilize the radical through a continued interaction (Atkin 
et al., 1973). In the crystal structure of the E. coli protein, the Tyr122 is 5.3 A from the 
closest iron and is located on an axis formed by the two iron atoms. Within this 
environment, the radical is expected to experience a significant magnetic field from the iron 
center and this interaction may be involved in stabilizing the radical. Studies of the 27 
temperature dependence of EPR relaxation and line shape have verified the presence of 
magnetic dipolar interactions between the iron center and free radical (Sahlin etal., 1987). 
Furthermore, when these interactions were compared in the mouse and E. coli R2 proteins, 
it was found that the effects were more pronounced for the mouse protein.  This indicates 
that the magnetic interaction between the iron center and radical in the mouse R2 is stronger 
than in the E. coli protein. 
According to this hypothesis, the iron-stabilized organic radical was the functional 
contribution of R2 to the active holoenzyme. A logical assumption that comes from this 
hypothesis is that the reduction of ribonucleotides may involve the participation of 
substrate- and/or protein-derived radical intermediates. This was not the first suggestion 
that transient radicals may be involved in the reduction of ribonucleotides. Just prior to the 
publishing of this hypothesis, the involvement of transient free radicals in the reduction of 
nucleoside triphosphates by the class II RNR from L. leichmannii had been proposed 
(Tamao and Blakley, 1973). This hypothesis remains valid today. 
Ever since the iron center was first reported (Brown et al., 1969b), the number of iron 
centers per R2 dimer has been disputed. Some data, reported prior to the publication of the 
crystal structure, suggested a single iron-oxo center formed at the dimer interface (Atkin et 
al., 1973; Sjoberg et al., 1987). Determination of the three-dimensional structure of R2 by 
X-ray crystallography put an end to this dispute, at least in the case of the protein from E. 
coli and mouse. The crystal structure of the E. coli R2 clearly shows that the dimer 
contains two equivalent iron centers. The location of these centers was confirmed by 
comparison with electron density maps of the iron-free, or apoR2, crystals. From the 
crystal structure it was determined that the iron atoms are ligated to four helices from the 
eight-helix bundle, two of which are located at the dimer interface. 
From the crystal structure of the E. coli R2, a detailed description of the iron center 
ligands and geometry was determined. This structure is shown in Figure 5. The iron 
ligands consist of three glutamic acids, two histidines, one aspartic acid, two water 28 
molecules, and the iron-linked oxygen atom. The ferric irons are bridged by two common 
ligands; the 02- forms one bridge between the iron nuclei, and the two carboxylate oxygens 
of Glul15 form the second bridge. Iron 1, as denoted in Figure 5, is further ligated to 
His118 and both carboxylate oxygens of Asp84. The sixth ligand to Iron 1 was interpreted 
from the electron density to be a water molecule. Iron 2 is ligated to two glutamic acids, 
G1u238 and G1u204, and to His241, as well as the two common ligands. As in the case of 
Iron 1, a water molecule occupies the sixth coordination of Iron 2. Because both 'y­
oxygens of Asp84 are ligated to Iron 1, the coordination around this iron atom has the 
characteristics of both trigonal bipyramidal and octahedral geometries. The second iron 
atom lacks a bidentate ligand and therefore has a more regular octahedral geometry. 
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Figure 5  Structure of the tyrosyl radical and dinuclear iron-oxo center. This 
figure shows the structure of the E. coli R2 metal center (adapted from Nordlund et al., 
1990) 
Sequence homologies, as discussed above, are relatively low among the R2 proteins 
from E. coli and mouse or vaccinia virus. Of the residues that are conserved within all 29 
species are the amino acids which serve as the ligands for the iron-oxo center.  Other 
conserved residues include the tyrosine which serves as the radical storage site, some 
hydrophobic residues in proximity to the radical site, and the network of amino acids which 
make up the putative electron transport chain. 
A major distinction between the eukaryotic and E. coli forms of R2 is in the stability of 
the iron center. The mouse R2, for instance, loses 50% of its iron after 30 minutes at 37°C 
(Mann et al., 1991), while the half-life of iron loss for the E. coli protein under similar 
conditions is on the order of several days (Atkin et al., 1973). 
The non-heme dinuclear iron center of R2 is found in at least two other classes of 
proteins and, as more metalloproteins are characterized, may prove to be a common 
structural motif. One of these classes which was mentioned earlier, the hemerythrins, 
functions as oxygen carrying proteins in certain marine invertebrates (Garbett et al., 1989). 
Methane monooxygenases, another class of proteins containing a non-heme dinuclear iron 
cluster, are enzymes found in methanotrophic bacteria that oxidize methane (Fox et al., 
1989). In each of these three groups of proteins, the iron center functions through its 
reactivity with molecular oxygen. The mode of reactivity, however, is different for each 
protein class. In the hemerythrins, the oxygen is bound by the iron center reversibly. In 
the methane monoxygenases, the protein-bound ferrous irons react with molecular oxygen 
to form an active enzyme which catalyzes the two-electron oxidation of methane and other 
small saturated hydrocarbons. Finally, in R2, the diferrous iron cluster activates molecular 
oxygen for the one-electron oxidation of a tyrosine residue. 30
 
Assembly of the tyrosyl radical and iron center in R2
 
The stoichiometry for the formation of the tyrosyl radical and iron-oxo center has been 
extensively studied both in the mouse (Ochiai et al., 1990) and the E. coli (Bollinger et al., 
1991) R2 proteins. Based on these studies, the stoichiometry is best described by the 
following reaction: 
Tyr + 2 Fe-F2 + 02 + e- + 2 H-F > 'Tyr + Fe+3-0-2-Fe-F3 + H2O 
This reaction, as written, is a four-electron reduction of molecular oxygen. Two  of the 
electrons come from the oxidation of two ferrous irons to two ferric irons. Oxidation of the 
tyrosine residue supplies another electron resulting in the formation of the tyrosyl radical. 
The source of the final electron is dependent on the experimental conditions. In the absence 
of other reductants, ferrous iron can provide the fourth electron. In this case, 3 moles of 
Fe
+2 are oxidized per mole of tyrosyl radical formed. Ifascorbate is added to the reaction, 
the last electron may ultimately come from this reductant. When ascorbate is present, the 
expected molar ratio of oxidized iron to tyrosyl radical should be 2 to 1. These theoretical 
values are in good agreement with the experimentally determined quantities for both the 
mouse and E. coli R2, suggesting that the formation of the iron center and tyrosyl radical is 
similar mechanistically in both cases. Formation of the tyrosyl radical in the mouse protein 
required 3.5 ± 0.5 moles of ferrous iron per mole radical, when iron was the sole 
reductant. When ascorbate was added, 2.6 ± 0.4 moles of iron were oxidized per mole of 
radical formed. For radical formation in the E. coli protein, the values were 3.2 ± 0.1 and 
2.5 ± 0.1 moles of iron required to produce one mole of radical in the absence and 
presence of ascorbate, respectively. 
In addition to the stoichiometry, a mechanism for the formation of the E. coli tyrosyl 
radical and iron-oxo center has been proposed (Bollinger et al., 1991). A detailed 31 
description of this reaction was made possible by the fact that the radical and iron center in 
the E. coli R2 can be removed and regenerated, and that the regeneration can be monitored 
by measuring the distinct spectroscopic signatures of the tyrosyl radical and iron-oxo 
center. Using stopped-flow absorption spectroscopy and rapid freeze-quench EPR to 
measure the kinetics of radical formation, two novel intermediates in the pathway leading to 
the active form of R2 were detected. The detection of these intermediates provided the 
necessary information required to deduce the mechanism. 
To decipher the mechanism, the radical regeneration reaction was performed under 
various iron concentrations and monitored with stopped-flow absorption spectroscopy. 
Although the absorption spectra of the iron center and tyrosyl radical overlap, the broad 
band of the iron cluster centered at 370 nm and the relatively sharp band of the tyrosyl 
radical at 410 nm allow the kinetics of the reaction to be determined. Close examination of 
the time-dependent absorption spectra of the reaction revealed two critical pieces of 
information which were used to deduce the mechanism. First, it was determined that 
production of the tyrosyl radical preceded formation of the final iron-oxo center. Second, 
in the early spectra, recorded at time points prior to formation of the active R2, was the 
presence of a transient chromophore which was spectroscopically distinct from the 
chromophore of the final diferric iron center. This new species was designated as 
intermediate (U). The rate constants of the formation and decay of intermediate (U) made it 
kinetically competent to be a precursor of the active R2. Furthermore, since the rate 
constant of decay for intermediate (U) was similar to the rate constant of formation for the 
tyrosyl radical, it was suggested that (U) may be directly responsible for production of the 
radical. Under conditions of excess ferrous iron or ascorbate, this intermediate was not 
observed, suggesting that excess reductant prevents the intermediate from accumulating to 
an extent observable by normal spectroscopic techniques. Figure 6 depicts the proposed 
mechanism for the formation of the active form of R2 from apoR2, ferrous iron, and 
molecular oxygen. 32 
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Figure 6 Mechanism of the formation of the iron center and tyrosyl radical 
of R2 (adapted from Bollinger et al., 1991) 
To further test whether intermediate (U) was responsible for the production of the 
tyrosyl radical, a mutant R2, in which Tyr122 was changed to a phenylalanine, was 
prepared. In this Y122F mutant, the radical-generating intermediate decayed at half the rate 
of the intermediate in the wildtype protein. Consistent with the role of (U) as the species 
which generates the tyrosyl radical, the increased half-life of the intermediate in the Y122F 
R2 mutant was presumably due to the fact that the phenyl ring of phenylalanine is harder to 
oxidize than the phenoxy ring of tyrosine. Concomitant with the decay of intermediate (U) 
in the Y122F mutant was the appearance of a new, short-lived, signal with a Xmax at 410 33
 
nm. The identity of this new signal was attributed to the formation of a tyrosyl radical 
formed at another location in the protein, although this was not demonstrated conclusively. 
The short-lived nature of this new radical species is probably due to reduction by a 
neighboring residue or by a solvent derived-reductant. 
The decay of intermediate (U) is kinetically consistent with the formation of a tyrosyl 
radical in both the wild-type and mutant proteins and this fact is used as evidence for the 
first step of the mechanism shown in Figure 6. Based on the similarity of the absorption 
spectra of sythetically prepared peroxodiferric organometallic compounds, the structure of 
the intermediate was proposed to be all-peroxodiferric species. Peroxo-compounds 
similar in structure to the p- peroxodiferric intermediate are generally good oxidizing agents. 
This fact makes the proposed intermediate chemically consistent with the type of species 
needed to oxidize the phenoxy ring of Tyr122. 
Intermediate (U) is not EPR active. However, EPR spectra of of the reaction mixture 
quenched at various times after the addition of iron revealed a new EPR signal, quite 
distinct from the tyrosyl radical spectrum, which was designated as intermediate (X). 
+2 When the reaction was carried out with 
57Fe , the new EPR signal was broadened 
significantly, indicating that intermediate (X) is due to an iron-coupled radical. Kinetic 
analysis of this new EPR signal showed that it was produced at approximately the same 
rate as the tyrosyl radical and decayed with a rate consistent with the formation of the final 
iron-oxo product. 
Based on the rapid freeze-quench EPR spectroscopy, stop-flow absorption 
spectroscopy, and the behavior of the Y122F mutant, a mechanism was proposed for the 
reconstitution of the radical under limiting iron conditions. In the mechanism, addition of 
Fe
+3 and 02 to apoR2 results in the rapid formation of the proposed p- peroxodiferric 
intermediate (U). Intermediate (U) undergoes a one-electron reduction by Y122, resulting 
in the formation of the tyrosyl radical and iron-coupled radical of unknown structure, 
intermediate (X). In the final step of the reaction, a slow one-electron reduction of 34 
intermediate (X) by ferrous iron or ascorbate results in formation of the final productthe 
active R2 protein. 
The results from these spectroscopic studies corroborate, as does the spatial proximity 
of the two species in the crystal structure, that the iron center participates directly in 
formation of the tyrosyl radical. We know today that the active form of R2 contains a p­
ox() bridged binuclear ferric iron center closely associated with the tyrosyl radical. In the 
crystal structure of the E. coli R2, the tyrosyl radical is 5.3 A from the iron-oxo center 
(Nordlund et al., 1990). The proximity of these two species is conducive for many kinds 
of interactions and may facilitate the generation and stabilization of the tyrosyl radical by the 
iron-oxo center. 
Protein R1 
Primary sequence 
Similar to the small subunit, the primary sequence of the large subunit from different 
phyla shows weak but significant sequence similarities distributed throughout the 
polypeptide. The amino acids which are conserved in essentially all R1 proteins are 
composed primarily of residues which contribute to the catalytic mechanism of RNR. 
These include the cysteine which is thought to form the cysteinyl radical, the redox-active 
cysteines which shuttle reducing equivalents to the active site, the residues which line the 
active site cavity, and the residues which make up the putative electron transport chain. 
The R1 amino acid sequences within the different phyla are significantly more conserved. 
For example, the amino acid sequences of the mouse and vaccinia virus R1 proteins are 
72.5% identical (Tengelsen et al., 1988). 35 
Structure of the R1 protein 
The crystal structure of the R1 protein from E. coli has been refined to an R-factor of 
21% at 2.5 A resolution (Uhlin & Eklund, 1994). Many of the structural features 
described in this work make it possible to describe the working mechanism of the Class I 
ribonucleotide reductases. In particular, the structure is supportive of the proposal that an 
electron transfer pathway, which connects the active site cysteinyl radical in R1 to the 
tyrosyl radical in R2, exists in the protein. 
The tertiary structure of the R1 subunit consists of three primary domains: a ten 
stranded a1r3-barrel of -480 residues, the a-helical N-terminal domain composed of -220 
residues, and a 70-residue small domain. 
The a113- barrel structure of the E. coli large subunit is composed of two halves.  Each 
half-barrel is composed of five parallel 13-strands connected in series by four a helices. As 
depicted in Figure 7, the 13-strands in the first half of the a/(3-barrel are labeled from PA to 
E, and the strands in the second half are labeled OF thru J. The a-helices are labeled aA 
through D and aF through H, for the first and second half-barrels, respectively. The two 
halves come together by the formation of antiparallel (3-sheets formed between the terminal 
strands, PA, F, E, and J, of each half-barrel. Thus, the hydrogen bonding between 
strands within each half-barrel is parallel while the bonding between the half-barrels is 
antiparallel. This gives the barrel a puesdo two-fold axis of symmetry. The number of 
hydrogen bonds between strands within each half-barrel ranges from three to six while the 
number of antiparallel hydrogen bonds formed between half-barrels is three at each 
junction. 
The 10-stranded a /13- barrel of R1 has a larger diameter and has the 1i- strands arranged 
differently from the more common a/1- barrel of triose phosphate isomerase (TIM barrel) 
which is composed of eight strands arranged in a highly symmetrical parallel fashion 
(Uhlin & Eklund, 1996). The wider barrel of R1 allows the insertion of a finger-like loop 36 
consisting of twenty residues. The finger is formed by a 0-hairpin loop which extends into 
the barrel from one end, reaching clear to the opposite end, and returning to the end where 
it originated. Active site residues are located at the tip of this twenty-residue loop, 
including Cys439. Much evidence suggests that this cysteine residue is the site of the 
protein radical which ultimately abstracts the 3'- hydrogen from the nucleotide diphosphate 
substrate. Two other cysteines, which are required for enzyme activity, are located on 
separate 0-strands of opposite half-barrels as indicated in Figure 7. These residues are 
Cys462, located on 13-strand F, and Cys225, located on 0-strand A. These cysteines have 
been shown to be the redox-active residues which ultimately reduce the ribose ring of the 
substrate (Mao et al., 1992a-c). 
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Figure 7 The organization of the a/0 barrel of E. coli Rl. The elements aA -aD 
and 13A-13E belong to the first half-barrel, and ocF-al and OF-07 to the second half-barrel. 
The two halves are connected by the center loop which contains, at the tip of the loop, the 
residue which forms the putative cysteinyl radical (C439). Also shown in this figure are 
the binding surfaces for the small and N-terminal domains, and the R2 C-terminal peptide. 37 
After each catalytic event, these cysteines are oxidized to a cystine residue which must be 
reduced prior to the next round of catalysis. Figure 8 shows the crystal structure of the E. 
coli R1 protomer solved by Uhlin and Eklund. Highlighted in the structure are the three 
active site cysteines. In the crystal used to solve the R1 structure, Cys225 and Cys462 are 
found in the oxidized disulfide form. Although these cysteines are separated by over two 
hundred residues, it is clear from the three-dimensional structure of R1 that they are 
positioned such that the side chains extend into the active site, poised to contribute reducing 
equivalents to the substrate. Also highlighted in the structure is the side chain of Cys439, 
the active site cysteine which is thought to form the transient radical responsible for 
abstraction of the 3'-hydrogen of the substrate. 
The hydrogen-bonded network between the internal loop and the barrel strands is quite 
extensive, especially at the top where the active site is found. Seven residues from 
different strands make side chain contacts with the loop close to the n- hairpin region. 
These interactions form a concave surface, presumably forming the substrate binding 
pocket. The position of the internal loop within the barrel is further stabilized by infra -loop 
hydrogen bonds as well as hydrogen bonds formed between the loop and highly conserved 
barrel strand residues, Glu441 and Cys225. Several water molecules also mediate the 
contacts between the loop and the inside of the barrel. The extensive hydrogen bonding 
between the loop and the barrel may be necessary to stabilize the loop and correctly position 
the active site cysteines. The correct spatial positioning of Cys439 may be critical for 
radical formation and substrate hydrogen abstraction (Sjoberg, 1994). 
The contact area between the two half-barrels, on the side of the barrel where 13J and E 
form an antiparallel pleated sheet, is partially covered by the small domain. Also found at 
this region of the barrel is the putative binding site for the C-terminus of the R2 protein. 
Assignment of this region to the R2 binding site is based on the fact that electron density 
corresponding to the R2 C-terminal peptide, a required component of the crystallization 
mixture (Uhlin et al., 1993), bound to this region in the crystal. 38 
Figure 8 Three-dimensional structure of E. coli Rl. The structure was solved by 
Uhlin and Eklund, 1994, and is oriented such that the viewer is looking down the center of 
the barrel domain. At the top of the barrel, the active site cysteines have been highlighted 
(carbon side chains in blue and sulfur in yellow). C225 and C462 are shown in this figure 
as a cystine disulfide, the form of the enzyme used to determine the crystal structure. 
C439, the transient cysteinyl radical, is also highlighted in the figure. The proximity of 
these catalytically-essential cysteines is consistent with the proposed mechanism of 
catalysis for RNR. 39 
The R2 C-terminal peptide is found inserted into a narrow groove formed between two 
parallel a-helices. One of the helices which form the groove is part of the small domain. 
The other helix, barrel helix aI, provides the second face of the groove. The highly 
specific interaction between the R2 C-terminal peptide and this groove provides the 
physical link between the R1 and R2 homodimers. The R1 residues which contribute to 
the R2 peptide binding site are not conserved among different but related species, reflecting 
the species-specific nature of this protein-protein interaction. The positioning of this 
peptide relative to the active site is consistent with the proposal that the R2 C-terminus 
provides the electron transfer link between R1 and the R2 tyrosyl radical. 
The N-terminal domain is composed of 12 a-helices, the first four of which form a left-
handed 4-helix bundle. This 4-helix bundle packs against the barrel opposite of the surface 
where the small domain and R2 carboxy terminus bind. The position of the N-terminal 
domain against the barrel adds further definintion to the substrate binding pocket. 
The R1 from E. coli behaves as a dimer in sedimentation equilibrium centrifugation 
experiments and is thought to be a homodimer in the active holoenzyme (Brown and 
Reichard, 1969a; Thelander, 1973). The R1 dimer interface is formed by two helices of 
the a/I3 barrel of one monomer, aA and aB, and the symmetry-related pair of the other 
monomer. The R1 dimer has an unusual S-shape which appears inherently flexible. This 
flexibility may facilitate the movement of domains and/or subunits of the R1 dimer and 
these intramolecular rearrangements may form the structural basis for the allosteric 
regulation and catalysis. 
In an effort to identify the location of the allosteric sites on R1, crystals were either 
grown in the presence of dTTP, or soaked in a solution containing dATP and then analyzed 
by X-ray crystallography. Difference Fourier maps gave positive peaks corresponding to 
these nucleotides at the amino end of aA close to the homodimer interaction surface. 
Earlier studies, using R1 which had been photoaffinity-labeled with dTTP, demonstrated 
that this allosteric effector specifically labeled Cys289, localizing the specificity site to the 40 
region around residues 288-294 of R1 (Eriksson et al., 1986). Cys289 and the 
surrounding residues are part of ocB of the 10-stranded a/13-barrel structure of Rl. This 
area is directly adjacent to the amino terminus of ctA, corroborating the results of the 
crystallographic studies done on the R1-nucleotide complex. 
The location on R1 of the other allosteric nucleotide binding site, the activity site, has 
not yet been conclusively identified. However, it has been proposed that the activity site 
may be formed by the first 50-60 N-terminal residues of R1 (Eliasson et al., 1996). This 
proposal is based on the finding that the subclass of type I RNRs, type lb (Jordan et al., 
1996), lack the last 50 N-terminal residues present in the type Ia enzymes. The type Ib 
enzymes also lack the dATP-mediated inhibition observed by the type Ia enzymes, 
suggesting that the N-terminus may be involved in forming the activity site. Further 
support of this proposal is the finding that a D57N mutation in the mouse R1 protein makes 
the mutant protein insensitive to inhibition by dATP (Caras and Martin, 1988). 
Modeling of the ribonucleotide reductase holoenzyme 
A model for the a2132 holoenzyme complex can be made by superimposing the 2-fold 
axes of the individual three-dimensional structures of the R1 and R2 dimers and placing the 
complementary concave face of the R1 dimer onto the top lobes of the heart-shaped R2 
dimer (Uhlin and Eklund, 1994). In this conformation, the binding site for the R2 C-
terminal peptide determined by the crystallographic studies is in the right vicinity to allow 
docking of the flexible R2 carboxy terminus. Modelling of the complex in any other 
conformation will not bring Tyr122 closer to the active site of Rl. 
Before the crystal structures of R1 and R2 were determined the active site was thought 
to be located at the R1-R2 interface where the Tyr122 radical could directly interact with the 
substrate. However, the three-dimensional structure of the R2 protein showed that this 
could not be the case, since the Tyr122 was buried within the core of the protein 10 A from 41 
the nearest surface. Furthermore, structural changes resulting in exposure of the tyrosyl 
radical to the active site during complex formation are unlikely since no change in the EPR 
or absorbance spectra is observed upon binding of R2 to R1 (Sahlin et al., 1987). In the 
current model of the holoenzyme, the distance between the tyrosyl radical of R2 and the 
active site in R1 is approximately 35-40 A. These discrepancies led to the proposal that the 
radical may be transferred to the active site during catalysis via an electron transfer pathway 
composed of several highly conserved hydrogen-bonded residues contributed from both 
the R1 and R2 dimers (Nordlund et al., 1990; Nordlund and Eklund,1993). The R1 
structure reinforces this hypothesis. 
The tyrosyl radical in R2 is an oxidized species (Backes et al., 1989). Therefore, in 
contrast to most biological electron transfer processes which are reductive in nature, the 
proposed electron transfer pathway in RNR implies an oxidative transfer event. 
Examination of the crystal structure, as well as sequence comparisons and analysis of 
mutant proteins led to the selection of the following residues as participants in the transfer 
pathway. In the three-dimensional structure of R2, the residue which forms the stable 
tyrosyl radical (Y122) is hydrogen-bonded to Asp84. Asp84 is the bidental ligand of Iron­
1. Another Iron-1 ligand, His118, forms a hydrogen bond with the 8-oxygen atom of 
Asp237. Asp237 forms a hydrogen bond to the &nitrogen of Trp48. Trp48 is a highly 
conserved residue which is located on the top lobe of the R2 structure at the proposed R1 
binding site. Although Trp48 is located on the R1 binding surface, it is probably not the 
terminal electron transport link in R2. Two other residues located in the R2 carboxy 
terminus, G1u350 and Tyr356, have been implicated in the transfer of electrons between R1 
and R2. This portion of the R2 protein is not defined in the crystal structure, but site-
directed mutagenesis of these residues has provided compelling evidence for this 
assignment (Climent et al., 1992). Although the sequence of the R2 C-terminus is highly 
species-specific, G1u350 and Tyr356 are invariant. Mutant E. coli R2 proteins were 
prepared in which either G1u350 or Tyr 356 were converted to alanine. Both of these 42 
mutants bound R1 and substrate with binding constants very similar to wild-type R2. 
However, the catalytic activities of these proteins were severely impaired. The E350A 
mutant was 240 times less active than wild-type, while the Y356A mutant was totally 
inactive. These results indicate that these residues play catalytic rather than structural roles 
in ribonucleotide reduction and suggest that the R2 C-terminus is not only required for R1­
R2 association, but that it may also function as the electron transport connection between 
R1 and R2. 
The proposed electron transport circuit is completed by two tyrosines in the R1 
structure, Tyr730 and 731. These two residues are located on 0-strand J of the R1 barrel 
structure adjacent to the binding site for the R2 C-terminal peptide. This positioning within 
the R1 structure is consistent with the formation of a connection between the C-terminal R2 
electron transport residues and the active site in Rl. In the crystal structure of R1, Tyr731 
is hydrogen-bonded to Tyr730, which is hydrogen bonded to Cys439 at the active site. To 
test the possible role of these residues in electron transport, site-directed mutagenesis was 
used to change each of these tyrosines to phenylalanine (Ekberg et al., 1996). These R1 
mutants were enzymatically inactive even though it was established that the three-
dimensional structures were unchanged and R1-R2 complex formation as well as substrate 
binding were not impaired. Furthermore, the mechanism-based inhibitor 2'-azido-2'­
deoxyCDP was incapable of scavenging the radical in these mutants, and no azido-CDP­
derived radical intermediate was formed. Interaction of this nucleotide analogue with wild-
type holoenzyme results in destruction of the tyrosyl radical (Thelander et al., 1976) and 
concomitant generation of a nitrogen-centered substrate radical (Sjoberg et al., 1983). 
These results indicate that disruption of the hydrogen-bonded link connecting the active site 
cysteine with the R2 binding surface leads to loss of electron transfer. 
Thus, the electron transfer pathway in E. coli RNR which connects the stable tyrosyl 
radical in R2 to the transient cysteinyl radical in R1 is thought to involve Asp84, Iron-1, 43 
His118, Asp237, Trp48, G1u350, Tyr356 in R2 and Tyr731 and Tyr730 in Rl. Figure 9 
depicts the residues from R1 and R2 which make up the putative electron transport chain. 
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Figure 9 The electron transfer pathway from E. coli RNR. This hydrogen 
bonded array of highly conserved residues was proposed by Uhlin and Eklund, 1994, to 
shuttle the radical between the active site on R1 and Tyr122 of the R2 protein. 44 
Inhibition of ribonucleotide reductase by hydroxyurea 
Ribonucleotide reductase is an obvious target for antiproliferative agents because of the 
key role that it plays in DNA synthesis. Many drugs which inhibit RNR act by targeting 
the unique feature of the enzyme that is required for activitythe tyrosyl radical. 
Hydroxyurea, a drug used for many years in the treatment of chronic myelogenous 
leukemia (CML) and other myeloproliferative syndromes (Sather et al., 1978), is the most 
common and best characterized example of drugs which inhibit DNA synthesis by 
scavenging the tyrosyl radical of RNR. 
Hydroxyurea was first synthesized in 1869 (Dresler and Stein, 1869) and an inhibitory 
effect on leukocyte production was noted in 1928 (Rosenthal et al., 1928). However, the 
drug received little attention until antineoplastic activity was observed in 1960 (Stock et al., 
1960). In 1964, a decrease in CDP reduction in hydroxyurea-treated rat and human bone 
marrow cells was reported (Frenkel et al., 1964), localizing the effects to RNR. Then in 
1972, it was demonstrated that hydroxyurea specifically inhibited RNR by destroying the 
free radical of the enzyme (Ehrenberg & Reichard, 1972). Hydroxyurea has been used 
clinically in the treatment of a wide variety of solid tumors, acute and chronic leukemia 
(Bolin et al., 1982), and has even been used to control the proliferation of psoriasis 
(McDonald, 1981). Hydroxyurea enters cells by a diffusion process (Tagger et al., 1987). 
The drug enters all tissues, including the central nervous system, with a maximal velocity 
that appears infinite (Morgan et al., 1986). 
Much work has been done using analogues of hydroxyurea to determine the structural 
features of the molecule required for activity, and in the attempt to design more effective 
and specific antiproliferative agents (Kjoller-Larson et al., 1982). The general structure 
required for activity was found to be 
O  R 
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Substitution of the R2 moiety with one- or two-carbon alkyl groups did not significantly 
affect activity. Substitution of the R1 moiety, the 1° amine in hydroxyurea, with a variety 
of substituents had varying effects. In general, it was determined that the activity of the 
hydroxyurea analogue was inversely proportional to the bulk of the R1 substituent. Based 
on the structure-activity relationship determined in these studies, it was estimated that the 
free radical of the E. coli enzyme was buried in a pocket approximately 4 A wide and at 
least 6 A deep. The mouse enzyme was found to be sensitive to much bulkier analogues, 
suggesting that the pore leading to the radical in this form of the enzyme was larger than in 
E. coli. The crystal structures of the two forms of RNR have corroborated these 
conclusions. 
Hydroxyurea is a specific inhibitor of the iron-containing, or Class I, RNRs. It 
functions by quenching the tyrosyl radical, presumably through a one-electron reduction of 
the oxidized tyrosyl residue. Hydroxyurea reduces the tyrosyl radical of mouse R2 
approximately three times as fast as the radical in the E. coli protein (Karlsson et al., 1992; 
Nyholm et al., 1993). In addition, the radical and iron center of the mouse protein are 
reduced simultaneously (Nyholm et al., 1993), while the iron center of the E. coli protein 
remains intact. Interestingly, even though all forms of RNR are believed to use the radical-
mediated catalytic mechanism described earlier, the adenosylcobalamin-containing Class II 
enzymes are resistant to the radical scavenging properties of hydroxyurea (Hamilton et al., 
1972). 
The effects of hydroxyurea on the E. coli enzyme have been well characterized. When 
hydroxyurea reacts with the E. coli enzyme, only the tyrosyl radical is reduced, leaving the 
iron center intact. This form of the protein is known as metR2 (Sahlin et al., 1989). The 
general features of the Mossbauer spectra of native and hydroxyurea-treated R2 are 
essentially the same, verifying that the iron center remains unperturbed by hydroxyurea 
(Petersson et al., 1990). The difference spectrum, created by subtracting the spectrum of 46 
the metR2 from that of native R2, contains the electronic spectral bands assigned to the 
iron-oxo center, and lacks the bands due to the tyrosyl radical. 
In vitro studies done on the E. coli enzyme have demonstrated that during substrate 
turnover, the radical is several times more sensitive to hydroxyurea than when the enzyme 
is in a resting state (Atkin et al., 1973). The increase in sensitivity to hydroxyurea which 
occurs in conjunction with an increase in the level of enzyme activity has also been 
observed for the ribonucleotide reductase from bacteriophage T4 (Berglund and Sjoberg, 
1978). 
The hydroxyurea sensitivity of the radical from the E. coli enzyme is also dependent on 
the regulatory state of the enzyme (Karlsson et al., 1992). By indirectly measuring the 
tyrosyl radical half-life under various conditions, the effects of holoenzyme formation and 
the nucleotide environment on the susceptibility to hydroxyurea were determined. Using 
the half-life of the R2 protein alone as the reference, it was found that formation of the 
R1R2 complex reduced the hydroxyurea sensitivity of the radical 1.4 to 2.5 fold. It has 
been shown by EPR (Backes et al., 1989) and resonance Raman (Sahlin et al., 1987) 
spectroscopy that formation of the R1R2 complex does not influence the structure of the 
radical or iron centers. Thus, the decreased sensitivity to hydroxyurea of the R2 radical 
upon formation of the holoenzyme is thought to be due to a physical phenomena in which 
the R1 blocks accessibility to the radical, rather than a change in the structure of the radical 
center. 
The susceptibility of the radical in the E. coli R1R2 complex is changed significantly 
through binding of the allosteric effectors ATP and dATP. Activation of the holoenzyme 
by addition of a positive effector, such as ATP or dATP at low concentration (2 plV1), made 
the radical more susceptible to hydroxyurea. Conversely, addition of dATP at 
concentrations in which the enzyme is completely inhibited (100 t_tM), made the radical 
much less susceptible to hydroxyurea. 47 
Addition of either substrate (rCDP) or product (dCDP) to the E. coli holoenzyme made 
the R2 radical three times more susceptible to hydroxyurea destruction compared to 
susceptibilty of the R1R2 complex without these nucleotides present. When a positive 
effector was added along with substrate or product, the rate of hydroxyurea inactivation 
increased dramatically to values which were too rapid to accurately determine in these 
experiments. 
These results, taken together, suggest that the radical sensitivity to hydroxyurea is 
proportional to the activity-state of the enzyme. That is, when the enzyme is poised to 
reduce substrate, the radical somehow becomes more accessible to hydroxyurea. 
One possible mechanism behind the increased susceptibility of the radical in the ternary 
complex is a conformational change in R2 which accompanies the binding of an activating 
allosteric effector and/or substrate/product to R1. Although it is assumed that 
conformational changes in R1 driven by the binding of effectors to the allosteric sites are 
responsible for changes in enzyme's substrate specificity and relative activity, there is no 
evidence that these conformational changes are propagated to the R2 protein. However, the 
compact structure which is formed when the holoenzyme is modeled such that the dimer 
axes are superimposed (Uhlin and Eklund, 1994) places the top lobes of the heart-shaped 
R2 dimer in contact with a large portion of the R1 surface. Part of the R1 surface which is 
is contact with R2 includes the last resolvable N-terminal residues, and it is this region that 
has been implicated as forming part of the activity site (Eliasson et al., 1996). Therefore, it 
is feasible that allosterically driven conformational changes in R1 may also change the R2 
conformation and hence hydroxyurea sensitivity of the radical center. 
Another possible explanation of the increased sensitivity of the ternary complex 
involves the putative electron transfer pathway. This pathway is responsible for transfer, 
back and forth, of the electron from the substrate bound in the R1 active site to the tyrosyl 
radical in R2 during each catalytic cycle. It is postulated that the electron transport is 
triggered by binding of a nucleoside triphosphate to an allosteric site and further enhanced 48 
by binding of substrate (or product) to the active site. This electron transport presumably 
creates transient radicals at residues along the hydrogen-bonded pathway. These 
transiently occupied sites may be more effeciently scavenged by hydroxyurea than the 
tyrosyl radical in R2, simply because of their proximity to bulk solvent. This may be 
especially true for the transport chain residues located at the interface between R1 and R2. 
If this model is correct, the electron transport triggered by the allosteric activation of the 
enzyme will increase the frequency of inactivation of the radical (decreasing the half-life) 
which occurs at these transiently occupied sites. 
Pool size change 
The effect of hydroxyurea treatment on the in vivo dNTP pools has been investigated in 
many cell types. When E. coli is treated with hydroxyurea, all four of the 
deoxyribonucleoside triphosphate pools are depressed (Neuhard, 1967), as expected for a 
system in which the inhibited enzyme produces all four dNTP precursors. However, in 
cultured mammalian cells this is not the case. Surprisingly, addition of hydroxyurea to 
mammalian cells results in depletion primarily of the purine dNTPs (Adams et al., 1971; 
Skoog and Nordenskjold, 1971; Akerblom and Reichard, 1985; Slabaugh et al., 1991). 
Even more surprising, in most cases the dTTP pool is elevated by hydroxyurea treatment. 
Effects of hydroxyurea in combination with other compounds 
The effects of various combinations of hydroxyurea with iron-chelating agents have 
been tested for RNR inhibition (Cory et al., 1981). It was found that adding iron-chelators 
like EDTA, desferroxamine, and 8-hydroxyquinoline in combination with hydroxyurea 49 
increased the inhibition of RNR activity in cultured cells. This result is consistent with the 
requirement for iron in the regeneration of the tyrosyl radical. 
Recently, hydroxyurea has been shown to be a possible candidate for AIDS therapy, 
especially when used in conjunction with 2', 3'-dideoxyinosine (ddI) (Lori et al., 1994). 
The human immunodeficiency virus (HIV) requires dNTPs for the reverse transcriptase­
catalyzed synthesis of viral DNA. Since hydroxyurea treatment leads to a depletion of 
dNTPs, any process which requires these precursors should be inhibited to some degree. 
Lori and coworkers found that, by decreasing the dNTP pools, hydroxyurea inhibits HIV 
DNA synthesis both in stimulated and quiescent human lymphocytes infected with HIV-1. 
This inhibition resulted not only in less production of viral DNA, but the DNA that was 
produced was in the form of incomplete chains (Gao et al., 1993). Furthermore, it was 
found that when hydroxyurea was combined with the nucleoside analog ddI, the inhibition 
was greater than the additive effects of the two drugs separately. As discussed earlier, 
hydroxyurea treatment of cells results primarily in a decrease in the purine dNTPs. ddI is 
metabolized in the cell to the active form of the drug, a purine dideoxynucleoside 
triphosphate. The active form of ddI is then able to compete with the purine dNTPs for 
incorporation into viral DNA. Once incorporated, the growing DNA strand can no longer 
elongate, since the incorporated nucleotide analog lacks the 3'-hydroxyl required for the 
next polymerization step. The basis for the synergistic effect of hydroxyurea and ddI is 
presumably due to the increased utilization of the metabolized form of ddI by reverse 
transcriptase required to compensate for the depressed dATP pool (and to a lesser extent 
dGTP) resulting from the hydroxyurea treatment. Results obtained using the thymidine 
analog, azidothymidine(AZT) instead of ddI support this presumption. Cells treated with 
AZT plus hydroxyurea show severalfold less inhibition of viral DNA synthesis compared 
to treatment with ddI plus hydroxyurea. Because the dill' pool in hydroxyurea-treated 
cells is not depressed to any significant extent in most cell types, the active metabolite of 
AZT will not compete as effectively for incorporation into viral DNA as the ddI metabolite 50 
can. Thus, one sees the synergistic effect of hydroxyurea and nucleoside analog  only 
when that analog competes with the dNTP pool which is specifically depressed by 
hydroxyurea. Furthermore, because hydroxyurea targets a host cell enzyme rather than 
inhibiting the virus directly, the high rate of formation of drug-resistant forms of I-1W 
commonly observed with conventional antiviral drugs should not be a problem. 51 
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Chapter 2 
Inactivation of Vaccinia Virus Ribonucleotide Reductase 
by Hydroxyurea 
Stephen P. Hendricks and Christopher K. Mathews 57 
Summary 
Hydroxyurea inhibits DNA synthesis by destroying the catalytically essential tyrosyl 
radical of Class I ribonucleotide reductase, thereby blocking the de novo synthesis of 
deoxyribonucleotides. Unexpectedly, in mammalian cells, including cells which are 
infected by vaccinia virus, this block results in a differential decrease in the pools of the 
four DNA precursors. This led to the suggestion that the four activities of ribonucleotide 
reductase may be differentially sensitive to hydroxyurea. Two independent methods were 
developed to test this idea; a spectroscopic technique was used to directly measure the 
hydroxyurea-induced decay of the radical/iron center chromophore, and a biochemical 
technique that was used to measure the hydroxyurea inhibition as a function of enzyme 
activity. Neither technique seemed to indicate that any one of the four ribonucleotide 
reductase activities was more sensitive than any other to hydroxyurea. However, other 
factors that influence the sensitivity of the radical and iron center were identified. 
Specifically, the sensitivity of the radical and iron center to hydroxyurea appeared to be 
dependent upon the activity level of the enzyme. When no allosteric effectors were present, 
the holoenzyme was most resistant to hydroxyurea. When the enzyme was activated for 
substrate turnover by the addition of nucleoside triphosphate effectors, the half-life of the 
tyrosyl radical/iron center chromophore in the presence of the inhibitor was significantly 
reduced. Futhermore, addition of substrate to the activated holoenzyme further sensitized 
the enzyme to hydroxyurea. 58 
Introduction
 
Hydroxyurea (HU) inhibits DNA replication in cells that use the Class I form of 
ribonucleotide reductase (RNR) by inactivating the tyrosyl radical required for enzyme 
activity (Ehrenberg and Reichard, 1972). This inhibition is also observed in viruses, like 
vaccinia, which code for a Class I RNR. For example, when vaccinia virus-infected 
BSC40 monkey kidney cells are treated with HU, the synthesis of viral DNA is inhibited. 
HU inhibits the de novo synthesis of deoxyribonucleotides, thereby starving the host cell 
and viral replication complexes for precursors. One might expect that the inhibition of 
RNR by a drug like HU should result in an equivalent decrease in the rate of formation of 
all four products of the enzyme. However, when the triphosphate forms of these products, 
the 2'-deoxyribonucleoside 5'-triphosphates (dNTPs), were measured in vaccinia-infected 
cells, it was found that hydroxyurea treatment led to a differential decrease in the four 
dNTP pools. In particular, the concentration of the 2'-deoxyadenosine 5'-triphosphate 
(dATP) pool was decreased to the greatest extent (Slabaugh et al., 1991). 
Specifically, when vaccinia-infected BSC40 cells were treated with 0.5 mM HU, the 
dATP pool was depressed to 10% of the value from the control. At higher HU 
concentrations (2 and 5 mM), the dATP pool was reduced to less than 5% of the control. 
The other dNTP pools were not affected as much. At 0.5 mM HU, the 2'-deoxycytidine 
5'-triphosphate (dCTP) and 2'-deoxyguanosine 5'-triphosphate (dGTP) pools were both 
reduced to approximately 50%, and at 2.0 mM these pools were reduced to approximately 
30%, of the control. Surprisingly, the 2'-deoxythymidine 5'-triphosphate (d 1 i I') pool 
nearly doubled at all hydroxyurea concentrations studied (0.5 to 5 mM) (Slabaugh et al., 
1991; Figure 5). This trend in HU-induced dNTP pool changes, in particular the enigmatic 
increase in the d'ITP concentration, has been observed in studies done on numerous other 
mammalian cell types (Bianchi et al., 1986a; Nicander and Reichard, 1985a; Adams et al., 
1971; Skoog and Nordenskjold, 1971). 59 
Consistent with the finding that dATP was the most depleted dNTP, Slabaugh and 
coworkers found that the addition of deoxyadenosine (dAdo), the corresponding 
nucleoside of dATP, to the vaccinia-infected cells could reverse the HU-mediated inhibition 
of viral DNA synthesis. None of the other deoxyribonucleosides, deoxyguanosine 
(dGuo), deoxycytidine (dCyd), or deoxythymidine (dThd), were capable of reversing the 
effects of hydroxyurea, nor did they augment the dAdo effect. It is important to note for 
the purpose of later discussion that the dAdo rescue was observed only when erythro-9-(2­
hydroxyl-3-nonyl) adenine (EHNA), a potent inhibitor of adenosine deaminase, was added 
in conjunction with the nucleoside. 
A hypothesis that was developed to explain these data presumes that the differential 
changes that occur in the dNTP pools after HU treatment are the result of RNR being 
differentially sensitive to the radical scavenging properties of the drug. According to this 
hypothesis, the relative sensitivity will depend on which allosteric effector is bound, and 
therefore, which substrate the enzyme is activated to reduce. The fact that the largest 
decrease occurs in the dATP pool suggests that the most sensitive conformation occurs 
when the enzyme is stimulated to reduce adenosine 5'-diphosphate (rADP). In other 
words, when the allosteric activator for rADP reduction, dGTP, is bound to the specificity 
site, the enzyme adopts a conformation that makes the tyrosyl radical most accessible to 
HU. This will result in inhibition of the enzyme primarily when poised to reduce rADP, 
resulting in a greater depletion of the 2'-deoxyadenosine 5'-diphosphate (dADP) pool. The 
decreased dADP flux will then be translated down the de novo pathway, resulting in the 
experimentally observed depletion of the dATP pool. The dCTP, dTTP, and dGTP pools 
should be less affected by HU because the RNR conformations associated with the rCDP-, 
rUDP-, and rGDP-reducing activities will be less sensitive to the drug. I joined the 
Mathews laboratory to test this hypothesis. 
This chapter describes two independent in vitro techniques I have developed to test this 
hypothesis, and the results of studies done using these techniques. The first technique is a 60 
physical method which monitors the HU-induced decay of the radical directly, and the 
second technique is an enzymatic assay which follows the destruction of the radical as a 
function of the relative enzyme activities. 
The physical method I used to determine the relative sensitivity of RNR takes advantage 
of a chromophore that arises from the tyrosyl radical and iron-oxo center of R2. The Class 
I RNRs, which include the Escherichia coli, mouse and vaccinia enzymes, are characterized 
as having an iron-oxo center that is closely associated with a catalytically essential tyrosyl 
radical. These species give rise to unique chromophores that absorb light in the visible 
region of the electromagnetic spectrum. In the E. coli R2 protein, the tyrosyl radical 
chromophore gives rise to a peak at 410 nm and a broad band centered at approximately 
390 nm. The iron-oxo center has an absorbance band centered at approximately 370 nm 
and contributes some overlapping absorbance to the 390 and 410 nm absorbance bands 
(Ehrenberg and Reichard, 1972). The tyrosyl radical and iron-oxo chromophores of the 
mouse and vaccinia proteins absorb light at slightly lower energy, giving a relatively sharp 
peak at 417 nm. Treatment of the E. coli enzyme with HU or NH4OH results in 
destruction of the 410 and 390 nm absorbances with little or no change in the iron-oxo 
bands. The mammalian forms of R2 behave differently when treated with these inhibitors. 
Treatment of the mouse or vaccinia R2 with HU results in destruction of both the tyrosyl 
radical and iron-oxo center absorbance bands on a similar time scale (Nyholm et al., 1993; 
Howell et al., 1992). In addition, at least in the case of the mouse R2, the destruction of 
these chromophores is accompanied with release of iron from the protein (Nyholm et al., 
1993). The different behaviors of the E. coli and mammalian proteins with respect to HU 
inactivation may reflect a more exposed iron center in the mammalian R2, or may be related 
to different redox potentials of the iron centers. 
To test whether the radical was differentially sensitive, HU was mixed with purified 
vaccinia RNR and the decay of the absorbance at 417 nm was monitored over time. By 
comparing the chromophore decay rates of the enzyme in the presence of different dNTP 61 
effectors, the relative sensitivity of the radical and iron-oxo center was determined under 
different allosteric conformations. In addition, the chromophore decay was measured 
while the enzyme was turning over substrate in order to determine whether the overall 
activity of the enzyme altered its sensitivity to HU. 
Although this technique proved useful for investigating the radical sensitivity, the 
results were not very reproducible due primarily to practical problems associated with the 
vaccinia RNR proteins. The highly variable decay rates made it difficult to determine 
whether any of the four activities was more sensitive than the others to HU. Therefore, I 
sought an additional, more reproducible technique to answer the question. One obvious 
way to approach this problem is to follow the inhibition as a function of the enzyme 
activity. For this purpose, it would be useful to have the ability to simultaneously measure 
all four RNR activities under physiological effector concentrations in order to mimic the in 
vivo nucleotide environment of the enzyme. However, the routine method used to assay 
RNR activity uses a single substrate, usually tritiated cytidine diphosphate ([3H]rCDP), 
and thin-layer chromatography (TLC) to separate the substrate from the product. The TLC 
separation does not have satisfactory resolution to resolve the four possible 2'­
deoxyribonucleoside 5'-diphosphate (dNDP) products. Therefore, most of the data 
regarding RNR enzyme activity, including substrate specificity and allosteric effects, 
collected prior to this report were obtained using single substrate assays. 
To better address the question of differential sensitivity, I developed a novel assay in 
which the four activities of RNR can be simultaneously monitored in a single reaction vial. 
This four-substrate assay, as we refer to it, can be used to determine how perturbations of 
RNR effect each of the four activities under identical conditions (Hendricks and Mathews, 
1997). I used this assay to determine the extent that HU inhibited each of the four vaccinia 
RNR activities. In addition, the method has also proved useful for studying other aspects 
of RNR enzyme activity. For example, the assay can be performed using any desired 
combination of allosteric effectors and substrates in order to study the role of the allosteric 62 
environment in the regulation of RNR activity. The following chapters describe such 
studies done using the recombinant enzymes from T4 bacteriophage and vaccinia virus. 
Chapter 3 describes the assay in more detail and Appendix I gives the step by step 
procedure. This chapter summarizes the results of the HU inhibition of vaccinia RNR 
obtained using both the physical and enzymatic techniques. 
Materials and Methods 
Overexpression and Purification of Recombinant SubunitsBoth subunits of vaccinia 
ribonucleotide reductase were previously cloned into IPTG-inducible pET expression 
vectors and were overexpressed as described (Slabaugh et al., 1993; Howell et al., 1992). 
The purification procedure for the R2 subunit was essentially as reported (Howell et 
al., 1992) except for the incorporation of an additional radical reactivation step. In this 
step, recombinant apoR2 was activated to form the tyrosyl radical and iron-oxo center by 
addition of ferrous iron under anaerobic conditions. The reactivation was accomplished 
during gel exclusion chromatography by addition of ferrous ammonium sulfate to 
extensively degassed column buffer. Once the size exclusion column was equilibrated with 
this solution, partially purified R2 was applied, allowed to bind iron, and then eluted as 
normal. The tyrosyl radical was formed when the protein eluted from the anaerobic 
environment of the column and was exposed to air in the fraction collector. 
Purification of the R1 protein was based on the protein's affinity for dATP. A dATP-
Sepharose affinity resin was synthesized by coupling 2'-deoxyadenosine-5'-(7-4­
aminopheny1)-triphosphate (USB), via the aminophenyl moiety, to cyanogen bromide-
activated Sepharose (Pharmacia Biotech). Details of the coupling procedure can be found 
in Appendix II. Routinely, 3-5 g of cells containing overexpressed vaccinia R1 were lysed 
in a French press and centrifuged at 12,000 rpm for 20 minutes. The clarified lysate was 
filtered and applied to a column packed with 1.0 ml of dATP-Sepharose resin, and the 63
 
column was washed extensively with column buffer composed of 50 mM N-[2­
hydroxyethyl]piperazine-W42-ethanesulfonic acid] (HEPES), 100 mM KC1, 1mM 
dithiothreitol (DTT), pH 8.2. After washing the column back to baseline with column 
buffer, a 7.0 ml-wash of column buffer containing 5 mM ATP was used to elute any E. 
coli R1, or other bound proteins resulting from the expression system. Finally, the 
recombinant vaccinia R1 protein was eluted with column buffer containing 75 mM ATP. 
Centricon-30 centrifugation devices (No. 4209; Amicon Inc., Beverly, MA) were used to 
concentrate the purified R1 and remove the ATP used in the elution step. 
Hydroxyurea-Mediated Radical Decay AssaysPurified holoenzyme, or R2 alone, 
plus the appropriate effectors and substrates, were mixed with HU at time = 0 and the 
change in absorbance at 417 nm over time was recorded on a Beckman DU-64 
spectrophotometer. Typically, assays were done in 50 mM HEPES, pH 8.2, containing 15 
pM R2, 20 pM R1, 800 µM dNTP effector, 1 mM rNDP substrate, and 20 mM DTT, in a 
final volume of 75 !al. R1 was added in excess to assure that most of the R2 would be 
bound in the holoenzyme form. HU was added to a final concentration of either 3 or 20 
mM. 
Ribonucleotide Reductase Four-Substrate AssayThe assay was performed essentially 
as described in Hendricks and Mathews, 1997 (see Chapter 3). The assay is composed of 
two chromatographic steps. The first step, boronate affinity chromatography, separates the 
RNR products (dNDPs) from the substrates (rNDPs). In the second step of the assay, the 
dNDPs are resolved into individual nucleotides by high performance liquid 
chromatography (HPLC). Vaccinia R2 was added to the reaction in a two- to four-fold 
molar excess over vaccinia Rl. In all reactions, vaccinia R1 was present at 1.0 tM final 
concentration. ATP and DTT were present in all reaction mixtures at 2.0 mM and 50 mM, 
respectively. Except as indicated, all four rNDP substrates were added to the reactions at 
equimolar concentrations, usually 0.15 mM each. In the inhibitor-treated samples, the final 
HU concentration ranged from 0.2  2.5 mM. 64
 
Results 
Purification of the Recombinant ProteinsThe results of a typical purification of the 
R2 and R1 subunits of the vaccinia RNR are shown in Figures 2.1 and 2.2, respectively. 
As the gels indicate, the purification procedures used in these studies are effective at 
generating homogeneous proteins. 
Electronic Spectra of R2Figure 2.3 shows the UV-vis spectra from 350 to 450 nm of 
three different forms of R2. Panel A is the spectrum of R2 from E. coli. Several peaks of 
interest arising from the iron-oxo and/or tyrosyl radical can be seen in the spectrum. Most 
notable is the relatively sharp absorbance at 410 nm. This peak is due primarily to the 
tyrosyl radical chromophore. The broad band or shoulder centered at -370 nm is due to the 
iron-oxo center and has been assigned to the iron-oxygen bond stretching. A second band 
or shoulder, centered at -390 nm, is attributed primarily to the tyrosyl radical but contains 
some overlapping absorbance from the iron center chromophore (Ehrenberg and Reichard, 
1972). The assignment of these peaks was based initially on spectroscopic data including 
comparison to the spectrum of the 2,4,6-tri-tert-butylphenoxy radical, a model phenoxy 
radical produced chemically (Land et al., 1961), and the optical spectrum of hemerythrin 
(Garbett et al., 1969), an oxygen-binding protein containing a well characterized non-heme 
iron center. 
Figure 2.3, panel B, shows the spectrum of the recombinant R2 protein from mouse. 
The tyrosyl radical of the mouse protein gives rise to a shoulder at 395 nm and a peak at 
417 nm instead of the 390 nm shoulder and 410 nm peak observed in the E. coli R2 
protein. As well as the shift of the peak to lower energy, the shape of the radical peak at 
417 nm of the mouse protein is broader than the corresponding peak in the spectrum of the 
E. coli protein. The different shapes and positions of these peaks probably reflect 
differences in the protein structure surrounding the tyrosyl radical. As well as the 
differences in the residues found in this region of the protein, the distance, and hence the Vaccinia R2 purification procedure: 
streptomycin-SO4 ppt. 
(N114)2SO4 ppt. 
Superose (size exclusion) FPLC 
MonoQ (ion exchange) FPLC 
Typical results: 
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Figure 2.1 Purification of the vaccinia R2 subunit. The purification  scheme used 
for the recombinant vaccinia and mouse R2 proteins is shown at the top of this figure. The 
gel shown at the bottom of this figure shows the results of a typical vaccinia R2
purification. Final yields from this procedure were routinely 3-5 mg of R2 per liter of 
induced cells. The radical content of purified vaccinia R2, which was estimated using the 
mouse R2 radical extinction coefficient of 3400 M-1 cm-1 (Thelander et al., 1985),  was 
found to be slightly less than 0.5 radicals per polypeptide chain, or approximately 1 radical
per R2 dimer. 66 
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Figure 2.2 Purification summary gel of vaccinia Ri. The gel shows the results of 
a typical purification of recombinant vaccinia Rl. Typically, this purification procedure 
yielded 1.0 mg of vaccinia R1 per liter of induced cells. The structure of the dATP-
Sepharose affinity resin used to purify the R1 is shown above the gel. 67 
energy of the interaction, between the radical and iron center in the E. coli and mouse 
proteins is different. The distance between the tyrosyl radical and the closest iron atom in 
the E. coli protein is 5.3 A (Nordlund et al., 1990). The corresponding distance in the 
mouse R2 is slightly shorter (Kauppi et al., 1996). 
The iron center of the mouse protein gives rise to a shoulder centered at 370 nm, similar 
to the iron-oxo band in the E. colt R2 spectrum, and contributes some overlapping 
absorbance to the tyrosyl radical peaks (Thelander et al., 1985). The similar position of the 
iron-related band at 370 nm of the R2 from mouse and E. coli suggests that the iron-oxo 
centers of these proteins are similar in structure. Indeed, comparison of the crystal 
structures of these proteins corroborates the similarity of the iron centers. Both the ligands, 
as well as the geometry of those ligands around the iron atoms, of the two centers are 
almost identical (Kauppi et aL, 1996). 
The electronic absorption spectrum of vaccinia virus R2, shown in Figure 2.3, panel C, 
is almost identical to the absorption spectrum of the tyrosyl radical and iron-oxo center of 
the mouse R2. Based on sequence homologies, the vaccinia and mouse R2 proteins are 
predicted to be very similar in structure (Nordlund et al., 1990) and this is reflected in the 
electronic absorption and electron paramagnetic resonance (EPR) spectra of the two 
proteins (Howell et al., 1992). The electronic absorbance bands of the iron center and 
tyrosyl radical of the vaccinia R2 are virtually superimposable on the absorbance bands of 
the mouse R2 spectrum. 
Hydroxyurea-mediated chromophore decayFigure 2.4 shows the visible spectra of 
the vaccinia R2 protein taken at approximately 90 second intervals following the addition of 
HU. These spectra illustrate the simultaneous decay of both the tyrosyl radical and iron­
oxo chromophores that occurs in the mammalian forms of protein R2. 68 
Figure 2.3 Light absorption spectra of R2 from three different species. The 
electronic spectra, recorded from 350 to 440 nm, of the E. coli (panel A), mouse (panel B), 
and vaccinia (panel C) R2 proteins are shown on the following page. Protein concentra­
tions of the samples used for these measurements were -50 tM each. E. coli R2 was a gift 
from the laboratory of Dr. Britt-Marie Sjoberg. The mouse and vaccinia proteins were 
overexpressed and purified according to Material and methods. Spectra were recorded 
using a Beckman DU-64 spectrophotometer. A
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Figure 2.4 Hydroxyurea-mediated decay of the vaccinia R2 tyrosyl radical 
and iron-oxo chromophores. Time course of the chromophore decay of vaccinia R2 
after treatment with HU. The upper tracing was recorded just prior to HU addition. Each 
successive spectrum was recorded at 90 second intervals following addition of HU. This 
figure illustrates the simultaneous decay of the radical and iron-oxo center absorbance 
bands. 71 
Figure 2.5 shows the results of a HU-mediated radical decay experiment. The curves 
represent the loss of signal at 417 nm after treatment of enzyme with 10 mM HU. 
Comparison of the decay rates of R2 alone (second curve from top) and R2 plus R1 (top 
curve) suggest that the presence of R1 protects the R2 tyrosyl radical and iron-oxo center 
from HU. This protection was lost once allosteric effectors were added to the holoenzyme 
(two lower curves). 
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Figure 2.5 Hydroxyurea-mediated radical decays of R2 in different states. 
Experimental conditions were: 60 mM HU, 15 pM R2, 20 p,M R1, and 800 p,M dNTP. 72 
The decay rate of the 417 nm chromophore was further examined at lower hydroxyurea 
concentrations and different allosteric states. Figure 2.6 shows the exponential decay of 
the chromophore when the holoenzyme was combined with one effector (dTTP or dGTP), 
plus or minus the appropriate substrate (rGDP or rADP). When either dTTP or dGTP was 
added to the enzyme solution, the chromophore decayed according to the two upper curves. 
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Figure 2.6 The tyrosyl radical/iron-oxo center is more sensitive to
hydroxyurea during substrate turnover. 3 mM hydroxyurea and 1 mM rNDP 
substrate were used in these experiments. All other conditions were the same as those in 
Figure 2.5. 
Interestingly, when substrate was added (0.1 mM) to this mixture, the radical and iron­
oxo center became even more susceptible to hydroxyurea, as indicated by the decreased 73 
half-life seen in the lower curves. This phenomenon was also observed when ATP and 
rCDP were added to the reaction mixture. The decay rates for two different 
effector/substrate combinations are plotted on the same graph in order to illustrate what was 
observed in most experiments: the half-lives of the radical in the presence of either effector 
were indistinguishable and the same was true when substrates were added. The curves 
from Figures 2.5 and 2.6 were from experiments done on the same day, using the same 
enzyme preparation. These were selected as figures because they best illustrate the 
common trends consistent within each experiment. However, the obvious differences in 
half-lives shown in Figures 2.5 and 2.6 were generally not as extreme as these graphs 
depict. Furthermore, data obtained on different days, or obtained using different enzyme 
preparations, were hard to compare as the variability of the decay rates was large (see 
discussion). Although the absolute value of the rate constants varied greatly between 
experiments, the trends on a given day were consistent with what is shown in Figures 2.5 
and 2.6: R1 appeared to protect the radical and iron-oxo center when compared to the 
decay rate of the R2 protein without added Rl. This effect was observed until the addition 
of effectors, at which point the radical and iron-oxo center became increasingly more 
sensitive to hydroxyurea. Furthermore, as illustrated in Figure 2.6, the addition of 
substrate further increased the rate of chromophore decay. 
Measurement of HU-Inhibition using the Four-Substrate AssayFigure 2.7 shows the 
results of a typical four-substrate assay. In these experiments, duplicate reactions 
containing identical levels of enzyme, substrates, and allosteric effectors were prepared. 
HU was added to one of the samples at time = 0 and the reaction mixtures were incubated 
at 37° C. After a short incubation (6 minutes in this case) the reactions were quenched and 
processed according to the assay procedure. The difference between the peak areas for 
each dNDP product in the treated and untreated samples gives the amount of product 
formation inhibited by HU. 74 
Date: Tue, Aug 5, 1997 2:24 PM 
Data: sph.03-05AUG97-003 
Sample:  Vaccinia Virus RNR assay #20: 
10 pM dGTP, equimolar NDPs (0.15 mM) 
6 min. @ 37 deg. C 
dCDP 
Time  Height(Au)  Area(pV-sec)
dADP  2.655  0.689828  13697786 
10.340  0.102650  1300950 
dGDP  12.755  0.005806 
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r- Sample:  Vaccinia Virus RNR assay #20
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Figure 2.7 HPLC chromatograms  showing the results of vaccinia RNR
assays ± HU. The top chromatogram shows the results of the untreated control vaccinia
RNR assay, and the lower chromatogram is the results from the assay which included 2.5 mM HU. Typical assays contained 1 p.M R1, 4 p.M R2, 2 mM ATP, and 0.15 mM each of the four rNDP substrates. In this particular experiment, the allosteric effector dGTP was added to 10 1.tM final concentration. 75 
Tables 2.1 thru 2.3 contain the results of the four-substrate assay performed under the 
allosteric environments indicated at the top of each table. In these experiments, the HU-
mediated inhibition was determined for each of the RNR activities by comparing the peak 
areas of each dNDP in the samples treated with the inhibitor and the corresponding peak 
areas of the untreated controls. The values in each column represent the percentage of the 
control activity remaining after the sample was treated with HU. All experiments were 
performed with 2.0 mM ATP present in the reaction mixture. ATP is a general activator of 
RNR and its presence was necessary to activate the enzyme to levels detectable by the 
assay. The results for the inhibition of the rUDP reductase activity were not included 
because the turnover of this substrate is very low even under optimal allosteric conditions 
(Hendricks and Mathews unpublished; see Chapter 4). At early time points, the peak area 
corresponding to dUDP was close to the noise level of the method, making it difficult to 
accurately measure the difference between the HU-treated and untreated samples. 
The values from a given column of Tables 2.1, 2.2, and 2.3 represent the percentage of 
the control that each of the individual dNDP formation rates were inhibited by HU. A 
comparison of the values from a given column indicates that, in virtually every case, the 
percent inhibition was approximately the same for each substrate within the experimental 
error of the four-substrate assay (estimated at approximately 5% error, see Appendix V) 
indicating that no differential inhibition was detected by this method. 76 
Table 2.1 Effects of hydroxyurea on the activities of the vaccinia RNR when allosterically 
activated by ATP only 
[HU] (mM) 
% inhibition of 
reduction of  0.5  1.0  1.5  2.0  2.5 
rCDP  8  15  24  37 46 
rADP  7  21  27  36 44 
rGDP  5  18 36  41  49 
Table 2.2 Effects of hydroxyurea on the activities of the vaccinia RNR when allosterically 
activated by ATP + a single dNTP effector 
dNTP present
 
(101.1M)  dGTP  dATP  d'1TP
 
[HU] (mM)  1.0  2.5  1.0  2.5  1.0  2.5 
% inhibition of
 
reduction of
 
rCDP  21  35 ± 6  17  44 ± 5  31  48 ± 6 
rADP  14  38 ± 4  22  38 ± 4  29  39 ± 2 
rGDP  20  41 ± 3  16  37 ± 2  26  44 ± 3 
Experiments performed in presence of 2.5 mM HU were done in duplicate. The results 
from these experiments are reported as the mean ± (range/2). 77 
Table 2.3 Effects of hydroxyurea on the activities of the vaccinia RNR when allosterically 
activated by ATP, MP, dATP, and dGTP 
[HU] (mM) 
% inhibition of 
reduction of  1.5  0.5  0.2 
rCDP  32 ± 3  14  7 
rADP  28 ± 3  9  10 
rGDP  24 ± 5  11  4 
In these experiments, the dNTPs were added to 10 µM each and ATP was added to 2.5 
mM. Experiments done at 1.5 mM HU were done in duplicate. The results of these 
experiments are reported as the mean ± (range/2). 78 
Discussion
 
This chapter describes experiments designed to test the idea that the allosteric state of 
RNR is directly related to the HU sensitivity of the enzyme. The results obtained from 
both the spectroscopic method and four-substrate assay appear to indicate that the 
sensitivity of vaccinia RNR was not dependent on the identity of the bound dNTP. 
However, the decay rates of the chromophore at 417 nm measured using the spectroscopic 
method suggest that the sensitivity of the enzyme was directly proportional to the overall 
enzymatic activity. That is, when the enzyme was activated to reduce substrate by the 
binding of allosteric effectors, it was more susceptible than when no effectors were bound. 
Furthermore, when substrate was supplied, the enzyme became even more susceptible to 
the radical scavenger. These results are consistent with similar studies done on the E. coli 
RNR in which the rate of inhibition was determined by measuring the rCDP reductase 
activity remaining after treatment with HU (Karlsson et al., 1992). The repeatability and 
sensitivity of the spectroscopic method was greatly limited by the low solubility of vaccinia 
R1 and the variable radical and iron content of R2. In order to have a reasonable 
absorbance change (usually 0.04-0.05 absorbance units), the radical/iron-oxo concentration 
was required to be approximately 101.1M. The radical content of the purified R2 used in 
these experiments ranged from 30-50% (2 radicals per R2 equals 100%). Therefore, these 
experiments required 10 to 15 j_tM R2. In order to assure that a majority of the R2 was 
bound in the holoenzyme form, an excess of R1 was required. The molecular weight of 
vaccinia R1 dimer is 175 kDa and thus, a 20 [tM solution of R1 corresponds to 3.4 
mg/ml. Routinely, the vaccinia R1 protein would precipitate from solution when the 
concentration went much above 2 to 3 mg/ml. Therefore, in order to get enough sensitivity 
from this technique, I was constantly working on the fringe of the R1 solubility limit. To 
increase the solubility of R1, numerous buffer conditions were used, including various 
types and concentrations of buffer salts, dithiothreitol concentrations from 1 to 50 mM, 79 
addition of nucleotide effectors, and addition of the vaccinia R2 during the concentration 
step. None of these conditions significantly improved the solubility of vaccinia R1. The 
results obtained by this technique were further complicated by the R2 radical and iron 
content, which varied with each preparation. 
When no effectors were added to the protein solutions, the presence of R1 seemed to 
protect R2 from HU compared to the rate of chromophore decay when no R1 was present. 
Although this finding is interesting, it may have no physiological significance since within 
the cell the holoenzyme is probably always in contact with some level of dNTPs. From the 
standpoint of the electron transport system, the series of residues proposed to be involved 
in the transfer of the catalytic electron between R1 and R2, the result is especially 
intriguing. However, the decay rates determined without the addition of nucleotides had 
the largest variability. A possible contribution to this variability may be the presence of 
different levels of residual nucleotide in the R1 samples. A relatively high concentration of 
ATP (75 mM) was used to elute the R1 protein from the affinity column during the 
purification. Therefore, there was probably some residual nucleotide remaining in the R1 
preparation despite attempts to remove it. The removal of nucleotide from the purified R1 
was made technically difficult by the tendency of the protein to precipitate from solution. 
Again, the finicky solubility of vaccinia R1 proved to be a problem for the repeatability of 
the spectroscopic technique. 
Similar to the radical decay experiments, the results from the four-substrate assay 
showed no obvious difference in the HU-sensitivity of any of the RNR enzyme activities. 
Table 2.1 shows the amount of each RNR activity inhibited by HU when only the general 
allosteric activator, ATP, was present in the reaction mix. This set of experiments was 
designed to function as a control. The assumption I made was that no differential 
sensitivity should be observed in these experiments since ATP was the only allosteric 
effector present and therefore, RNR should be in essentially one conformation. Although 80 
this assumption may or may not be valid, the results show that none of the activities are 
statistically more sensitive to HU than any others. 
Table 2.2 shows the results of experiments designed to mimic the radical decay 
experiments. The decrease in each activity after HU treatment is tabulated in columns 
according to which dNTP was added to the reaction mix (ATP was also present in these 
experiments at 2.0 mM). These experiments were performed in the presence of a single 
dNTP m order to test the sensitivity of each activity while RNR was activated to 
preferentially reduce a specific substrate. The assumption was that if a certain dNTP 
effector produced a conformation which was especially sensitive to HU, then this should 
be apparent from the percentage of inhibition for that activity relative to the control. 
However, within the experimental error, none of the effectors made any of the enzyme 
activities more or less sensitive to HU. 
The four-substrate assay proved to be a nice system for these studies because it allowed 
the HU-induced changes in each of the individual turnover rates to be monitored while the 
enzyme was exposed to any combination of nucleotides desired. This enabled me to look 
for differential sensitivity within an allosteric environment designed to be similar to what 
the enzyme may be exposed to in vivo. Under these conditions, this assay provides a 
relatively good in vitro approximation of the in vivo system we seek to explain. Table 2.3 
summarizes the four-substrate assay results from experiments done in an in vivo-like 
nucleotide environment consisting of the allosteric effectors ATP, dATP, dGTP, and 
dl IP. As these data indicate, none of the RNR activities seem to be statistically more or 
less sensitive to HU inhibition at the concentrations tested. 
Although the results from these studies suggest that none of the activities of RNR are 
differentially sensitive to HU, it is still quite possible. I may have not been able to detect 
the difference in sensitivity because of the time scale of my experiments. The four-
substrate assay indicates only the extent of inhibition which has occurred several minutes 
after the addition of drug. If the enzyme is differentially sensitive to HU, evaluation of the 81 
inhibition at very short time points may be required in order to detect the difference. This 
may be necessary since the allosteric effectors rapidly equilibrate between the enzyme-
bound and unbound states on a time scale several orders of magnitude less than the time 
scale of the experiment. When several effectors are present, the enzyme probably 
undergoes rapid conformational changes as different nucleotides bind to the allosteric sites. 
By the time the experiment has been completed, any short term differential effects may 
become undetectable as the enzyme rapidly converts between less sensitive and more 
sensitive allosteric states. 
Relevant to this discussion, there may be another very important distinction between the 
in vivo and in vitro behavior of the HU-mediated radical decay. In E. coli, it has been 
demonstrated that there is an enzyme system, composed of a flavin reductase and a second 
poorly defined protein fraction, which is capable of regenerating the tyrosyl radical (Coves 
et al., 1993). An E. coli strain lacking the flavin reductase component is more sensitive 
than wildtype to HU treatment, indicating that this enzyme system provides a protective 
function against loss of the tyrosyl radical. Furthermore, it has been suggested that this 
system may play a role in regulating RNR activity by controlling the radical content of 
protein R2 (Fontecave et al., 1989). If eukaryotic cells possess a similar system, which is 
likely, then during HU treatment there may be a competition between radical decay and 
enzymatic radical regeneration. In this case, the increased inhibition of any enzyme activity 
which is associated with a more sensitive conformer may become evident only after enough 
time has passed for the cycle of decay and regeneration to repeat numerous times. This 
may be especially relevant if the relative sensitivities of the four reactions differ only 
slightly. 
If the results of these in vitro studies on the susceptibility of RNR also apply to the 
behavior of the enzyme in vivo, then an alternate explanation for the observed dNTP pool 
changes is necessary. One possible explanation involves the activities of several enzymes 
and therefore, a brief review of deoxyribonucleotide metabolism may aid this discussion. 82 
A surprising feature of dNTP metabolism is its dynamic nature. Once formed, the 
dNTPs do not remain in a static pool, sequestered somewhere in the cell, waiting to be 
utilized for DNA synthesis. Instead, the dNTP pools appear to undergo a continuous cycle 
of synthesis and degradation which results from the interplay between the de novo 
synthetic pathway and the activities of catabolic and salvage enzymes. For example, in 
mouse 3T6 fibroblasts the half-lives for the turnover of the dATP and dTTP pools are 4 
and 5 minutes, respectively (Bianchi et al., 1992; Nicander and Reichard, 1985a). Much 
of this turnover in cultured cells, at least in the case of pyrimidine dNTPs, results in the 
excretion of the nucleotide breakdown products into the surrounding media. In 
exponentially growing 3T6 cells for example, 28% of the de novo-synthesized dCDP is 
degraded to the nucleoside and excreted (Nicander and Reichard, 1985b). 
Figure 2.8 shows the overall metabolism of deoxyribonucleotides in mammalian cells. 
Metabolism of deoxyribonucleotides can be separated into three distinct pathways, the de 
novo pathway, the salvage pathway, and a catabolic pathway. In the first reaction of the de 
novo synthesis of deoxyribonucleotides, rNDPs are reduced by RNR to the corresponding 
dNDPs. The dNDPs rapidly equilibrate, through the action of several nucleotide kinases, 
between the mono- and triphosphate deoxyribonucleotides. Although the concentration of 
a particular deoxyribonucleotide may vary considerably depending on the particular 
conditions, the ratio between the mono-, di-, and triphosphate deoxyribonucleotides 
remains relatively constant (Reichard, 1988). Therefore, as dNTPs are removed from the 
nucleotide pool for the synthesis of DNA, a net phosphorylation of the dNMP pool allows 
the equilibrium to be maintained. 
As well as being phosphorylated to the triphosphate level, dNMPs can be 
dephosphorylated to their corresponding deoxyribonucleosides by the action of specific 5'­
nucleotidases. In general, the relative activities of these nucleotidases towards a given 
dNMP are directly proportional to the concentration of that nucleotide (Reichard, 1988). 
Once formed, the deoxyribonucleosides have many possible fates. Deoxyribonucleosides 83 
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Figure 2.8 Overview of deoxyribonucleotide  metabolism. 84 
may be cleaved to the nucleobase and deoxyribose-l-phosphate by nucleoside 
phosphorylases. Various pyrimidine-nucleoside phosphorylases cleave deoxyuridine 
(dUrd) and dThd, and purine-nucleoside phosphorylase (PNP) cleaves deoxyinosine 
(dIno) and dGuo. Loss of the catabolic activity of PNP in human lymphocytes results in 
elevated concentrations of the purine dNTPs to levels capable of inhibiting T cell 
proliferation. This results ultimately in a form of immunodeficiency (Zannis et al., 1978). 
Generally, dAdo and to a lesser extent dCyd are enzymatically deaminated to dIno and 
dUrd, respectively, before being cleaved by nucleoside phosphorylase (Plagemann and 
Erbe, 1973a). Deoxyadenosine is readily deaminated by adenosine deaminase (ADA), and 
the resulting dIno may then be further degraded by PNP. In most mammalian cells, the 
activity of ADA is high, which keeps the intracellular concentration of dAdo low. Similar 
to the PNP deficiency, a lack of ADA activity also results in an immunodeficiency 
syndrome (Daddona and Kelley, 1977). This form of immunodeficiency, called severe 
combined immunodeficiency syndrome (SCIDS), is associated with an elevated 
concentration of dATP in lymphocytes. The accumulation of dATP in these cells 
presumably blocks the de novo synthesis of deoxyribonucleotides, resulting in the 
inhibition of B and T lymphocyte proliferation. 
As stated earlier, a significant amount of nucleosides produced from the breakdown of 
de novo synthesized deoxyribonucleotides are excreted into the culture medium. 
Deoxyribonucleoside-specific permease proteins facilitate the reversible transfer of 
nucleosides across the cell membrane. The transfer process appears to be a form of 
facilitated diffusion and therefore, the transport of deoxyribonucleosides flows along any 
concentration gradient which may form as dNTP metabolism changes (Plagemann et al., 
1988). In general, the transfer of the pyrimidine deoxyribonucleosides is more efficient 
than the transfer of the purine deoxyribonucleosides. This fact is reflected in the apparent 
Kms for the transport process which are one to two orders of magnitude lower for the 
pyrimidine deoxyribonucleosides (Plagemann and Erbe, 1973b). In mammalian cells, the 85 
excretion rate of the purine deoxyribonucleosides, in particular dAdo, is much less than the 
corresponding rate for the pyrimidine deoxyribonucleosides. The excretion of dAdo from 
most cultured cells may be negligible because of the high activities of enzymes, like ADA, 
which catabolize the purine deoxyribonucleosides (Plagemann and Erbe, 1973b). In 
human lymphoblasts and hamster fibroblasts, for example, only 0.05 and 4.0%, 
respectively, of the dATP synthesized from the reduction of rADP is excreted into the 
media (Bianchi et al., 1994). Instead of being excreted as dAdo, this deoxyribonucleoside 
is quickly deaminated to dIno which is then excreted, or cleaved to hypoxanthine by PNP. 
The hypoxanthine can be shuttled back into ribonucleotide synthesis by hypoxanthine­
guanine phosphoribosyltransferase (HGPRT), or may undergo further degradation. In 
contrast, as much as 28% of the de novo synthesized dCTP is excreted from mouse 
fibroblasts in the form of deoxyribonucleosides (Nicander and Reichard, 1985b). Most of 
this deoxycytidine is excreted in its deaminated form, leading to an accumulation of dUrd in 
the medium. In addition, high levels of dCyd and dThd may also accumulate in the media 
of cultured cells (Bianchi et al., 1986a; Nicander and Reichard, 1985b; Slabaugh et al., 
1991). 
The last fate of deoxyribonucleosides shown in Figure 2.8 is the rephosphorylation of 
the nucleoside back to the dNMP level. In mammalian cells, thymidine kinase is 
responsible for the phosphorylation of dUrd and dThd. This kinase is feedback inhibited 
by dTTP (Cheng, 1978). The other prominent deoxyribonucleoside kinase activity in 
mammalian cells is deoxycytidine kinase. This broad specificity kinase phosphorylates 
dCyd and is also the major purine deoxyribonucleoside-phosphorylating activity in 
mammalian cells (Sarup and Fridland, 1987). The Km values for the phosphorylation of 
dCyd by deoxycytidine kinase are 100-200 times less than for the phosphorylation of dAdo 
and dGuo. The enzyme is strongly inhibited by dCTP, and phosphorylation of the purine 
deoxyribonucleosides can be inhibited by dCyd (Hurely et al., 1983). The greater activity 
of these kinases towards the pyrimidine deoxyribonucleosides may explain, at least in part, 86 
why dNTP pools are more readily labeled by exogenous pyrimidine rather than purine 
deoxyribonucleosides (Plagemann and Erbe, 1973a). 
The catabolism of dNMPs by the 5'-nucleotidases and the salvage of 
deoxyribonucleosides by the nucleoside kinases represent opposing reactions, and form a 
substrate cycle which has been proposed to be a regulatory mechanism for the maintenance 
of dNTP pool size (Nicander and Reichard, 1985b). The regulation of the de novo 
pathway through allostery of enzymes like RNR is well appreciated as a means for 
maintaining the proper levels of the dNTPs. In addition to this regulation, the ratio of the 
deoxyribonucleosides and their corresponding monophosphates may also play a significant 
role in maintaining proper levels of the dNTPs. The cycle of phosphorylation and 
dephosphorylation is schematically illustrated in Figure 2.9. 
According to the substrate cycle proposal, the balance between these two opposing 
reactions sets the intracellular concentration of a given deoxyribonucleoside and its 
monophosphate. When dNTP pools start to drop, a net phosphorylation of the nucleoside 
pool results in an increase in the dNMP concentration (Figure 2.9, right arrow). The 
increase in dNMP concentration results in transfer of nucleotide to the dNTP pools through 
the action of the nucleoside mono- and diphosphate kinases. Thus, the drop in dNTP 
concentration is compensated for by an increased rate of flux through the phosphorylation 
phase of the substrate cycle and a decrease in the excretion of deoxyribonucleosides. When 
the utilization of dNTPs is blocked, a net dephosphorylation of the dNMP pool by the 
nucleotid se activity results in increased levels of the deoxyribonucleosides (Figure 2.9, 
left arrow). This increase in concentration is accompanied by increased catabolism and/or 
transport of the deoxyribonucleoside (or nucleobase) out of the cell. 
Support for the substrate cycle hypothesis has come from studies on mutant cell lines 
defective in some aspect of dNTP metabolism and from studies done on normal cells 
exposed to inhibitors of dNTP metabolism. Pyrimidine dNTP metabolism was studied in a 
mutant hamster V79 cell line lacking a functional dCMP deaminase, to evaluate the role that 87 
Figure 2.9 dNMP/deoxyribonucleoside substrate cycle. The cycle shown on the 
following page is proposed to function as a regulator of dNTP metabolism through the 
action of two opposing reactions. The balance of these two reactions sets the intracellular 
concentration of a given nucleoside and determines whether that nucleoside will move into 
the cell, promoting the synthesis of dNTPs, or out of the cell, promoting dNTP 
degradation. Deoxyribonucleosides are phosphorylated by the nucleoside kinases, whose 
activities are allosterically regulated by their respective dNTPs. The activities of the 5'­
nucleotidases, which catalyze the opposing reaction, depend largely on the concentration of 
the dNMP substrate. The equilibrium of the substrate cycle is also affected by the activities 
of other catabolic and salvage enzymes. For instance, the deaminases and phosphorylases 
catalyze the degradation of deoxyribonucleosides, thereby increasing the excretion of 
nucleosides and nucleobases. The nucleotide kinases promote the anabolism of 
nucleosides, resulting in a net increase in the import of extracellular deoxyribonucleosides. 88 
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substrate cycles play in compensating for the lost enzyme activity (Bianchi et al., 1987). 
Normal V79 cells derive more than 80% of their dTTP from the deamination of dCMP. 
Not surprisingly then, the dCMP deaminase-minus mutants had a significantly lower dTTP 
pool and an elevated dCTP pool. The elevated dCTP pool can be explained by the 
decreased conversion of dCMP to dUMP and to an increase in the rCDP reducing activity 
resulting from a decrease in the dTTP- mediated inhibition of RNR. The changes in the 
dNTP concentrations which were observed in these mutant cells were accompanied by an 
increase in the rate of dCyd excretion and a corresponding increase in the rate of dUrd 
uptake from the media. According to the hypothesis, the uptake of dUrd and excretion of 
dCyd results from an attempt by the substrate cycle to compensate for the dNTP pool 
changes through adjustments of the dNMP/deoxyribonucleoside ratio.When mouse 3T6 
fibroblasts were treated with aphidocholin, the resulting block in DNA synthesis did not 
change the turnover rate of the pyrimidine dNTPs, but did increase the rate of dThd 
excretion (Nicander and Reichard, 1985a). Therefore, although DNA polymerization had 
stopped in these cells, dTTP was still being synthesized. According to the substrate cycle 
hypothesis, the increased excretion of dThd was a direct result of the increased flux of 
dI IP through the catabolic phase of the cycle. In this way, the substrate cycle can 
compensate for the decreased utilization of dTTP by DNA polymerase. 
When the de novo synthesis of dNTPs was blocked in 3T6 cells by treatment with 
hydroxyurea, the flux of pyrimidine deoxyribonucleotides through the substrate cycle was 
reversed relative to the case above in which DNA polymerase was inhibited by 
aphidocholin. Under these conditions, the turnover of the pyrimidine dNTP pools 
decreased 5- to 50-fold due to a significant drop in the rate of dNTP degradation. In these 
cells, the dCTP pool was maintained by a net influx of dCyd from the medium, and the 
dITP pool was fed by a net influx and phosphorylation of dUrd in addition to the 
continued deamination of the deoxycytidine nucleotide pool (Nicander and Reichard, 
1985a; Bianchi et al., 1986b). 90 
When 3T6 cells are treated with HU, the dNTP pools are depleted in a manner similar 
to the changes which occur in vaccinia-infected cells. In both cases, HU treatment 
primarily depletes the purine dNTPs, especially dATP, and to a lesser extent reduces the 
dCTP pool. The dTTP pool, on the other hand, increases to 150% and 200% of controls 
in 3T6 and vaccinia-infected BSC40 cells, respectively. One explanation which has been 
proposed to explain these dNTP pool changes in HU-treated 3T6 cells centers around the 
substrate cycle hypothesis (Bianchi et al., 1986a). According to this explanation, the dTTP 
pool continued to increase after HU treatment because the pool was fed by a net influx and 
phosphorylation of dUrd. In addition, the deamination of dCMP followed by the action of 
thymidylate synthase maintained the anabolic flux of pyrimidine deoxyribonucleotide into 
the d'1 '1'P pool. An influx of dCyd from the medium contributed to the maintenance of the 
dCTP pool. Therefore, when the de novo synthesis of deoxyribonucleotides is blocked, 
the substrate cycles respond by increasing the flux through the salvage phase of the cycle in 
an attempt to compensate for the decreasing dNTP concentrations. However, this response 
is capable of replenishing the pool only if the deoxyribonucleoside substrate is available for 
phosphorylation. The levels of the purine deoxyribonucleosides in the media, which by 
many accounts may approach zero (Plagemann and Erbe, 1971a; Reichard, 1988; 
Plagemann et al., 1988), are too low to support any appreciable salvage-mediated synthesis 
of dATP or dGTP. The high rate of purine deoxyribonucleoside catabolism effectively 
reduces the concentrations of dAdo and dGuo and therefore, when dNTPs are measured in 
HU treated cells these pools appear to be depleted to the greatest extent. 
A complication arises when one attempts to extend this explanation to the HU-induced 
dNTP pool changes in vaccinia-infected cells as observed by Slabaugh et al., (1991). In 
these experiments, the culture medium was replaced with fresh medium containing dialyzed 
fetal calf serum at the time that HU was added. Presumably then, any 
deoxyribonucleosides that had accumulated in the medium prior to the addition of HU 
would have been removed from the extracellular environment at the same time that the de 91 
novo synthesis was being inhibited. This fact seems to suggest that a mechanism other 
than the substrate cycle hypothesis may be responsible for the observed HU-induced dNTP 
pool changes observed in these studies. This led to a suggestion that perhaps HU 
preferentially inhibits the reduction of the purine rNDPs, especially the reduction of rADP. 
However, Slabaugh and coworkers performed another experiment in conjunction with 
the dNTP pool measurements that gave results which seem to contradict the notion that the 
medium was free from deoxyribonucleosides. In an effort to measure the effects of HU on 
the in vivo flux through RNR, vaccinia-infected cells were treated with HU and then 
exposed to a tracer amount of tritiated ribonucleoside ([3H]Cyd, [3H]Guo, or [3H]Ado). 
Like in the dNTP pool determinations, the media was changed at the point of HU treatment 
and then again when labeled ribonucleoside was added. After a labeling period of 1 hour, 
the cells were harvested and the infra- and extracellular fractions were examined to 
determine how much of the labeled ribonucleoside was converted to deoxyribo-containing 
molecules, and where in the cell these molecules ended up. At the lower HU 
concentrations, tritium was found in viral DNA and in the dNTP pools. However, when 
the media was tested for the presence of label an interesting fording was made. When the 
tritiated purine ribonucleosides were used to label the deoxy pools, no evidence of excreted 
breakdown products like [3H]dAdo or [3H]c1Guo was found. In contrast, when [3H]Cyd 
was used to label the cells, more counts were present in the form of excreted dCyd and 
dUrd than were present in the viral DNA and dNTP pools combined (Slabaugh et al., 
1991; Table I). 
These findings indicate that although the medium was changed at obvious times during 
the experiment, the very dynamic nature of dNTP metabolism facilitated the rapid flow of 
nucleotide into a cycle of dNTP anabolism and catabolism resulting in excretion of 
pyrimidine deoxyribonucleosides (dUrd and dCyd). Furhermore, these experiments 
support the findings made in other mammalian cells which suggest that the catabolism of 
the pyrimidine and purine deoxyribonucleotides culminates in significantly different end 92 
products. To a large extent the pyrimidine dNTPs are degraded to the level of 
deoxyribonucleosides which are excreted in large quantities into the surrounding medium. 
A large fraction of the purine dNTPs are degraded to the nucleobase, which may then be 
further degraded or fed back into ribonucleotide metabolism. 
Although it would have been quite interesting, and exciting, to have demonstrated that 
RNR was differentially sensitive to HU, my studies suggest that it is not. Therefore, an 
explanation centered around the substrate cycle hypothesis may be a plausible alternative to 
differential sensitivity. The following points are consistent with the substrate cycle 
hypothesis as an explanation for the HU-induced dNTP pool changes observed in vaccinia-
infected BSC40 cells. 
(i) HU inhibition of viral DNA replication was reversed by the addition of dAdo and 
EHNA. Presumably, dAdo was capable of reversing the block on replication because 
dATP was the smallest dNTP pool and therefore the "limiting reagent" for DNA synthesis. 
The fact that dAdo rescue was effective only in the presence of the deaminase inhibitor is a 
very important point. According to the substrate cycle explanation, the high level of ADA 
activity in mammalian cells plays a major role in the dATP pool depression seen in HU-
treated cells. When the de novo synthesis is blocked the salvage pathway becomes an 
important source of dNTPs. Obviously, the ADA activity in vaccinia-infected cells is 
sufficiently high to deaminate the majority of dAdo present in the cell, or the addition of 
EHNA would not be required for the rescue. Therefore, when ADA is not inhibited, the 
deamination of dAdo effectively reduces the concentration, and hence the flux of this 
deoxyribonucleoside through the salvage pathway, to negligible levels. Furthermore, 
when dNTP levels were measured in HU-treated cells grown in the presence of dAdo and 
EHNA, the dATP pool was no longer depleted. Instead, under these conditions, the dATP 
pool remained at the level of the untreated control at all HU concentrations studied 
(Slabaugh et al., 1991; Figure 6). Finally, the lack of purine deoxyribonucleosides in the 93 
media of HU-treated and untreated cells is consistent with the high level of dAdo 
catabolism. 
(ii) The dTTP pool was elevated by HU. This result is best explained as previously 
reported (Bianchi et al., 1986a,b). Essentially, the d11P pool increased because its 
utilization was blocked, and deamination of dCMP in combination with salvage synthesis 
continued to supply the pool. If deoxyribonucleosides equilibrate across the cell membrane 
in vaccinia-infected cells as they do in other cell types, then the high concentration of dCyd 
and dUrd detected in the culture media of these cells indicates that there should be a 
significant amount of intracellular pyrimidine deoxyribonucleosides available for 
phosphorylation by the salvage kinases. 
Other factors may also contribute to the depressed dATP pool. For example, at the 
lower HU concentrations tested (0.5 and 1.0 mM), in situ assays demonstrated that 
ribonucleotide reduction continued to occur, albeit at significantly lower rates (Slabaugh et 
al., 1991; Table I). In the mammalian form of RNR, rADP reduction is stimulated by 
dGTP. I have recently determined, using the four substrate assay, that the vaccinia enzyme 
behaves in a similar manner (Hendricks and Mathews, unpublished; see Chapter 4). 
Therefore, the HU-induced depression of the dGTP pool, a pool which is significantly 
underrepresented even in untreated cells (Mathews and Ji, 1992), will result in a lowered 
activation of the rADP-reducing activity of RNR and hence, a lower relative rate of dATP 
formation. Similarly, the elevated d 1 111 pool will stimulate the rGDP-reducing activity of 
RNR. This, along with the different catabolic pathways for dAdo and dGuo, may explain 
why the dGTP pool is not depleted to the same extent that the dATP pool is. 
If the substrate cycle hypothesis is a valid explanation of the HU-induced dNTP pool 
changes, then other inhibitors which specifically target RNR should result in similar dNTP 
pool changes. Indeed, this is the case for the drug 2'-azidocytidine (N3-Cyd). This 
nucleoside analog, after phosphorylation by a nucleoside kinase, is a suicide inhibitor of 
RNR which acts by scavenging the catalytically essential radical at the active site. 94 
Exposure of 3T6 cells to N3-Cyd results in changes in the dNTP pools which are 
remarkably similar to the changes observed in HU-treated cells (Akerblom and Reichard, 
1985). Like HU, treatment with N3-Cyd results in elevated dTIP and greatly depressed 
dATP levels. In addition, both drugs decrease the dCTP pool to approximately the same 
extent. The only significant difference between the dNTPs after treatment with these drugs 
is the level of dGTP. Other RNR inhibitors have similar effects. Mimosine, a non-protein 
amino acid found in certain plants, is an iron chelator that has been shown to inhibit RNR 
in vitro. Like these other inhibitors of RNR, treatment of mammalian cells with mimosine 
results in a major reduction of the purine dNTP pools and an elevation of the dTTP pool 
(Dai et al., 1994). 
Why should dAdo be metabolized to such a great extent while the purine dNTPs are 
simply dephosphorylated and excreted? The answer may lie in the multiple roles that 
adenosine, and its nucleotides play in cellular metabolism. Adenosine acts as a 
neurotransmitter and is involved in the regulation of platelet and neutrophile functions, of 
blood flow in the heart and kidney, and of lipid biosynthesis in adipocytes (Gerlach and 
Becker, 1987). The excretion of dAdo by inappropriate cells, or at inappropriate times, 
could possibly wreak havoc on the signaling systems used by that organism. Therefore, 
since the progenitor of each cell type discussed in this chapter was once part of a 
multicellular organism, evolution has probably selected against the excretion of intact dAdo 
by these cells. 95 
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Summary
 
We have devised an assay procedure that permits simultaneous monitoring of the four 
activities of ribonucleotide reductase. Using this assay, we have compared the reduction of 
all four substrates by the T4 bacteriophage aerobic ribonucleotide reductase within different 
allosteric environments. Specifically, we compared the relative turnover rates of the 
enzyme when activated with "in vivo" concentrations of the known allosteric effectors 
versus activation by ATP alone. Consistent with the known allosteric properties of this 
form of ribonucleotide reductase, our results show that ATP does act as a general activator, 
although the rate of purine nucleotide reduction was approximately five percent of the rate 
for the pyrimidine nucleotides. However, addition of the allosteric effectors at their 
estimated physiological concentrations dramatically changed the relative rates of substrate 
reduction, creating a more "balanced" pool of products. Addition of the substrates at their 
respective "in vivo" concentrations further pushed rates of product formation towards a 
ratio similar to the base composition of the T4 genome. The similarity of the product 
profile produced under "in vivo" conditions to the genomic composition of T4 phage is 
discussed. 99 
The first committed step in DNA biosynthesis occurs by direct reduction of the 2'­
hydroxyl of ribonucleotides and is catalyzed by the enzyme ribonucleotide reductase. 
Because this single enzyme is responsible for the production of all four deoxyribo­
nucleotides, and because these products are needed only at specific times in cell or viral life 
cycles, ribonucleotide reductase is highly regulated in both substrate specificity and overall 
activity. 
The allosteric properties of the enzyme, as well as the kinetic parameters for all four 
rNDP substrates, are well characterized for the T4 phage aerobic ribonucleotide reductase 
(Berglund, 1972), and are similar to those of the prototypical enzyme from Escherichia 
coli. However, to our knowledge, no studies have been done to determine what the 
simultaneous turnover rates for each of the substrates are under different concentrations, 
and combinations, of the enzyme's allosteric effectors and substrates. Of particular interest 
to our laboratory is the relative rates of formation for each of the four products when the 
effector and substrate environment of the enzyme is designed to mimic the in vivo 
conditions as measured in T4 phage-infected E. coli (Mathews, 1972; Neuhard and 
Nygaard, 1987). In other words, when the known allosteric effectors and substrates are 
supplied together in a single reaction mixture at their estimated physiological or "in vivo" 
concentrations, what are the relative rates of formation for each of the products? This 
question is of particular interest, because in vivo, T4 ribonucleotide reductase functions as 
part of an enzyme complex (Mathews, 1993) and one must consider the possibility that 
intracellular reaction fluxes are controlled by protein-protein interactions. 
Typically, ribonucleotide reductase has been assayed by using only one of the 
substrates because analysis of the simultaneous turnover of all four substrates by the 
enzyme was not possible with existing methods. The ability to follow the reduction of all 
substrates simultaneously and in a quantitative way, under various conditions, was the goal 
of this method development. We describe such an assay and its application to the T4 100
 
bacteriophage aerobic ribonucleotide reductase, in which the product profile was 
determined under different allosteric states. 
The key requirement of this assay is the quantitative resolution of the dNDP products 
from the rNDP substrates and nucleoside triphosphate effectors (ATP, dATP, dGTP, and 
d'ITP). This task is accomplished in two chromatographic steps. The first step involves 
separation of the deoxyribonucleotides from the ribonucleotides using boronate affinity 
chromatography. Molecules containing cis-diols readily bind to boronate affinity resins at 
basic pH by forming a complex between the vicinal alcohols of the ribose ring and boric 
acid functional groups. Thus, when a mixture of ribo- and deoxyribonucleotides is applied 
to a boronate column the deoxyribonucleotides pass through while the ribonucleotides are 
retained. This type of affinity chromatography is frequently used to separate dNTPs from 
rNTPs derived from cell lysates when doing dNTP pool assays (Shewach, 1992). In the 
second step, the boronate column eluate containing the deoxyribonucleotides is resolved 
into individual components by HPLC. The HPLC step utilizes a strong anion exchange 
column and an ammonium phosphate gradient to resolve the individual 
deoxyribonucleotides into quantifiable peaks. 
Materials and Methods 
Enzyme Assay Conditions The enzyme assay procedure was modified from what we 
used previously (Slabaugh and Mathews, 1984). Briefly, assays were performed in 50 
mM HEPES-KOH buffer (pH 8.2) containing: 5 mM magnesium chloride, 50 mM 
dithiothreitol, and 20 pM ferrous ammonium sulfate (prepared fresh). Assays done under 
"in vivo" conditions refer to enzyme reactions carried out with the following effector and/or 
substrate concentrations as measured in Mathews, 1972 and Neuhard and Nygaard, 1987: 
ATP, 2.7 mM; dATP, 175 gM; dTTP, 80 gM; dGTP, 125 4M; CDP, 80 p.M; UDP, 90 
1.tM; ADP, 250 pM; GDP, 130 [t.M. The concentration of the holoenzyme was typically 101 
0.25 µM unless otherwise indicated. The volume of each aliquot removed for assay was 
1004 The reaction was stopped by addition of 5 IA of 50% perchloric acid. Immediately 
after the addition of acid, the sample was vortexed and placed on ice. After 5 minutes on 
ice, KOH was added until the pH was between 8 and 9 (6-7 !al of 5 M KOH). The 
resulting suspension was then clarified by centrifugation and the supernatant recovered and 
analyzed by boronate affinity chromatography followed by HPLC, as described below. 
Boronate Chromatography Boronate affmity chromatography was performed 
essentially as described by Shewach, 1992. Briefly, hydrated Affi-Gel 601 (Bio-Rad) was 
packed into a 1-ml plastic tuberculin syringe fitted with a frit. The column was equilibrated 
with 50 mM NH4HCO3 buffer, pH 8.9, containing 15 mM MgC12 (buffer A). Precise 
volumes of concentrated NH4HCO3 and MgC12 solutions were added to the reaction 
mixture supernatant to 50 and 15 mM final concentrations, respectively, followed by 
addition of 100 p1 of buffer A. The resulting 200-m1 sample was applied to the boronate 
column and the first 200 p1 of eluate was discarded. The next 1.8 ml of eluate was 
collected while washing the column in buffer A. This volume of eluate was shown to 
contain <95% of the dNDPs present in the original sample (see Appendix V). It should 
also be noted that the rNDPs were retained by the boronate column better than the rNTPs. 
The 1.8-ml eluate was acidified to pH 3-4 with H3PO4 followed by HPLC analysis. 
Ion-exchange HPLC analysis Deoxyribonucleotide products were quantitated by 
HPLC using a Rainin HPLC system with detection at 260 nm. The boronate column eluate 
was loaded onto a 500-m1 loop and injected onto a PartiSphere-10 SAX column (4.6 x 25 
mm; Whatman Lab Sales) equilibrated in 0.15 M ammonium phosphate, pH 3.7. 
Deoxyribonucleotides were eluted with a biphasic gradient of ammonium phosphate buffer 
ranging in concentration from 0.15 to 0.80 M (pH 3.7) at a flow rate of 1.5 ml/min. The 
deoxyribonucleotides were identified on the basis of retention times and quantitated on the 
basis of peak area by comparison to authentic standards. 102 
Induction and Purification of the T4 Ribonucleotide Reductase E. coli strain MV1304 
carrying the cloned genes for both subunits of the T4 aerobic ribonucleotide reductase was 
a gift from Dr. G. R. Greenberg's laboratory. Induction of the proteins and purification of 
the holoenzyme using dATP-sepharose affinity chromatography were performed as 
described in Tseng et al., 1992. 
RESULTS 
Assay Method Validation Figure 3.1 illustrates a typical HPLC chromatogram of a 
mixture of authentic deoxyribonucleotide standards. The HPLC method gives good 
resolution of all possible ribonucleotide reductase dNDP products as well as resolution of 
the dNTPs which may be added as allosteric effectors. 
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Figure 3.1  Anion-exchange HPLC separation of dNDPs and dNTPs. A 
mixture of 500 pmol each of dCDP, dUDP, dADP, dGDP, dCTP, dTTP, dATP, and 
dGTP in a volume of 500 IA was injected onto a PartiSphere 10 SAX column and eluted 
with a biphasic gradient of 0.15 to 0.8 M ammonium phosphate buffer at a flow rate of 1.5 103 
In order to verify that the boronate column quantitatively retains ribonucleotides while 
allowing deoxyribonucleotides to elute freely, a mixture containing dCDP, dADP, dGDP, 
UDP, dGTP and ATP was prepared. One-half of the mixture was injected directly onto the 
HPLC column (see Figure 3.2A). The other half of the sample was applied to a boronate 
column, eluted as above, and then analyzed by HPLC (see Figure 3.2B). As is apparent 
from the chromatograms, the boronate column was extremely effective at binding 
ribonucleotides. This is demonstrated by the absence of UDP and ATP peaks in Figure 
3.2B. Furthermore, comparison of the area under each of the deoxyribonucleotide peaks 
between the two chromatograms showed that at least 95% of each of the dNDPs was 
recovered after the boronate step. 
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Figure 3.2 HPLC Analysis of a mixture of deoxyribo- and ribonucleotides 
before and after boronate column chromatography. Panel A, HPLC 
chromatogram of a mixture of dCDP, dADP, dGDP, UDP, dGTP (12.5 nmol each), and 
ATP (25 nmol). Panel B, HPLC analysis of the same mixture after removal of the 
ribonucleotides by boronate column chromatography. 104 
To demonstrate that the method is linear with respect to enzyme concentration, assays 
were performed using a saturating concentration of CDP and five different enzyme 
concentrations ranging from 0 to 20 lig of protein. As Figure 3.3 illustrates, the assay is 
linear within the range of enzyme concentrations used in this study. Using these data from 
the linearity experiment, we calculated the turnover number for CDP reduction under 
conditions of saturating substrate to be 0.5 sec-1. This value correlates well with the 
turnover number reported in the literature (Berglund, 1972) when DTT is the source of 
reducing equivalents for the T4 ribonucleotide reductase. 
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Figure 3.3 Linearity of CDP reduction with respect to enzyme concentration. 
Enzyme assay mixtures were incubated for 10 minutes at 37° C with varying final 
concentrations of T4 ribonucleotide reductase. CDP and ATP were added at 0.5 and 1.0 
mM, respectively. Each data point represents the average of two separate determinations. 105 
Measurement of the Simultaneous Reduction of all Four rNDP Substrates Figure 3.4 
shows the HPLC results of a typical ribonucleotide reductase assay with the reaction 
mixture incubated at 37° C and sampled at 5-minute intervals. In this particular experiment, 
the substrates and effectors were added at their "in vivo" concentrations,  as defined in the 
Materials and Methods. As the chromatograms demonstrate, the formation of each of the 
four dNDP products can be followed quantitatively over time in a single reaction mixture. 
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Figure 3.4 HPLC analysis of product formation followed over time.  100-41 
aliquots were removed from the assay mixture at 5 minute intervals, subjected to boronate 
chromatography, and then analyzed by HPLC as described in the experimental procedures. 
In this particular example the assay mixture contained "in vivo" concentrations of allosteric 
effectors and substrates. 106 
Figure 3.5 is a graphical representation of the same data after conversion of peak areas 
into nanomoles of the corresponding product. Using the initial rates of product formation, 
we calculated the percent of total product formed for each dNDP. These data, along with 
the percent of total for each product formed in assays done under different effector and/or 
substrate concentrations, are tabulated in Table 3.1. 
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Figure 3.5  Relative rates of formation of deoxyribonucleoside diphosphates. 
Graphical representation of data from Figure 3.4 after conversion of peak areas to nmol 
product. 107 
Table 3.1 Relative rates of product formation by T4 ribonucleotide reductase 
% of total product formed 
I assay conditions  dCDP  dUDP  dADP  dGDP 
ATP only  85  11  4  >1 
in vivo substrates 
in vivo effectors  48  17  28  7 
equimolar substrates 
in vivo effectors  43  14  31  12 
in vivo substrates 
% of total nucleotides in  18*  (32)**  32  18
 
T4 genome
 
*cytosine is present in T4 bacteriophage as 5-hydroxymethylcytosine 
**32% of the T4 genomic composition is thymine 
dTTP Inhibition of CDP Reduction The T4 aerobic ribonucleotide reductase, unlike 
the enzyme from E. coli, is considered to be relatively insensitive to allosteric inhibition 
(Berglund, 1972). However, studies done in our laboratory, using crude extracts from T4­
infected E. coli, have shown that CDP reductase activity is inhibited by dTTP in situ, but 
that this inhibition is lost upon purification of the enzyme (Ji et al., 1991). The basis for 
the loss of feedback inhibition may involve a number of factors, including disruption of 
protein-protein interactions within the T4 enzyme complex, or, as suggested by Peter 
Reichard in a personal communication, loss of ATP during the purification process. 
Reichard's suggestion is based on the observation that, for the purified enzyme from E. 
coli, d11P inhibition of CDP reduction occurs only when ATP is present at intracellular 
concentrations (Brown and Reichard, 1969). Using this new assay, we tested whether, in 108
 
the case of the T4 enzyme, the presence of ATP was sufficient to restore feedback 
inhibition by dTTP in vitro. Purified enzyme was mixed with either ATP and dTTP, or 
ATP alone, and the reduction of CDP was followed over time. Figure 3.6 shows the 
results of these experiments. As is evident by the similarity of the two lines, the addition of 
ATP does not sensitize the CDP reductase activity of the T4 enzyme to dTTP inhibition. 
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Figure 3.6 dTTP inhibition of CDP reduction. Purified T4 ribonucleotide reductase 
was incubated at 37° C with either ATP and dTTP (2.7 mM and 2001.1M, respectively), or 
ATP alone (2.7 mM) and the reduction of CDP was followed over time. No significant 
difference in the rate of CDP reduction was evident in these experiments. 109
 
Discussion
 
This paper presents a novel method for the simultaneous assay of all four 
ribonucleotide reductase activities. More important, using this assay, we have determined 
how the simultaneous rates of these individual activities are influenced by the initial 
substrate concentrations and allosteric environment of the enzyme. To our knowledge, this 
represents the first study of this kind on ribonucleotide reductase and presents a new way 
of evaluating the role of the enzyme in regulating the levels of the DNA precursors. 
Consistent with the known allosteric properties of the T4 aerobic ribonucleotide 
reductase (Berglund, 1972), our results show that ATP does act as a general allosteric 
activator for all four substrates, although pyrimidine nucleotide reduction greatly exceeded 
reduction of the purine nucleotides. When ATP was present as the only allosteric effector 
and the substrates were supplied at "in vivo" concentration levels, the reduction of GDP 
and ADP represented less than 5% of the total reaction flux (Table 3.1, row 1). 
When the four ribonucleotide reductase activities were measured with the enzyme under 
"in vivo" allosteric conditions, dramatic changes in the product profile, or relative amounts 
of each product formed, were observed. When the "in vivo" levels of the nucleoside 
triphosphate effectors were supplied to the enzyme along with equimolar amounts of the 
four rNDP substrates (0.1 mM each), the percent of purine reduction increased to 35% of 
the total (Table 3.1, row 2). Even more interesting were the results obtained when both the 
effectors and the substrates were supplied to the enzyme at their respective "in vivo" 
concentrations (Table 3.1, row 3). Under these conditions, the amount of purine reduced 
increased to 43% of the total product formed, closely approaching the 50% expected in 
dsDNA. Of the purine nucleotide reduced in this experiment, dADP represented 31% of 
the total product formed. This is in surprisingly good agreement with the 32% adenine 
present in the T4 genome. The rate of formation of the other purine, dGDP, was lower 
than predicted from the genomic composition of guanine in T4 (12% vs. 18%). This was 110 
true even though the Km for GDP is almost identical to the Km's for CDP and ADP when 
the prime effectors are present (Berglund, 1972). Low GDP reduction rates may simply be 
an inherent property of Class I ribonucleotide reductases and this may explain, at least in 
part, why the dGTP pools in many cell types are underrepresented (Mathews and Ji, 
1992). It is also possible that the estimated "in vivo" effector and/or substrate 
concentrations used in these experiments do not faithfully represent the true concentrations 
sensed by the enzyme in vivo. 
Formation of dCDP occurred at a much higher rate than that expected from its percent 
contribution to the T4 genome. This may be explained by the fact that a significant portion 
of the dCDP produced by ribonucleotide reductase is shuttled into the production of 
thymine nucleotides via deamination of the cytosine base. If ribonucleotide reductase does 
produce products in proportions relative to the proportions seen in the genome, then we 
would predict from these data, since all hydroxymethylcytosine nucleotide must come CDP 
reduction, that approximately one-half of the total dCDP produced under "in vivo" 
conditions, or approximately 21% of the total product produced, would be diverted into the 
thymine nucleotide pathway. The diverted dCDP, after the action of enzymes including 
dCMP deaminase, combined with the dUDP produced directly by ribonucleotide reductase, 
make up 35% of the total deoxyribonucleotide produced. This fits well with the 32% 
thymine present in the T4 genome. The flux of dCDP through dCMP deaminase predicted 
from these experiments suggests that roughly 65% of the total thymine pool results from 
cytosine deamination. This is remarkably close to thymine production in the T4 host, E. 
coli, in which 75% of the dTTP is derived from CDP reduction (Molgaard and Neuhard, 
1983). The remaining portion of dCDP which is not shuttled into the thymine pathway 
represents 22% of the total amount of dNDP formed. The T4 genome is composed of 18% 
hydroxymethylcytosine. Therefore, the level of dCDP that we predict is not shuttled into 
thymine biosynthesis is sufficient to fulfill its contribution to the T4 genome. 111
 
The significance of this work is twofold. First, we describe a new assay procedure that 
is applicable to any ribonucleotide reductase, including the anaerobic rNTP reductases, 
which is relatively simple to carry out, and which permits simultaneous monitoring of the 
four activities of the enzyme. Since the creation of DNA precursor imbalances by drugs 
which specifically target ribonucleotide reductase are well documented (Bianchi et al., 
1986; Slabaugh et al., 1991) and are important clinically (Lori et al., 1994), the procedure 
should prove useful in evaluating therapeutically significant ribonucleotide reductase 
inhibitors. Second, we applied this assay to the T4 phage aerobic rNDP reductase, an 
enzyme whose allosteric control features are still not well understood. Berglund's original 
studies on the purified enzyme suggested that it is relatively insensitive to allosteric 
inhibition. More recently, our laboratory showed that in vivo and in crude preparations, 
the CDP reductase activity of the enzyme is sensitive to dTTP, suggesting the presence of 
regulatory factors that might be removed during enzyme purification. The present study, 
carried out with purified recombinant enzyme, shows that in the presence of near-
physiological concentrations of substrates and effectors, the enzyme functions at relative 
rates that correspond closely to in vivo reaction fluxes. Thus, while the enzyme might be 
regulated in part by protein-protein interactions as part of its functioning within the dNTP 
synthetase complex, adequate information for modulating its four activities is built into the 
structure of the protein itself. 112 
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Chapter 4 
Allosteric Regulation of the Ribonucleoside Diphosphate
 
Reductase from Vaccinia Virus
 
Stephen P. Hendricks and Christopher K. Mathews 114
 
Summary
 
This chapter describes experiments that examine the effects of nucleotide effectors and 
substrates on the relative turnover rates of the four activities of vaccinia virus ribonucleotide 
reductase (RNR). When individual nucleoside triphosphates were added to the vaccinia 
RNR, the substrate specificity and overall activity were modulated in a manner similar to 
the allosteric behavior of the mammalian enzymes. Specifically, dTTP activated rGDP 
reduction, dGTP activated rADP reduction, and ATP acted as a general allosteric activator. 
Furthermore, the four activities of the vaccinia RNR were strongly inhibited by dATP. 
This result is contrary to the allosteric behavior of RNR from other large DNA viruses, like 
T4 and herpes, which are relatively insensitive to dATP inhibition. These data indicate that 
the allosteric regulation of the vaccinia RNR closely resembles that of the host cell enzyme 
and is therefore a good model for the study of mammalian RNR allostery. 
In addition to the effects of individual allosteric effectors, the influence of complex 
nucleotide environments on the relative rates of rNDP reduction were examined. For 
example, physiological mixtures of the known effectors and substrates were added to the 
assay mixture to determine how the vaccinia enzyme behaved under in vivo-like conditions. 
Similar to what was found for the T4 enzyme, these experiments indicate that the presence 
of physiological concentrations of the effectors and substrates promote the production of 
dNDPs in a ratio that approximates the nucleotide composition of the vaccinia genome. 
Finally, this report includes two additional observations that are related to the regulation 
of RNR activity. Evidence is presented that the substrates, and possibly the products, of 
RNR are also involved in regulating enzyme activity. In addition, data are presented 
demonstrating that a chimeric form of RNR, composed of vaccinia R1 and mouse R2, is 
catalytically active. To my knowledge, this is the first report of an active chimeric RNR 
holoenzyme. 115
 
Introduction 
The allosteric regulation of RNR is well characterized for several forms of the enzyme 
(Larsson and Reichard, 1966a,b; Berglund, 1972; Eriksson et al., 1979; Chang and 
Cheng, 1979; Eliasson et al., 1996). The three classes of RNR, although very different in 
structure, have very similar allosteric behavior in terms of substrate specificity. In all 
classes, ATP, and dATP when it is not inhibitory, activate reduction of the cytidine and 
uridine ribonucleotides. Reduction of adenosine and guanosine ribonucleotides are 
stimulated by dGTP and dTTP, respectively. 
However, due primarily to the limitations of the traditional RNR assay method, only 
the isolated effects of individual allosteric effectors have been determined. With the advent 
of the four-substrate assay (Hendricks and Mathews, 1997), the effects of more complex 
nucleotide environments on substrate turnover rates can be examined. In addition, other 
factors that influence the relative turnover rates, such as protein-protein interactions, can be 
evaluated by this technique. This chapter describes the effects of different concentrations 
and combinations of nucleotide effectors and substrates on the vaccinia virus RNR, and 
further illustrates the utility of the four substrate assay. 
Materials and Methods 
Overexpression and Purification of Recombinant Subunits Both subunits of vaccinia 
ribonucleotide reductase were previously cloned into WIG-inducible pET expression 
vectors and were overexpressed as described (Slabaugh et al., 1993; Howell et al., 1992). 
The mouse R2 expression system was a gift from the laboratory of Lars Thelander, 
University of Umea. Overexpression of the mouse R2 was performed according to the 
procedure used to express the vaccinia R2. The mouse R2 clone contains two selectable 116 
markers encoding drug resistance gene products and therefore the addition of 25 µg/ml 
chloramphenicol was required in conjunction with 1001.1g/m1 ampicillin. 
The purification procedure for the vaccinia R2 subunit was essentially as reported 
(Howell et al., 1992) except for the incorporation of an additional radical reactivation step. 
Mouse R2 was purified by using the same procedure used to purify the vaccinia R2. 
Purification of the vaccinia R1 protein was performed using dATP-Sepharose affinity 
chromatography. Details for preparing dATP-Sepharose can be found in Appendix H. 
Routinely, 3-5 g of cells containing overexpressed vaccinia R1 was lysed in a French press 
and centrifuged at 12,000 rpm for 20 minutes. The clarified lysate was filtered and applied 
to a column packed with 1.0 ml of dATP-Sepharose resin previously equilibrated with 
buffer composed of 50 mM N- [2- hydroxyethyl ]piperazine- N' -[2- ethanesulfonic acid] 
(HEPES), 100 mM KC1, and 1mM dithiothreitol (DTT), pH 8.2. After washing the 
column back to baseline with buffer (-100 ml), a 7.0 ml-wash of column buffer containing 
5 mM ATP was used to elute any E. coli R1 or other bound proteins resulting from the 
expression system. Finally, the recombinant vaccinia R1 protein was eluted with column 
buffer containing 75 mM ATP. Centricon-30 centrifugation devices (No. 4209; Amicon 
Inc., Beverly, MA) were used to remove the ATP used in the elution step, and concentrate 
the purified Rl. All steps of the purification were performed on ice or at 4° C. 
Ribonucleotide Reductase Four-Substrate Assay The assay is described in more 
detail in Chapter 3 (Hendricks and Mathews, 1997). Essentially, the technique is 
composed of two chromatographic steps. The first step, boronate affinity chromatography, 
separates the RNR products (dNDPs) from the substrates (rNDPs). In the second step of 
the assay, the dNDPs are resolved into individual nucleotides by high performance liquid 
chromatography (HPLC). 
The concentrations of the vaccinia and mouse R2 proteins used in these experiments 
were 2 or 4 i_tM, as indicated. In all reactions, vaccinia R1 was added to 1µM final 
concentration. ATP and DTT were present in all reaction mixtures at 2.5 mM and 50 mM, 117 
respectively. The rNDP substrates were either added at equimolar (0.15 mM each) or "in 
vivo" concentrations. The "in vivo" concentrations for rCDP, rUDP, rADP, and rGDP 
were set to 50, 250, 600, and 100 p.M, respectively. These values were based on the 
experimentally determined molar ratio of rNDPs measured in vaccinia-infected B SC40 cells 
(see below). The "in vivo" dNTP concentrations used in these assays were 15, 10 and 5 
p.M dATP, dTTP, and dGTP, respectively. These concentrations were based on dNTP 
measurements made in vaccinia-infected BSC40 cells (Slabaugh et al., 1991) which were 
determined to be 15, 10, and 5 picomoles per 106 cells of dATP, dTTP, and dGTP, 
respectively. The volume of a vaccinia-infected BSC40 cell was not determined in these 
experiments. However, nucleated mammalian cell volumes range from approximately 1 to 
3 picoliters per cell (Hauschka, 1973). For dATP, this corresponds to a concentration 
range of 5 to 15 p.M. Various dNTP concentrations within this range were used in the "in 
vivo" studies and are defined in each experiment. 
Measurement of rNDP levels in vaccinia-infected BSC40 cells Monkey kidney 
BSC40 cells were infected with vaccinia virus strain WR as previously described (Slabaugh 
et al., 1984). Cells were harvested 4 hours post infection so that the nucleotide pool 
measurements would reflect the levels that occur during peak viral DNA replication. Cell 
extracts were prepared by treating cells with 0.4 M aqueous perchloric acid (PCA). After 5 
minutes on ice, the PCA-extracted cells were pelleted by centrifugation, and the supernatant 
neutralized with NaOH (neutralization with KOH resulted in a significant loss of 
nucleotides from the soluble fraction). The extract was lyophilized to dryness and 
resuspended in 75 mM NH4H2PO4 buffer (pH 3.7) just prior to analysis. The total 
nucleotide extract was analyzed by HPLC using the anion exchange column and 
ammonium phosphate buffer system used in the four-substrate RNR assay. Peak identities 
were verified by "spiking" the extract with authentic standards. For a more detailed 
description of this procedure refer to Appendix TU. 118
 
Results 
Activation of the vaccinia RNR by the general allosteric effector, ATP Figure 4.1 
shows the HPLC results from a vaccinia virus RNR assay performed within an allosteric 
environment consisting only of the general activator, ATP. In this particular experiment, a 
reaction mixture containing 1 gIVI R1, 4 gM R2, 2.5 mM ATP, and the four rNDP 
substrates at 0.15 mM each, was sampled at 4 minute intervals and processed according to 
the assay procedure. As the chromatograms illustrate, within an allosteric environment 
consisting exclusively of ATP, the vaccinia RNR reduces primarily rCDP and rGDP. 
These conditions also gave the maximal rate of total rNDP reduction of all conditions used 
in this chapter. Typically, the specific activity of the vaccinia RNR, measured using the 
four-substrate assay, was on the order of 80 nmol dNDPmin-lmg R1-1. The specific 
activity determined from the data shown in figure 4.1 was 77 nmol dNDPmin-lmg R1-1. 
This corresponds to a turnover number of 12.4 min-1. 
Regulation of the vaccinia RNR by nucleoside triphosphate effectors  In order to 
determine if the vaccinia RNR is allosterically regulated like the other class I enzymes, the 
four-substrate assay was performed using a single dNTP and ATP, along with all four 
rNDP substrates. Figure 4.2 shows the HPLC results from these experiments. Table 4.1 
is a qualitative summary of the allosteric effects of single dNTP effectors on the vaccinia 
RNR. 119 
0.0 
Retention Time (min.) 
Figure 4.1 ATP activation of the vaccinia ribonucleotide reductase measured 
using the four substrate assay. In this experiment, 100-41 aliquots were removed 
from the reaction mixture at 4-minute intervals, subjected to boronate chromatography, and
analyzed by HPLC as described in the "Materials and Methods" section. In this particular
experiment, the four rNDP substrates were added to 0.15 mM each and ATP, the only 
nucleoside triphosphate effector present in the reaction mixture, was added to 2.5 mM. 120 
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Figure 4.2 Allosteric regulation of vaccinia virus ribonucleotide reductase by
individual dNTPs. All reaction mixtures contained ATP at 2.5 mM and all four rNDP 
substrates at 0.15 mM each. Individual dNTP effectors were added to a final concentration 
of 10 fi.M. Reaction mixtures was incubated at 37° C for 6 minutes. 121 
Table 4.1 Allosteric regulation of vaccinia ribonucleotide reductase by individual dNTPs 
dNTP  Activatest  Inhibitst 
(1011M)  reduction  reduction 
of  of 
dCTP  no effect  no effect 
dTTP  rGDP  rCDP and rADP 
dGTP  rADP  rCDP 
dATP  rCDP*  all 
tThe results summarized in this table represent changes that occur in rNDP turnover rates 
relative to the rates observed when the enzyme is stimulated by ATP only. 
*Activation of rCDP reduction by dATP was evident only when ATP was not added to the 
reaction mixture. When dATP was added in conjunction with ATP (0.5 to 2.5 mM), all 
activities were inhibited relative to a control reaction containing only ATP. 122 
Inhibition of the vaccinia RNR by dATP Figure 4.3 shows the inhibitory effects on 
total RNR activity by the allosteric effector, dATP. From the inhibition curve, it is evident 
that only 50-60% of the potential reducing activity is utilized in the concentration range 
defined as "in vivo". These data indicate that the vaccinia RNR is inhibited by dATP 
similarly to the previously characterized mammalian RNRs. 
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Figure 4.3 Inhibition of the vaccinia RNR by dATP. This graph shows the 
amount of total vaccinia RNR activity remaining after addition of dATP to the reaction 
mixture. The decrease in activity was calculated by comparing the total amount of rNDP 
reduced in the presence of 2.5 mM ATP with the amount reduced when the reaction 
contained 2.5 mM ATP plus dATP at the indicated concentration. 123 
rNDP concentrations in vaccinia-infected BSC40 cells The results of the rNDP 
measurements, reported as the average of two determinations, are listed in the second 
column from the left of Table 4.2. The HPLC method used to determine these values gives 
good baseline resolution of all rNDPs of interest (see Figure 3.1). In addition to retention 
times, peak identification was verified by "spiking" the extract with authentic samples. 
Therefore, the moles of each rNDP calculated from the peak areas in the chromatograms 
should be a reasonable measure of the actual concentrations. The only obvious 
contaminants that could lead to overestimation of the rNDPs are the corresponding dNDPs. 
In most cases, the rNDPs and the dNDPs coelute. However, for the purposes of this 
study, the contribution to peak area by the dNDPs is assumed to be negligible. This 
assumption is valid if one considers that the intracellular concentration of rNDPs exceeds 
that of the dNDPs by 100- to 1000-fold (Traut, 1994). From the rNDP concentrations 
determined by this method, an approximate molar ratio was calculated. This ratio is 
reported in the third column of Table 4.2. The calculation of the "in vivo" molar 
concentration of each rNDP from the picomole value determined in these experiments was 
complicated by the fact that the volume of a vaccinia-infected BSC40 cell was not 
determined. However, using a mid-range value of 2 picoliters per cell for the volume of a 
mammalian cell (Hauschka, 1973), the "in vivo" concentrations were calculated from the 
picomoles of rNDP/106 cells determined experimentally. These estimated concentrations, 
shown in the fourth column of Table 4.2, are remarkably close to the average concentration 
of rNDPs in mammalian cells reported in the literature. The standard deviation associated 
with each of the averaged literature values gives a sense of the extent to which the 
concentrations of the RNR substrates can vary within mammalian cells. 124 
Table 4.2 Ribonucleoside Diphosphate Concentrations in Vaccinia-infected BSC40 Cells 
pmol rNDP  molar  "in vivo" conc.2  ave. conc. (1M) 
rNDP  /106 cells1  ratio  (1M)  from literature3 
rCDP  98 ± 13  1  50  51 ± 17 
rUDP  451 ± 39  5  250  163 ± 116 
rADP  1196 ± 88  12  600  576 ± 449 
rGDP  216 ± 29  2  100  94 ± 78 
1Numbers reported in this column represent the average of two determinations. These 
results are reported as the mean ± (range/2) 
2The volume of a vaccinia-infected BSC40 cell was not determined. Instead, in order to 
convert pmol rNDP/106 cells into "in vivo" molar concentrations, a mid-range value of 2 
picoliters per cell was used. 
3Traut, T. W. (1994) Mol. Cell. Biochem. 140, 1-22. Average concentrations were 
calculated from at least 15 measurements made both in cultured mammalian cells and cells 
derived from whole animal tissues. Standard deviations are shown primarily to illustrate 
the large variance of rNDPs in animal cells. 125
 
Comparison of the product ratio formed under various nucleotide environments 
Figure 4.4 shows the results of experiments in which the composition and concentrations 
of the substrates and allosteric effectors were varied in order to determine the influence of 
the total nucleotide environment on the relative turnover rates of the vaccinia RNR. The left 
hand column indicates the nucleotide effectors present in the reaction mixture and the center 
column gives the HPLC trace resulting from those conditions. The right hand column 
gives the percentage of the total product formed for each individual dNDP calculated from 
the peak area of the chromatogram and expressed as the molar ratio. In order to aid a 
comparison of the two forms of RNR, Table 4.3 summarizes the vaccinia results in a 
format similar to that used for the T4 enzyme (Hendricks and Mathews, 1977; see Chapter 
3)  .  The last row of Table 4.3 shows the base composition of the vaccinia virus genome. 126 
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Figure 4.4 Comparison of the four activities of the vaccinia RNR assayed 
under different allosteric environments. ATP was present at 2.5 mM in all reaction 
mixtures. In the assay mixtures containing equimolar rNDPs, all four substrates were 
present at 0.15 mM each. Mixtures with "in vivo" dNTPs contained dATP, d 1TP, and 
dGTP at 15, 10, and 5 .tM , respectively, and those with "in vivo" rNDPs contained 
rCDP, rUDP, rADP, and rGDP at 50, 250, 600, and 100 tM  , respectively. 127
 
Table 4.3 Relative rates of product formation by vaccinia virus ribonucleotide reductase 
under different allosteric environments 
percentage of total product formed as 
dCDP  dUDP  dADP  dGDP Assay conditions1 
ATP only  76  3  2  19 
equimolar substrates 
ATP only  49  15  8  28 
"in vivo" substrates 
"in vivo" effectors  60  3  15  22 
equimolar substrates 
"in vivo" effectors  34  12  29  26 
"in vivo" substrates 
% of total nucleotides in  17  (33)2  33  17 
vaccinia's genome 
1A11 reaction mixtures contained ATP at 2.5 mM. Equimolar substrates were present at 
0.15 mM. "In vivo" substrates levels were 50, 250, 600, and 100 i.tM, rCDP, rUDP, 
rADP, and rGDP, respectively. "In vivo " allosteric effector concentrations were 15, 10, 
and 5 p.M dATP, d'FIV, and dGTP, respectively. 
232% of vaccinia genomic composition is thymine. 128 
Substrate inhibition of rADP reduction It was of interest to determine whether the 
Kms determined by traditional means, i.e. through the analysis of turnover rates for single 
substrates, were of the same magnitude as Kms determined under physiological-like 
conditions using the four-substrate assay. The initial experimental design was to simply 
look at the turnover rates of the four substrates within an "in vivo" environment of 
nucleotide effectors and substrates. Specifically, a mixture of substrates was prepared in 
which the rNDPs were present at the molar ratio reported in Table 4.2. (1 : 5 : 12 : 2 ; 
rCDP : rUDP : rADP : rGDP). This mixture of rNDPs is referred to as a bioproportional 
substrate mixture. Reaction mixtures were prepared with identical concentrations of 
enzyme, ATP (2.5 mM), and dNTPs (dATP, 15 [IM; dTTP, 10 JIM; dGTP, 5 i_tM), and at 
the start of each assay a precise volume of the bioproportional substrate mixture was added. 
Each successive sample included a slightly larger volume of the substrate mixture. 
Analogous to the determination of Kms, these preliminary experiments were expected 
to yield the concentration at which the substrate saturates half of the potential binding sites. 
However, when the data from this experiment were analyzed, the unexpected result shown 
in Figure 4.5 was observed. Examination of the HPLC traces revealed that the production 
of dADP under these conditions is contrary to the normal Michaelis-Menten behavior 
initially expected. The data from Figure 4.5 were converted to graphical form to better 
illustrate the surprising result that reduction of rADP decreased as the bioproportional 
substrate concentrations were increased. These data are shown in Figure 4.6. 
These results prompted me to repeat the experiment using the same conditions, except 
with a 10-fold increase in range of bioproportional substrate concentrations. Figure 4.7 
shows the results of these experiments. As these data indicate, at these higher substrate 
concentrations, both the reduction of rADP and rGDP were inhibited as their concentrations 
increased. 129
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Figure 4.5 HPLC results from assays containing different volumes of a 
bioproportional rNDP mix. In these assays, the concentration of rNDP substrates were 
increased while the "bioproportional" molar ratio of the individual rNDPs was kept constant. 
This was accomplished by adding different volumes of a mixture containing the "in vivo" 
ratio of rNDPs (1 : 5 : 12 : 2 ; rCDP : rUDP : rADP : rGDP) to each reaction mixture. The 
concentrations of the nucleoside triphosphate effectors were set to "in vivo" levels (ATP, 2.5 
mM; dATP, 1511M; dTTP, 10 liM; and dGTP, 51.tM) and kept constant in all of these 
reactions. 130 
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Figure 4.6 Substrate inhibition of rADP reduction. These graphs represent the 
data from Figure 4.5 after conversion of peak areas into nanomoles of dNDP formed. 
Although the formation of dUDP, dCDP, and dGDP behave according to normal 
Michaelis-Menten kinetics, dADP formation was inhibited as the substrate concentration 
increased. 131 
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Figure 4.7 Substrate inhibition of rADP and rGDP reduction. The conditions 
used in this experiment are identical to those given in Figure 4.6 except that the 
"bioproportional" substrate mixture was added at a ten-fold higher concentration range. 132 
Activity of a chimeric RNR holoenzyme A mixed-species RNR was formed from the 
vaccinia R1 and mouse R2 proteins and assayed for activity using the four-substrate assay. 
Figure 4.8 shows the HPLC results from such an assay in which a reaction mixture 
containing vaccinia R1, mouse R2, ATP, and equimolar substrates was sampled at 3 
minute intervals. Neither subunit showed activity when assayed alone (data not shown). 
The results from this experiment clearly indicate that this chimeric RNR is active. The 
specific activity calculated from these data was 48 nmol dNDPmin-lmg R1-1 which 
corresponds to a turnover number of 7.6 min-1. 
dCDP 
N 
dADP 
dGDP 
dUDP 
9 
Retention Time (min.) 
Figure 4.8  Results from an assay of a vaccinia R1 /mouse R2 chimera. In this 
experiment, a reaction mixture containing 1 i_tM vaccinia R1, 41.tM mouse R2, 2.5 mM 
ATP, and equimolar substrates (0.15 mM each) was sampled at 3 minute intervals. 
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Discussion
 
Allosteric regulation of the vaccinia RNR In this chapter, the isolated effects of single 
nucleoside triphosphates and the combined effects of complex nucleotide environments on 
the allosteric regulation of the vaccinia RNR was examined using the four-substrate assay. 
The vaccinia RNR was assayed in the presence of single dNTP effectors and the resulting 
product profile, or relative amounts of each dNDP formed, was compared to a control 
reaction containing only ATP. The results, depicted in Figure 4.2, indicate that the 
allosteric effectors modulate the activities of the vaccinia RNR similarly to the way they 
modulate the true mammalian enzymes. ATP acts a general activator of the mammalian and 
vaccinia RNRs and in the case of the vaccinia enzyme, ATP alone gave the highest turnover 
rate of all nucleotide effector combinations tested. Typically, the turnover number of ATP-
activated vaccinia RNR was about 13 min-1. This number is slightly lower than the values 
reported for the recombinant mouse and vaccinia enzymes of 24 and 18 min-1, respectively, 
determined by the traditional single-substrate assay (Davis et al., 1994; Slabaugh et al., 
1993). 
From Figure 4.2, it is evident that dCTP has no effect on product formation by the 
vaccinia RNR. In no form of the enzyme has dCTP been shown to act as an allosteric 
modifier. In contrast, the addition of dTTP to the reaction mixture dramatically changed the 
product profile. From the HPLC trace in Figure 4.2 of the assay containing dTTP, the 
inhibition of rCDP reduction and stimulation of rGDP reduction is clearly evident. A 
similar effect is observed when dGTP is added to the reaction mixture, except in this case 
the reduction of rADP is stimulated rather than the reduction of rGDP. Addition of dATP 
to the reaction mixture didn't significantly change the ratio of dNDPs formed. Instead, it 
simply inhibited all reactions to approximately the same extent. Table 4.1 summarizes 
these results. 134
 
The potency of dATP as an inhibitor of vaccinia RNR is illustrated in Figure 4.3. An 
interesting aspect of this inhibition is the fact that a significant amount of the potential 
activity is lost under estimated physiological concentrations. This may reflect an 
inadequacy in the way that the "in vivo" molar concentrations were estimated, or may 
reflect the possibility that dNTP concentration gradients exist within the cell. This 
inhibition may also be an indication of how tightly the enzyme is regulated in vivo. The 
mammalian forms of RNR are inhibited by dATP to approximately the same extent as is the 
vaccinia enzyme. For example, the enzyme from calf thymus has 43% of the control 
activity at 10 tM dATP (Eriksson et al., 1979). When dATP inhibition was evaluated in 
vaccinia-infected cell extracts, the viral-induced RNR activity was much more resistant to 
effects of this dNTP. In order to inhibit 50% of the activity in vaccinia-infected cell 
extracts, 100 tM dATP was required (Slabaugh et al., 1984). The discrepancy between 
the extent of dATP inhibition in extracts and purified enzyme may be explained by the 
presence of dATP-hydrolyzing enzymes present in the crude cell extracts. 
The initial studies I did on the T4 and E. coli enzymes using the four substrate assay 
prematurely led me to believe that low rGDP-reducing activity was a general property of 
RNRs. When the T4 enzyme is measured under optimal conditions for rGDP reduction 
(ATP plus all of the dNTP allosteric effectors; Table 3.1), the highest rGDP-reducing 
activity measured was 12% of the total nucleotide produced. Similar levels of rGDP­
reducing activity were observed for the E. coli enzyme (data not shown). In many cell 
types, the dGTP pool is severely underrepresented (Mathews and Ji, 1992). Therefore, the 
low production of dGDP by the T4 and E. coli enzymes led to speculation that a low 
rGDP-reducing activity may be common to all forms of RNR and that this may explain, at 
least in part, why the dGTP pool tends to be underrepresented in many cell types. For 
some reason, it may be that rGDP is just not a very good substrate for these forms of 
RNR. However, when the vaccinia RNR was assayed, this was not the case. Under all 135 
conditions tested, the production of dGDP always exceeded the percent contribution that 
dGMP makes to the vaccinia genome. 
In vivo, RNR is exposed to a complex ensemble of nucleotide effectors and substrates. 
In experiments similar to those performed on the T4 enzyme (see Chapter 3), the influence 
of different nucleotide environments on the relative rates of product formation was 
examined. Possibly the most significant observation made from these experiments is of the 
role that the relative substrate concentrations play in determining the product profile. As 
Figure 4.4 shows, the ratio of substrates is at least as important as the dNTP effectors in 
regulating the four turnover rates. 
When the vaccinia RNR is assayed in the presence of in vivo concentrations of rNDPs 
and dNTPs, the ratio of dCDP, dUDP, dADP, and dGDP as the percentage of the total 
dNDP formed was 34 : 12 : 29 : 26, respectively. The percentage of dAMP in vaccinia 
DNA is 33% and therefore, under these conditions the production of dADP by the vaccinia 
RNR should adequately fill the need for this deoxyribonucleotide. The same is true for the 
reduction of rGDP, but, as mentioned above, in this case the enzyme appears to supply 
more than is actually needed for DNA synthesis. The percentage of dCMP in vaccinia 
DNA is 17%. Therefore, one-half of the dCDP formed by the vaccinia RNR will be used 
to fulfill the contribution that dCMP makes to the vaccinia genome. The remaining dCDP 
can be shuttled into thymidine nucleotide biosynthesis via dCMP deaminase (see Figure 1). 
The total amount of deoxyribonucleotide available for dTTP synthesis will be the sum of 
the deaminated dCMP (17%) and the dUDP produced from reduction of rUDP (12%). 
Thymidine nucleotides comprise 33% of the vaccinia genome. This percentage is 
reasonably close to the amount of deoxyribonucleotide available for dTTP synthesis by this 
analysis (29%). Thus, like the T4 enzyme, when exposed to substrates and effectors at 
their estimated in vivo concentrations, the RNR from vaccinia is programmed to produce 
dNDPs at relative rates that correspond closely to the composition of the respective 
nucleotides in vaccinia DNA. 136 
The vaccinia and T4 RNRs have other regulatory features in common also. For 
example, the production of dUDP was always low regardless of which allosteric effectors 
were added to the reaction mixture. When ATP was the only allosteric effector present in 
the reaction mixture, the initial rate of formation of dUDP, as a percent of the total dNDP 
produced, was 11, 9, and 3%, for the T4, E. coli, and vaccinia enzymes, respectively (see 
Tables 3.1 and 4.3, E. coli data not shown). When the T4 and vaccinia RNRs are assayed 
in the presence of "in vivo" levels of substrates and allosteric effectors, the amount of 
dUDP formation increases, but only to 14, and 12% of the total product formed, 
respectively. The low production of dUDP by both the eukaryotic and prokaryotic forms 
of RNR is consistent with the results of in vivo studies on thymine metabolism which have 
shown that the majority of thymine nucleotides are generated from deamination of dCMP 
(Bianchi et al., 1987; M011gaard and Neuhard, 1983). 
Why should deamination of dCMP be the major source of dTTP in the cell? Perhaps 
the low rUDP reducing activity of RNR has evolved as such in order to limit the production 
of dUTP. Recall that in eukaroytes, the production of dTTP via dCMP deamination 
bypasses the formation of dUTP because it produces dUMP, the substrate of thymidylate 
synthase, directly (see Figure 1). On the other hand, the dUDP produced from the 
reduction of rUDP is phosphorylated to dUTP and then cleaved by dUTPase to dUMP. 
Therefore, dCMP deamination may have evolved as the major pathway for the synthesis of 
d  11' in order to limit the intracellular concentration of dUTP. 
Support for this hypothesis comes from studies on thymine metabolism. When 
thymidylate synthase is severely inhibited, dUTP accumulates in the cell, indicating that the 
system responsible for the degradation of this nucleotide can be overwhelmed. 
Furthermore, these cells die from a phenomenon known as "thymineless death" which, 
under these conditions, is thought to be due to the incorporation of uracil into DNA 
(Ingraham et al., 1986). 137 
Substrate inhibition of RNR activity In an attempt to estimate the concentrations of 
half-saturation for each rNDP under in vivo-like conditions, the vaccinia RNR was assayed 
in the presence of different volumes of a particular mixture of rNDPs referred to as 
bioproportional substrates. This bioproportional substrate mixture was composed of the 
four rNDPs at the molar ratio shown in Table 4.2. When the results of these assays were 
analyzed, an unexpected observation was made. As the concentration of each substrate 
was increased in the reaction mixture through the addition of successively larger volumes 
of the bioproportional substrate mixture, the production of dADP was inhibited. In the 
concentration ranges used in the experiment depicted in Figure 4.5 and 4.6, the other 
activities behaved as expected. When the bioproportional substrate concentrations were 
elevated 10-fold from the concentrations used in the experiment in Figure 4.5, the 
inhibitory behavior expanded to include the reduction of rGDP. The results from this 
experiment are presented in graphical form in Figure 4.7. 
This non Michaelis-Menten behavior is quite fascinating. If rNDPs were simply 
competing for the active site, the turnover rates would be expected to increase as the 
concentration of the substrate increased. Instead, the decrease in rADP reduction that 
occurs with increasing rNDP concentration indicates that the inhibition may be achieved 
through binding of rNDPs (or dNDPs) to one or both allosteric sites. Although the 
conventional dogma of RNR allostery presumes that only the triphosphates bind the 
allosteric sites, it seems reasonable that molecules as similar in structure as rADP and ATP, 
for example, could bind the same nucleotide binding site. In the bioproportional mixture, 
rADP is the most abundant substrate by as much as 12-fold. This biased rNDP ratio may 
facilitate the preferential binding of rADP to an allosteric site. In most forms of RNR, 
binding of the adenine-containing nucleotides to the specificity site stimulates reduction of 
the pyrimidine rNDPs at the expense of the purine substrates. If binding of rADP to the 
specificity site results in similar allosteric behavior, then the expected outcome would be 
stimulation of pyrimidine reduction at the expense of rADP reduction. Therefore, as the 138 
concentration of rADP is increased, the rate of rADP reduction should decrease relative to 
the reduction of the other substrates. This hypothesis is also consistent with the inhibition 
of 'GDP reduction observed at the higher levels of the bioproportional mixture. 
Initially, I was concerned that the turnover number calculated from the results of the 
four-substrate assay was only about 75% of the value reported in Slabaugh et al., 1993. I 
rationalized that competition between the substrates for active site binding might explain the 
lower turnover rate. Indeed, the results of assays done using bioproportional substrate 
levels clearly indicate that substrate inhibition does play a role in the activity of the vaccinia 
RNR. However, it appears that the form of this substrate inhibition is significantly more 
complex than I originally presumed. 
Although the conventional belief is that RNR is regulated only by nucleoside 
triphosphates, regulation of ribonucleotide reductase activity by substrates and products 
does have precedence in the literature. Not surprisingly, competitive inhibition between 
alternate substrates has been shown to occur in several ribonucleotide reductase systems 
including the enzymes from calf thymus (Eriksson et al., 1979), human lymphoblasts 
(Chang and Cheng, 1979), Ehrlich ascites cells (Cory et al., 1985), and herpes simplex 
virus type I (Averett et al., 1983). However, noncompetitive inhibition by alternate 
substrates has also been demonstrated in several of these same systems. 
Studies done using the human lymphoblast (Molt-4F) ribonucleotide reductase, purified 
from cultured cells, revealed that reduction of any of the rNDPs could be noncompetitively 
inhibited by other ribonucleoside diphosphates (Chang and Cheng, 1979). For example, 
rADP reduction was inhibited noncompetitively by all of the other substrates. The 
noncompetitive inhibition displayed by alternate substrates was observed even when these 
substrates shared a common allosteric activator. rCDP and rUDP, both of which are 
reduced when ATP is bound to the enzyme, could act as noncompetitive inhibitors of the 
reduction of each other. 139
 
The ribonucleotide reductase from herpes simplex virus type I (HSV-1) is also 
regulated by nucleoside diphosphates (Averett et aL, 1983). This ribonucleotide reductase 
is distinct from all other type I enzymes in that it is only weakly inhibited, and shows no 
activation by dNTPs. In addition, it does not appear to require the presence of the general 
activator, ATP, for activity. When competition experiments were performed with this 
enzyme, each rNDP substrate was a competitive inhibitor with respect to each other rNDP 
substrate. The inhibition constants (Kis) obtained for each alternate substrate as an 
inhibitor was in each case similar to the Km of that rNDP as a substrate, consistent with the 
linear competitive model of inhibition in which substrate and inhibitor compete for the same 
binding site (Spector and Cleland, 1981). 
The products of the HSV-1 ribonucleotide reductase (dNDPs) were also shown to be 
competitive inhibitors versus the substrates (rNDPs). However, in this case, the Kis for 
the dNDP products revealed a more complex pattern of inhibition. For example, the Kis 
for dCDP and dGDP as inhibitors of rCDP reduction were 4.8 and 9.0 pM, respectively. 
These values are of similar magnitude as the Km for rCDP. In contrast, the Ki for dADP 
as an inhibitor of rCDP reduction was 140 i.tM, much greater than the Km for rCDP. 
Thus, binding of dGDP or dCDP to the active site will have a much greater inhibitory effect 
on rCDP reduction than binding of dADP. Binding of dADP will presumably inhibit the 
reduction of a substrate other than rCDP. Thus, it appears that by inhibiting the reduction 
of specific substrates, the dNDPs are in effect promoting the reduction of the other 
substrates. 
Although no evidence for allosteric control of the HSV-1 RNR exists, the relative 
turnover rates of the four substrates appear, instead, to be regulated by the levels of 
substrates and products. A model for the regulation of this form of ribonucleotide 
reductase is one in which the substrates compete for binding to the active site according to 
their relative concentrations and Kms. The resulting deoxyribonucleotide products further 
compete with the substrates for binding to the active site. However, the inhibitory patterns 140 
of the dNDPs are significantly different from the simple competitive inhibition observed 
when the substrates act as inhibitors. Although the dNDPs are believed to compete with 
substrate for binding to the active site, the inhibition constants are suggestive of a more 
sophisticated form of regulation in which the products direct reduction (through inhibition) 
of specific substrates in a way that may maintain the balance of products required for 
efficient viral DNA replication. With what is known about the relationship between dNTP 
pool imbalances and mutagenesis, it seems imperative that the four activities of this enzyme 
be regulated in some way such that an optimal level of all four products is maintained. In 
the herpes simplex I RNR, this regulation appears to be modulated by the substrates and 
products. 
The RNR from Ehrlich ascites cells has been shown to be sensitive to regulation by 
both rNDPs and dNDPs (Cory et al., 1985). In assays done on RNR purified from this 
mouse tumor cell line, it was found that the nucleoside diphosphates displayed similar 
allosteric modulation as their nucleoside triphosphate counterparts. For instance, rADP 
was found to activate rCDP reduction; dGDP activated rADP reduction; and rGDP 
reduction was activated by dTDP. The inhibitory pattern of regulation by the nucleoside 
diphosphates was also similar to the inhibition displayed by the nucleoside triphosphates. 
Like dATP, dADP inhibited the reduction of all four substrates. The chemical similarity of 
these two nucleotides suggests that dADP may also function as an inhibitor through 
binding to the activity site. Reduction of rUDP was inhibited by both dGDP and dTDP, 
and dGDP inhibited the reduction of rGDP. Analogous to the inhibition by dGTP and 
d I IP, these inhibitory effects may also be attributed to the binding of the 
deoxyribonucleoside diphosphate to one of the allosteric regulatory sites. Indeed, when the 
nature of the inhibition by these deoxyribonucleoside diphosphates was examined using 
Dixon plots (1/v vs [I]), it was found that the dNDPs were acting as noncompetitive 
inhibitors with respect to substrate, indicating that the inhibition was more complex than 141
 
simply competition for the substrate binding site. The Ki values in these experiments 
ranged from 5-100 [iM, with the lowest values recorded when rUDP was the substrate. 
Interestingly, of all four substrates, rUDP reduction by the Ehrlich tumor RNR was the 
most sensitive to the inhibitory effects of dNDPs. The inhibition of UDP reduction by 
dTDP, dGDP, and dADP was at least equal to that observed by dTTP, dGTP, and dATP, 
respectively. The K, for dGDP, the most potent dNDP inhibitor of UDP reduction, was 5 
1.iM, essentially the same value as the Ki for dGTP. Even dCDP significantly inhibited 
rUDP reduction while, as in the case of most ribonucleotide reductases, dCTP was found 
to be allosterically inert. These findings may be relevant to my studies on the vaccinia 
ribonucleotide reductase. I have been puzzled ever since I first assayed the vaccinia 
enzyme by the relatively low rate of rUDP turnover. With the data on the Ehrlich tumor 
ribonucleotide reductase in mind, I propose that one explanation for the low rUDP turnover 
may be due to the inhibitory effects of the newly formed dNDPs in the reaction mix. In the 
traditional assay performed with one substrate at a time, these dNDP inhibitory effects 
would not be seen. 
Clearly, the regulation of ribonucleotide reductace activity by nucleoside diphosphates 
is an interesting in vitro phenomenon, but is this form of regulation physiologically 
relevant? Are the concentrations of these compounds in the cell high enough to play a 
significant role in regulating ribonucleotide reductase product formation? The 
concentrations of rNDPs in mammalian cells are, in general, 10-20 fold higher than the 
concentrations of dNTPs (Traut, 1994). Therefore, even though the effects of these 
nucleotides are less pronounced than those of their dNTP counterparts, their relatively high 
concentrations suggest that they may be capable of participating in the regulation of RNR. 
The deoxyribonucleoside diphosphates, on the other hand, are normally present at 
extremely low concentrations. Typical concentrations for these nucleotides, when 
measurable, are in the 0.1 -1 µM range (Traut, 1994). However, nucleotide labeling 
studies done in both He La and Chinese hamster ovary (CHO) cells have shown that 142 
dNDPs are elevated during S-phase (Hordern and Henderson, 1982). Therefore, it seems 
possible that at critical times during the cell cycle when the rate of ribonucleotide reduction 
is greatly enhanced, the resultant increase in dNDPs may provide another level of control in 
maintaining a balanced supply of DNA precursors. 
The model that I have formulated from my research, as well as research reported in the 
literature, is one in which the regulation of RNR is not quite as simple as once presumed. 
Although the dNTPs are important regulators of RNR, they are not the only nucleotides 
which must be considered if one desires a better understanding of the intricate in vivo 
regulation responsible for maintaining a balanced pool of the DNA precursors. 
In this model, the regulation of RNR by nucleotides consists of three levels. At the 
first level are the substrates of RNR. These nucleotides compete with each other for 
binding to the active site according to their Km s. In addition, in several cases, the 
substrates may also inhibit or activate reduction of alternate substrates through binding to 
the allosteric sites. The significant role that the relative substrate concentrations play in 
determining the relative turnover rates of the vaccinia and T4 bacteriophage enzymes is a 
conclusion from my research which has contributed greatly to the formulation of this 
model. 
At the second level of regulation are the direct products of RNR, the dNDPs. These 
nucleotides may act to regulate RNR by binding either to the active site or the allosteric 
sites. In many cases, the Ki's of the dNDPs are of the same order of magnitude as the 
corresponding constants of the dNTPs indicating that they can compete effectively with the 
dNTPs for binding to the enzyme. Thus, at times during the cell or viral cycle when their 
concentrations are elevated, dNDPs may be just as potent regulators of RNR activity as the 
dNTPs. In fact, the effective concentration that RNR senses in vivo may be greater for the 
dNDPs than for the dNTPs. This assumption is justifiable if one considers that the dNDPs 
are the direct products of RNR and therefore will be in direct contact with the enzyme. The 143 
dNTPs, on the other hand, are the products of one or more enzymes down the pathway and 
must "feed back" in order to act as effectors of RNR activity. 
The third level of ribonucleotide reductase regulation, according to this model, is 
achieved by the final products of the deoxyribonucleotide biosynthetic pathway, the 
dNTPs. These nucleotides function to fine tune the relative turnover rates of RNR by 
inhibiting certain activities and activating others. 
Obviously, these three levels of nucleotide regulation are intimately connected and act in 
conjunction to determine the final flux through RNR. Thus, the regulation of RNR via the 
substrates, the direct products of the RNR reaction, and the final products of the 
biosynthetic pathway initiated by RNR, results ultimately in a precisely regulated output of 
the DNA precursors. 
The vaccinia-mouse RNR chimera To assess whether a functional viral RNR was 
required for replication of the vaccinia genome, three insertionally inactivated vaccinia R1 
mutants were prepared (Child et al., 1990). Although the insertional inactivation of the R1 
gene was shown to abolish viral RNR activity, all three mutant viruses replicated to levels 
comparable to wild-type virus in tissue culture cells. However, when the virulence of the 
mutants was examined in an animal model, it was found that lack of functional R1 
produced viruses that were mildly attenuated. Approximately a 10-fold increase in the 
number of mutant viruses was needed to reach the lethal dose for 50% of a population of 
mice. 
An obvious question which arises from this study is what is the de novo source of 
dNTPs for replication of the vaccinia genome in these mutants? Does this mutant rely on 
the host cell RNR activity, or does a chimeric form of RNR composed of host cell and 
vaccinia proteins function to provide deoxyribonucleotides? I tested the possibility that a 
chimeric form of RNR was functional by assaying proteins I had available, the vaccinia R1 
and mouse R2. Figure 4.8 shows the results of a chimeric RNR assay. Based on these 
results, it appears that the mouse R2 can function as a radical source for the vaccinia Rl. 144 
The appropriate controls indicated that neither subunit had any detectable intrinsic activity 
of its own (data not shown). Furthermore, the specific activity of the chimera was on the 
same order of magnitude as that of the vaccinia holoenzyme (7.6 and 13 nmol min-1, 
respectively) indicating that it is high enough to rule out residual E. coli RNR activity, 
resulting from the overexpression system. As a comparison, the chimeras formed from the 
T4 bacteriophage and E. coli proteins show no detectable activity (Berglund, 1972). To 
my knowledge, this represents the first report of an active chimeric RNR. 
When one considers what is known about the interactions between R1 and R2, this 
result may not be so surprising. The large and small subunits of the Class I RNRs interact 
primarily through highly specific contacts formed between the R2 carboxy terminus and its 
corresponding binding site located on the R1 protein. The R2 carboxy terminus sequences 
are not conserved but are highly species-specific. In many cases, the formation of an active 
holoenzyme can be inhibited by short peptides with sequences similar to the penultimate C-
terminal residues of R2. The last 12 residues of the mouse and human R2 proteins are 
identical, and the last 10 of these are virtually identical to the vaccinia protein. For 
purposes of comparison, the last 10 C-terminal residues of the R2 from mouse/human and 
vaccinia are shown below: 
mouse/human  E NS F TLDADF-0O2­
vaccinia  - D N H F SLDVDF-0O2­
The underlined residues represent amino acids in the vaccinia R2 protein which differ from 
those of the mouse and human  .  All of the differences except one represent conservative 
substitutions. 
Even more interesting than the fact that these proteins form an active enzyme, is the 
observation that the chimeric holoenzyme generates products at a significantly different 
ratio from that of the vaccinia RNR under identical nucleotide concentrations. Comparison 145 
of Figure 4.1 and 4.8 illustrates this observation. When the four substrates are present at 
equimolar concentrations and ATP is the only added allosteric effector, the vaccinia 
holoenzyme primarily reduces rCDP and rGDP (Figure 4.1). In contrast, under similar 
conditions the vaccinia R1 and mouse R2 chimera prefers rCDP and rADP as substrates for 
reduction. The reduction of rGDP by the chimeric enzyme is very low, and as evident in 
Figure 4.8, the production of dGDP is detectable only at the later time points of the 
reaction. Therefore, ATP activation of these two holoenzyme forms results in distinctly 
different substrate preferences. 
There are at least two possible models which may explain the different product profiles 
generated by these two holoenzyme forms. One possible source for the different substrate 
specificities may result from a slight noncomplementarity between the interacting surfaces 
of vaccinia R1 and mouse R2. Clearly the complementarity between these surfaces is 
sufficient to drive formation of the heterotetramer, or such high RNR activity would not be 
observed. However, if the interacting surfaces in the chimeric enzyme do not complement 
each other in the same way that they do in the holoenzyme formed by subunits from a 
single species, then formation of the chimeric enzyme may drive minor structural changes 
in one or both of the subunits. The structural changes induced by the formation of the 
chimera may result in a perturbation of the R1 allosteric sites, altering the allosteric effects 
of ATP on substrate specificity. The dramatic effects that nucleotide effectors have on 
RNR activity indicate that the substrate specificity is exquisitely sensitive to minor 
structural changes in Rl. Therefore, the perturbation of R1 structure that may result from 
the interaction of dimer surfaces with inexact complementarities may explain the observed 
differences in substrate specificities between the wild-type and chimeric enzymes. 
A second possible explanation for the different substrate specificities is contrary to the 
presumption that the only function of R2 is to serve as a radical storage site for Rl. The 
R1 subunit is generally referred to as the "business end" of the holoenzyme because it 
contains the active site, where ribonucleotide reduction occurs, and presumably the two 146 
allosteric sites. Therefore, it is normally assumed that the specificity of the holoenzyme is 
an inherent property of R1 protein, exclusively. On the other hand, since R2 is thought to 
serve primarily as a radical storage site, the function of this protein is frequently compared 
to that of a cofactor. 
However, it is possible that the R2 protein also contributes to the allosteric regulation of 
RNR by physically forming part of an allosteric binding site. If this is true, then the R2 
from a different, but closely related, species may physically alter the structure , and hence 
the function, of that allosteric site. Since limited knowledge about the structure of the 
allosteric sites of RNR exists, a contribution by the R2 protein to the formation of these 
sites cannot be ruled out. Indeed, the activity site is thought to be formed by the N-
terminus of the R1 protomer. In the crystal structure, the last resolvable N-terminal 
residues are located in the region adjacent to the binding site for the R2 C terminus. 
Furthermore, the contribution of R2 to the formation of an allosteric site is consistent with 
the poor efficiency at which nucleotides specifically label the isolated R1 protein in cross-
linking and crystallography studies (Eriksson et al., 1986; Uhlin and Eklund, 1994). 
Localization and structural characterization of the allosteric sites of RNR will serve to test 
this hypothesis. However, this structural information will probably not be available until 
the crystal structure of the holoenzyme has been solved. 147
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Concluding Remarks 
Since my first exposure to biochemistry, I have been intrigued by the relationship 
between protein structure and function. This intrigue was the primary driving force that led 
me to study ribonucleotide reductase (RNR). From the perspective of structure/function 
relationships, I cannot think of a more interesting enzyme than RNR. 
I joined the Mathews laboratory to study how the regulatory state of RNR affects the 
sensitivity of the enzyme to the inhibitor hydroxyurea, a clinically-significant drug that 
targets the catalytically essential radical of RNR. This work led me to explore further the 
intricate pattern of regulation that fine tunes the relative flux rates of this enzyme and has 
culminated in a new model for the control of RNR activity. 
My thesis project was to test the possibility that the individual activities of the vaccinia 
virus RNR may be differentially sensitive to hydroxyurea. The initial approach I used to 
address this question involved measurement of the radical/iron-oxo decay rates under 
different allosteric conditions. These experiments led to the conclusion that the 
susceptibility of RNR is directly correlated to the activity level of the enzyme. Activation of 
RNR by the addition of effectors increased the sensitivity of the enzyme to hydroxyurea. 
Addition of substrate to the activated enzyme, further increased the sensitivity. However, 
technical difficulties associated with the method made it difficult to say with much 
confidence whether or not the individual activities were differentially sensitive to the 
inhibitor. 
It is often quoted that, "Necessity is the Mother of invention." This is a concept that 
certainly applies in the case of my research. The lack of reproducibility of the radical/iron­
oxo decay measurements incited me to approach the question from a different perspective. 
Instead of following the chromophore decay directly, I decided to follow the radical 
destruction as a function of the relative enzyme activities. This approach led to the 
development of the RNR four-substrate assay, a novel procedure that has proved 150 
invaluable in investigating the inhibitory effects of hydroxyurea, as well as other aspects of 
RNR regulation. The results obtained by use of the four-substrate assay indicate that all 
four activities of vaccinia RNR are equally susceptible to hydroxyurea inhibition. 
The development of the four-substrate assay dramatically increased the scope of my 
project by prompting us to ask questions regarding the regulation of RNR that either were 
unanswerable by the traditional one-substrate assay, or that had not been previously 
considered. For example, using the four-substrate assay to measure the activities of the T4 
phage RNR, we asked what the relative substrate turnover rates would be in a reaction 
mixture containing the known allosteric effectors and substrates, at their estimated in vivo 
concentrations. Although it is assumed that under these conditions RNR will generate 
appropriate levels of the four products, it had never been demonstrated experimentally. 
The studies conducted using the four-substrate assay indicate that the T4 RNR, when 
functioning within an in vivo-like nucleotide environment, generates the four products in a 
ratio that approximates the nucleotide composition of the T4 genome. Similar results were 
found for the RNR encoded by vaccinia virus. 
The studies I have done on the vaccinia and T4 RNRs suggest that much of the 
regulatory functions of these proteins have been retained, even though these viruses are 
vastly separated by evolution. For example, the modulation of substrate specificity by the 
allosteric effectors is very similar for both of these forms of RNR. Furthermore, both the 
T4 and vaccinia RNRs reduce uridine diphosphate at very low rates, an observation that is 
consistent with in vivo thymine metabolism. 
However, other aspects of the regulation of these enzymes are significantly different. 
One of the biggest distinctions in the way these RNRs are regulated is in their response to 
deoxyadenosine triphosphate (dATP). At 50 tM dATP approximately 50% of the vaccinia 
enzyme activity, present in reaction mixtures without dATP is inhibited. At 15 µM, the 
estimated physiological concentration of dATP in vaccinia-infected cells, approximately 151 
20% of the vaccinia enzyme activity is inhibited. In contrast, no indication of dATP 
inhibition of the T4 RNR was observed at the concentrations used in my experiments. 
The rate of guanosine diphosphate (rGDP) reduction is also significantly different for 
these eukaryotic and prokaryotic viral forms of RNR. When ATP is the only allosteric 
activator present in the reaction mixture, the T4 enzyme reduces very little rGDP. As the 
nucleotide environment approaches the estimated physiological concentrations of effectors 
and substrates, the rate of rGDP reduction increases significantly. However, although it 
gets close, the rate never quite reaches what is expected based on the contribution that 
deoxyguanosine nucleotides make to the T4 genome. The vaccinia enzyme behaves 
conversely. The rate of rGDP reduction under non-physiological nucleotide concentrations 
is well above what is expected from the guanine content of vaccinia DNA. As the 
nucleotide effectors and substrates approach estimated physiological concentrations, the 
rate of rGDP reduction decreases. However, under the conditions used in my experiments, 
rGDP reduction always remains higher than expected. 
This observation may be related to an area of research that is of particular interest to the 
Mathews laboratory, oxidative damage of deoxyguanosine nucleotides. It has been 
proposed that the deoxyguanosine triphosphate pool is underrepresented in mammalian 
cells because it is particularly prone to oxidative damage. If this theory proves to be valid, 
then it is possible that the high rate of rGDP reduction by the mammalian form of RNR 
may be a mechanism that has evolved to counteract the depletion of deoxyguanosine 
nucleotides resulting from oxidative damage. At this point, however, this explanation for 
the high rate of rGDP reduction by the mammalian form of RNR is pure speculation. 
Another unexpected observation that was made using the four-substrate assay was the 
important role that substrate concentrations play in regulating the activities of RNR. For 
both forms of RNR used in my studies, the product output best approximated the genomic 
composition when both the allosteric effectors and substrates were present in the reaction 
mixture at near physiological concentrations. Furthermore, the inhibitory phenomena 152 
observed when different amounts of the "bioproportional substrate" mixture (see Chapter 
4) were added to the reaction mixtures exemplifies the potential role that substrates play in 
regulation of the activities of RNR. 
The results from these studies have changed my thinking in regards to the regulation of 
RNR. Instead of the triphosphate nucleotides being the main small-molecule determinants 
of RNR activity, my studies suggest that the substrates, and perhaps the products, also 
play a significant role in the control of reduction rates. In this model, the level of each 
RNR activity is intricately controlled by a complex interplay of nucleoside triphosphate 
effectors, substrates, and products. This interplay may be in the form of competition 
between nucleotides for binding to the allosteric sites, or the active site, or both. 
Hopefully, subsequent studies will unravel the details of what appears to be a very 
complicated regulatory scheme. I would expect nothing less than a highly sophisticated 
pattern of regulation from such a extraordinary enzyme as ribonucleotide reductase. 153
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Appendix I
 
RNR Four-Substrate Assay Procedure
 
Preparation of the reaction mixture 
Reaction mixture volumes are 100 ill per point. Routinely, reactions are performed in 50 
mM HEPES buffer (pH 8.2) containing 0.1 M KC1, 50 mM DTT, and 4 JIM 
Fe(NH4)2(SO4). 1.0 [tM R1 and a molar excess of R2 are a typical protein concentrations. 
Substrates and effectors are added to the reaction mixture at the desired concentrations at 
the start of the reaction. 
1.	  After the addition of substrate, the reaction mixture is incubated in a water bath for a 
specific amount of time. 
2.	  Reactions are quenched by the addition of 5 ill of 50% perchloric acid (PCA). After 
addition of PCA, samples are vortexed and placed on ice. After 5 minutes on ice, 
the reaction mixture is neutralized by the addition of 1M NaOH (-28 ill). 
3.	  Add 5 [11 of 1M NH4HCO3 (pH 8.9) and 1.5 i.t.M of 0.1 M MgC12 to each sample 
and transfer to Nanospin device, or equivalent, to remove protein. Centrifuge for 6 
minutes at 15000 rpm. Add 100 µl of boronate column buffer (see below) to sample 
and centrifuge again for 6 minutes. 
4.	  Remove filtrate from Nanospin tube and apply to boronate column. 
Boronate chromatography 
Ribonucleotides are removed from the sample by boronate chromatography on Bio-Rad 
Affi-gel 601. Deoxyribonucleotides do not bind to the column and are collected in the 
flow-through. To prepare the column resin, weigh out 0.17 to 0.18 gm of Affi-gel 601 162
 
and resuspend in 1.5 ml of column buffer. Allow to swell -30 min. prior to filling 
column. 
1.  Apply sample to a column constructed from a 1.0 ml tuberculin syringe containing 
1.0 ml of Affi-gel 601 preequilibrated with buffer containing 50 mM NH4HCO3 and 
15 mM MgC12 (pH 8.9). Discard the first 200 ill of eluate. 
2.  Elute deoxyribonucleotides by washing column with column buffer while collecting a 
1.8 ml fraction. 
4.  Acidify the boronate column eluate to pH 3-4 prior to HPLC analysis. 
note: Affi-gel resin can be regenerated and reused many times. To regenerate, wash 
column extensively (20-30 ml) with 0.1 M sodiumtetraborate (borax) (pH 8.9). 
Reequilibrate with 20to 30 ml of 50 mM NH4HCO3, 15 mM MgCl2 (pH 8.9) buffer 
prior to use. Store column at 4° C. Column can be reused as many as 20 times 
without loss of performance. 
HPLC analysis 
The dNDP products and dNTP effectors are separated and quantitated by anion-exchange 
HPLC on a Partisphere-10 SAX column (4.6 mm x 25 cm, Whatman) with detection at 
260 nm. Column is equilibrated in 0.075 M monobasic ammonium phosphate (pH to 3.7 
with H3PO4), and deoxyribonucleotides are eluted with a biphasic gradient of monobasic 
ammonium phosphate ranging in concentration from 0.075 to 1.0 M (pH 3.7) at a flow rate 
of 1.5 ml/min. dNDP quantities are determined by peak areas and are calculated from the 
response factors obtained from authentic standards. See Appendix V for validation of the 
four-substrate assay. 163
 
Appendix II
 
Preparation of y-phosphate linked dATP-sepharose
 
Required Reagents 
i) 2'-deoxyadenosine-5'-(y-aminopheny1)-triphosphate
 
USB catalog no. 77121
 
ii) Cyanogenbromide activated Sepharose 4B
 
Pharmacia Biotech (code no. 17-0430-01)
 
Procedure 
1.	  7.5 g of Sepharose 4B was suspended in 2 mM HC1 and poured onto a scintered 
glass funnel. The resin contained in the funnel was then washed with  2 liters of 2 
mM HC1 over a 15-20 minute period. 
2.	  The ligand (y-aminophenyl dATP) was dissolved in 40 ml coupling buffer (0.1 M 
NaHCO3, 0.5 M NaC1, pH 8.3) and the absorbance of a 10X dilution at 260 nm 
was recorded. 
3.	  After the HC1 wash of the Sepharose is finished, the resin was then washed with 
several hundred milliliters of coupling buffer and added to the ligand solution. 
4.	  The suspension was rotated, or rocked (do not use magnetic stirring), for 3 hours at 
room temperature. 
5.	  After coupling for 3 h, the gel was allowed to settle and the absorbance at 260 nm of 
a 10X dilution of the supernatant was recorded (this allows the coupling efficiency to 
be calculated; >90 % coupling is normally seen). 
5.	  Supernatant was decanted and the resin was resuspended in 0.1 M Tris-HC1, pH 8.3, 
and rotated overnight at 4 deg. C (this blocks unreacted active sites). 164
 
6.  Resin was washed in alteration 3 times with 0.1 M acetate, 0.5 M NaC1, pH 4.0 and 
0.1 M Tris -HCI, 0.5 M NaC1, pH 8.3. Store in refrigerator in Tris buffer containing 
NaN3. 
note: This resin goes a long way. For a 1-2 liter culture of overexpressed R1 I 
usually pour a 1.0 ml column. The column can be re-used approximately ten 
times. 165
 
Appendix III
 
Procedure for dNDP & dNTP analysis of whole cell extracts
 
Extraction 
The following extraction procedure is adapted from E. Muller (1994) J. Biol. Chem. 269, 
24466-24471. The procedure described below was used for extracting BSC40 cells and 
yeast. The procedure should also be useful for extracting other types of cells, with minor 
modifications. 
1.	  3 plates BSC40 cells (-107 cells/plate) or 100 ml of yeast cells grown to 50-100 Klett 
units (-2 x 107 cells/nil). 
2.	  Remove 1.0 ml for quantification of cell number. 
3.	  Pour cells into graduated cylinder, record volume, and harvest cells by rapid filtration 
on nylon membranes (47 mm x 0.8 pm, Schleicher & Schuell, or equivalent). For 
cultured cells grown on plates: wash the cells with ice-cold PBS, scrape cells with 
rubber policeman into a centrifuge tube, add 10 ml PBS per plate to resuspend cells, 
centrifuge at low speed to pellet cells. Resuspend cells again in known volume of 
PBS, remove aliquot for determination of cell number, and centrifuge again at low 
speed to pellet cells. In order to extract enough dNTPs for analysis from cultured 
cells, 3 plates of approximately 106 cells/plate are required for each determination. 
4.	  Place nylon filter, cell-side down, onto a crystallization dish containing 2.0 ml of ice-
cold 10% trichloroacetic acid (TCA). Swirl plate gently on ice for 10 minutes. In 
the case of cells scraped from plates, resuspend the washed pellet containing 3 plate 
equivalents of cells in 2.0 ml of ice-cold water. Once suspended, add 2.0 ml of 10% 
TCA and place on ice for 5 min., swirling occasionally. 166
 
5.	  When extracting yeast, transfer the filter and solution to a 50-m1 conical tube and
 
vortex. Place on ice for an additional 20 minutes.
 
6.	  Centrifuge extract to pellet cell debris and collect supernatant containing dNTPs. 
7.	  Neutralize TCA extract with 3.3 ml cold Freon-amine reagent. Freon-amine reagent 
is prepared by mixing 2.2 ml of N-trioctylamine with 7.8 ml Freon (store in 
refrigerator and use within a couple days). Vortex the neutralized solution, 
centrifuge to separate phases and transfer the upper phase to a new tube. Check 
pH. If pH > 6, go to step 8. If pH < 6, extract again with Freon-amine reagent. 
8.	  Lyophilize extract to dryness. 
Boronate chromatography 
Ribonucleotides are removed from the extract by boronate chromatography on Bio-Rad 
Affi-gel 601. Deoxyribonucleotides do not bind to the column and are collected in the flow-
through. 
1.	  Resuspend lyophilized extract in 0.9 ml H2O, add 100 t1 1.0 M ammonium acetate 
(pH 8.8). Adjust pH to 8.8 if necessary and centrifuge if any insoluble material 
remains. 
2.	  Apply sample to a 1 x 5 cm column of Affi-gel 601 pre equilibrated with 0.1 M 
ammonium acetate (pH 8.8). 
3.	  Elute dNTPs by washing column with 0.1 M ammonium acetate (pH 8.8). Collect 
1.0 or 2.0 ml fractions. Pool fractions containing UV absorbing material (260 nm). 
4.	  Lyophilize pooled fractions to dryness. 
note: Affi-gel resin can be regenerated and reused many times. To regenerate, wash 
column extensively with 0.1 M sodiumtetraborate (borax) (pH 8.8). Reequilibrate 
with ammonium acetate buffer prior to use. Store column at 4° C. 167
 
HPLC analysis 
For more detail on HPLC analysis see Hendricks, S.P., & Mathews, C.K. (1997) J. Biol. 
Chem. 272, 2861-2865. dNTPs are separated and quantitated by anion-exchange HPLC 
on a Partisphere-10 SAX column (4.6 mm x 25 cm, Whatman) with detection at 260 nm. 
Column is equilibrated in 0.075 M monobasic ammonium phosphate (pH 3.7), and dNTPs 
are eluted with a biphasic gradient of monobasic ammonium phosphate ranging in 
concentration from 0.075 to 1.0 M (pH 3.7) at a flow rate of 1.5 ml/min. Prior to HPLC 
analysis, the boronate eluate must be treated with periodate to remove any contaminating 
ribonucleotides which may have eluted through boronate column. 
1.	  Resuspend sample in 80 ill of H2O. Add 16 ill 0.5 M Na104 (prepared fresh). 
Vortex and incubate at 37° C in the dark for 2 minutes. 
2.	  Add 20 µl 4 M CH3NH2-HC1 (freshly prepared and neutralized to pH 7 with 
ammonium hydroxide). Vortex and incubate at 37° C for 30 minutes. 
3.	  Add 4 ill 1M rhamnose to quench remaining periodate. 
4.	  Adjust pH of sample to match pH of HPLC mobile phase (pH 3.7) with phosphoric 
acid and inject a reasonable portion onto the HPLC ("reasonable" depends on HPLC 
system and detection limit, as well as extraction efficiency. Generally you should 
have enough dNTPs in the yeast extract to do 2 to 4 injections. Extracts from 
cultured mammalian cells may only contain enough dNTPs for 1 or 2 injections). 168
 
Appendix IV
 
Measurement of Escherichia coli RNR Activity 
by Use of the Four-Substrate Assay: 
Application of the Method to the Measurement of Nucleoside Diphosphate Kinase Activity 
and Inhibition of ADP Reduction by 5'-adenylylimidodiphosphate 
The R1 and R2 subunits of the ribonucleotide reductase from Escherichia coli were 
provided by the laboratory of Britt-Marie Sjoberg, Stockholm University, Sweden. The 
results of assays done using the E. coli holoenzyme illustrate that the four-substrate assay 
may also be useful for the measurement of nucleoside diphosphate kinase (NDPK) activity, 
as well the activities of other enzymes involved in the biosynthesis of deoxyribo­
nucleotides, and can be used to investigate potential kinetic coupling between these 
enzymes. Furthermore, the results of experiments included in this appendix illustrate the 
utility of this assay in evaluating the effects of nucleotide effector analogues on the 
regulation of ribonucleotide reductase. 
Reaction conditions 
The reaction mixture was prepared essentially as described in Appendix I. The reaction 
buffer in these experiments was composed of 50 mM HEPES (pH 7.6), 15 mM MgCl, and 
50 mM DTT. ATP was added to a final concentration of 2.0 mM. Protein concentrations 
in the reaction mixture were 3.0 and 4.5 µM, R1 and R2, respectively, and were based on 
the published molar extinction coefficients (R1: e(280_311) nm) = 180,000 M-lcm-1, and R2: 
e(280-310 nm) = 120,000 M-lcm-1; Karlsson et al., (1992) J. Biol. Chem. 267, 12622). 
The four NDP substrates were added to the reaction mixture at equimolar concentrations 
(0.15 mM each) at time = 0. In these experiments, the reactions were quenched at the times 
indicated by the addition of 5 ill 1M hydroxyurea followed by immediate immersion into 169 
liquid nitrogen (note that this is significantly different from the routine method used to 
quench the reaction and was used only in a limited number of experiments). 
Results 
Figure A4.1 shows the results from one of the E. coli ribonucleotide reductase assays 
done using the four substrate assay. What is obvious from this figure is that this particular 
preparation of E. coli RNR was contaminated with a high level of NDPK-like activity. 
This was corroborated by SDS-PAGE analysis of the individual subunits (gel not shown) 
which demonstrated the presence of many hands other than those corresponding to the R1 
and R2 proteins. 
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Figure A4.1  Analysis of the E. coli RNR activity as analyzed by the four-
substrate assay. In this experiment, ATP was the only allosteric effector added to the 
reaction mixture. The substrates were present at equimolar concentrations. 170 
In the context of the biosynthesis of deoxyribonucleotides, NDPK catalyzes the 
following general reaction: 
ATP + dNDP  ADP + dNTP 
Since the reaction mixture contained a relatively high concentration of ATP (as compared to 
the substrate concentrations), there will be plenty of nucleoside triphosphate available to 
serve as a phosphate donor for the production of dNTPs. As dNDPs are produced in the 
reaction catalyzed by E. coli RNR, they will undergo phosphorylation to the corresponding 
dNTP by the contaminating NDPK-like activity. This partially explains why dCDP, for 
example, increases in concentration after 2.5 minutes and then appears to decrease at later 
time points. The increase in dCTP which occurs over time corroborates this point. In 
contrast, the dADP peak increased steadily over time. This is explained by considering the 
NDPK-catalyzed reaction shown above. As ATP is dephosphorylated, ADP is produced. 
Therefore, the supply of this particular RNR substrate will be maintained in the reaction 
mixture during the entire course of the experiment, while the other substrates, CDP, UDP, 
and GDP, will be depleted over time due to the RNR and NDPK-like activities. 
Although the RNR preparation used in these experiments was contaminated with an 
NDPK-like activity, the following qualitative conclusions regarding the regulation of the E. 
coli RNR can be made: 
i) Like the other forms of RNR examined in my research, when ATP was the only 
nucleoside triphosphate effector added to the reaction mixture, the E. coli enzyme 
primarily reduced CDP. In contrast, the reduction of UDP was minimal. 
ii) Similar to the T4 RNR, but unlike the vaccinia RNR, GDP reduction by the E. coli 
enzyme was low compared to the reduction of the other substrates. 171  Activation of RNR by 5"-Adenylylimidodiphosphate 
In order to obtain more information about the regulation of the E. coli RNR, I decided 
to use a non-hydrolyzable ATP analogue, 5'-adenylylimidodiphosphate (AMP-PNP), to 
activate the enzyme. AMP-PNP has been used previously to activate RNR in cell extracts 
containing high levels of ATPase activity (Slabaugh et aL, 1991). With the assumption that 
this ATP analogue should not be capable of functioning as a phosphate donor for NDPK, 
the contaminating NDPK-like activity should be negligible in the presence of AMP-PNP. 
Figure A4.2 shows the results of the E. coli RNR assay performed in the presence of 
AMP-PNP. 
dCDP 
d UD P  dGDP GDP d/ 0 
dADP 
Time (min.)  45.0 
Figure A4.2 Activation of the E. coli RNR by AMP-PNP. The conditions used in 
these experiments were identical to those of Figure A4.1, except that ATP was replaced 
with AMP-PNP (1 mM). 
0.0 172
 
As predicted, the substitution of AMP-PNP for ATP in the reaction mixture decreased 
the formation of dNTPs to negligible levels. However, the results also indicate that AMP­
PNP does not activate RNR in the same way that ATP does. When AMP-PNP was added 
to the reaction mixture, the reduction of ADP was completely inhibited, while the rates of 
formation of the other products were approximately the same as the rates observed when 
ATP was used as the allosteric activator. 
The inhibitory effect of AMP-PNP on the reduction of ADP does not appear to be 
limited to the E. coil RNR. Similar results were obtained when the vaccinia RNR was 
assayed in the presence of AMP-PNP (data not shown; see SPH notebook #7, page 20). 173
 
Appendix V 
Ribonucleotide Reductase Four-Substrate Assay Method Validation 
The method validation procedure described in this appendix is used to verify that the 
ribonucleotide reductase four-substrate assay is functioning properly. This validation 
procedure, or a modification of this procedure, should be performed whenever the results 
of an experiment are in question, or when a new batch of boronate column resin is 
purchased. Furthermore, it is recommended that this validation procedure be performed by 
persons using the assay method for the first time. 
Validation procedure 
To evaluate the performance of the HPLC system, and to determine, or verify, the 
response factors and retention times for each nucleotide, a sample containing each of the 
deoxyribonucleotides of interest is prepared, using good analytical technique, and analyzed 
according to the HPLC method described in Appendix I. Figure A5.1 shows a typical 
HPLC analysis of deoxyribonucleotide authentic standards. In this example, precise 
volumes of carefully prepared nucleotide stock solutions were added to HPLC buffer A to 
give a final concentration of 0.6 p.M each. 500 ill of this nucleotide mixture was injected 
onto a Partisil 10 SAX column and separated using an NH4H2PO4 gradient (0.075 to 1.0 
M, pH 3.7). 
From these data, the response factors, or the peak area corresponding to 1.0 mole of a 
particular nucleotide, can be determined for each species by dividing the peak area by the 
number of moles injected. These values are then used to calculate the moles of dNDP 
formed in the assay from the peak areas corresponding to each product. The absolute value 
of these response factors will vary as the detector lamp ages (or with different detectors) 174 
and therefore, should be determined for each set of experiments. Of course, the retention 
times of the standards need to be determined each time fresh buffer is prepared. This is an 
obvious time to also determine the response factors. 
Date: Sun, Mar 22, 1998 7:01 PM 
Data: sph.03-22MAR98-008 
Sample:  Method Validation: 
deoxyribonucleotide authentic std. mix (6/23/97 stock) 
300 picomoles each injected 
Processing File:  steve's process 
Method: sph.03 
Inject Vol: 500 
Sampling Int: 0.3 Seconds 
Chromatogram: 
%B 
100 
80 
60 
40 
20 
0 
0.0  45.0 
Analysis:  Channel A 
Peak No.  Time  Type  Height(Au)  Area(pV-sec) 
1  10.245  *N  0.029146  440173 
2  12.520  *N  0.055250  782497 
3  14.395  *N  0.055032  1021196 
4  19.360  *N  0.049450  953333 
5  24.860  *N  0.029786  544219 
6  26.605  *N  0.041428  753570 
7  28.915  *N  0.053176  1135116 
8  33.750  *N  0.046444  700281 
Figure A5.1 HPLC chromatogram of the deoxyribonucleotide authentic 
standards. Peak identities are: Peak No. 1, dCDP; 2, dUDP; 3, dADP; 4, dGDP; 5, 
dCTP; 6, dTTP; 7, dATP; and 8, dGTP. 175 
To evaluate the performance of the boronate column chromatography for each of the 
four ribonucleotide reductase reactions, two solutions are prepared, each of which contains 
two NDPs and two dNDPs of different nucleobase identity. In the example shown in this 
appendix, mixture 1 contained CDP, ADP, dUDP, and dGDP, and mixture 2 contained the 
converse of mixture 1, dCDP, dADP, UDP, and GDP. The concentrations of the 
nucleotides should be set to levels similar to what would be present in a typical reaction 
mixture. In addition, all other components present in the reaction mixture, excluding the 
enzyme, should be added to the sample. In the following example, the nucleotides were 
added to a final concentration of 0.1 mM each in HEPES buffer containing 2 mM MgC12 
(pH 8.2). A 100-111 aliquot (the same volume as the reaction mixture used in the assay) of 
mixture 1 was added to 1.7 ml of boronate column buffer (50 mM NH4HCO3, 15 mM 
MgC12, pH 8.9). The sample was diluted in this way in order to mimic the sample dilution 
that occurs as a result of the boronate chromatography step. After acidification to pH 3-4 
with H3PO4, 500 µl of this "pre-boronate" sample was injected onto the column. Figure 
A5.2 shows the results of the HPLC analysis of mixture 1 prior to boronate column 
chromatography. 
To determine the retention of ribonucleotides and recovery of deoxyribonucleotides 
from the boronate chromatography step, another aliquot of mixture 1 was treated identically 
to that of an actual assay sample, and the HPLC results compared to the those of the "pre­
boronate" sample. To 100 gl of mixture 1, 5 IA of 1 M NH4HCO3, pH 8.9, and 1.5 [1.1 
1M MgC12 were added, followed by the addition of 100 pi of boronate column buffer. The 
resulting 200-p1 sample was applied to a 1.0 ml boronate column and washed with 
column buffer while collecting 1.8 ml of eluate (see Appendix I for more detail). The 
boronate column eluate was acidified, as above, prior to the injection of 500 IA onto the 
column. 
Figure A5.3 shows the results from the HPLC analysis of the "post-boronate" sample. 
Comparison of the HPLC results obtained from the pre- and post-boronate column samples 176 
allows the efficiency of the boronate chromatography step to be assessed. In this particular 
example, no UDP or GDP was detected in the post-boronate sample, indicating the 
effectiveness of the boronate resin at removing ribonucleoside diphosphates. Furthermore, 
the area counts corresponding to the dCDP and dADP peaks in the post-boronate sample 
can be compared to the corresponding peak areas in the pre-boronate sample to determine 
the recovery of deoxyribonucleotides after boronate chromatography. In this particular 
example, 95.2 and 95.8% of dCDP and dUDP, respectively, were recovered from the 
boronate column. 
Date: Sun, Mar 22, 1998 1:38 PM 
Data: sph.03-22MAR98-002 
Sample:  Method Validation: 
dCDP, UDP, dADP, and GDP; before boronate column 
Processing File: steve's process 
Method: sph.03 
Inject Vol: 500 
Sampling Int: 0.3 Seconds 
Chromatogram: 
Analysis: 
Peak No. 
1 
Channel A 
Time 
9.865 
Height(Au) 
0.288684 
Area(pV-sec) 
4413666 
2  12.735  0.465796  6330311 
3  14.255  0.465794  8200027 
4  19.060  0.475510  8189979 
4 
t1:1 
co 
0.0  45.0 
Figure A5.2 HPLC analysis of nucleotide mixture 1 prior to boronate 
chromatography. Peak identities are as follows: Peak No. 1, dCDP; 2, UDP; 3, dADP; 
and 4, GDP. 177 
Date: Sun, Mar 22, 1998 2:27 PM 
Data: sph.03-22MAR98-003 
Sample:  Method Validation: 
dCDP, UDP, dADP, and GDP; after boronate column 
Processing File: steve's process 
Method: sph.03 
Inject Vol: 500 
Sampling Int: 0.3 Seconds 
Chromatogram: 
2 
1 
-fAlk 
0.0  45.0 
Analysis:  Channel A 
Peak No.  Time  Type  Height(Au)  Area(pV-sec) 
1  9.850  *N  0.266600  4202976 
2  14.260  *N  0.413940  7856406 
Figure A5.3 HPLC analysis of nucleotide mixture 1 following boronate 
chromatography. Peak identities are: Peak No. 1, dCDP; and 2, dADP. 178 
A similar analysis of the pre- and post-boronate column HPLC results of mixture 2 will 
allow the performance of the boronate column chromatography to be evaluated in terms of 
the other four nucleotides of interest. Figures A5.4 and A5.5 show the HPLC analyses of 
the pre- and post-boronate column samples, respectively, prepared from nucleotide mixture 
2. Again, the HPLC chromatogram corresponding to the post-boronate sample showed no 
indication of the presence of ribonucleoside diphosphates. Recovery of the dNDPs present 
in mixture 2 from the boronate column were calculated to be 99.1 % for dUDP, and 94.2 
% for dGDP. The recovery of dUDP is probably overestimated in this example because of 
the fact that dUDP and ADP are not completely resolved, making the dUDP peak area 
difficult to accurately determine. 
One more important point regarding the repeatability and accuracy of the four-substrate 
assay should be made here. The method has a built-in mechanism by which the proper 
functioning of the assay can be evaluated in each and every sample. As Figure A5.6 
illustrates, the HPLC method used in the assay gives resolution of ADP and dADP. At 
concentrations lower than those shown in this example, these peaks are baseline resolved. 
If the boronate chromatography doesn't function efficiently, substrate will leak through the 
column and be collected in the initial eluate containing the products of the reaction catalyzed 
by ribonucleotide reductase. Because the substrate, ADP, is resolved from the product, 
dADP, the presence of a doublet at the relative retention time of dADP should alert the 
researcher to the fact that the boronate column step may not be functioning properly. 
Furthermore, as is illustrated in Figure A5.4, ADP is also resolved from the product 
dUDP. Therefore, if ADP does leak through the boronate column, the absorbance due to 
this substrate will he distinguishable from the absorbance arising from products. Although 
it is not shown in Figure A5.6, GDP and dGDP are also resolved by the HPLC method. 
This gives the assay procedure another built-in check on the performance of the method. 
Interestingly, the pyrimidine ribonucleotides and the corresponding deoxyribonucleotides 
are not resolved under these HPLC conditions. 179 
Date: Sun, Mar 22, 1998 3 :28 PM
 
Data: sph.03-22MAR98-004
 
Sample:  Method Validation: 
CDP, dUDP, ADP, and dGDP; before boronate column 
Processing File: steve's process
 
Method: sph.03
 
Inject Vol: 500
 
Sampling Int: 0.3 Seconds
 
Chromatogram: 
3 
U)
 
4 
co 
0
 
0  J. 
0.0  45.0 
Analysis:  Channel A 
Peak No.  Time  Type  Height(Au)  Area(pV-sec) 
1  10.060  *N  0.264578  4408601 
2  12.945  *N1  0.480544  6128723 
3  13.440  *N2  0.540250  9376769 
4  19.385  *N  0.365222  6569200 
Figure A5.4 HPLC analysis of nucleotide mixture 2 prior to boronate 
chromatography. Peak identities are: Peak No. 1, CDP; 2, dUDP; 3, ADP; and 4, 
dGDP. 180 
Date: Sun, Mar 22, 1998 4:16 PM 
Data: sph.03-22MAR98-005 
Sample:  Method Validation: 
CDP, dUDP, ADP, and dGDP; after boronate column 
(started collecting after sample completely entered gel) 
Processing File: steve's process 
Method: sph.03 
Inject Vol: 500 
Sampling Int: 0.3 Seconds 
Chromatogram: 
1 
I  2 
0.0  45.0 
Analysis:  Channel A 
Peak No.  Time  Type  Height(Au)  Area(pV-sec) 
1  12.830  *N  0.429562  6074434 
2  19.255  *N  0.328770  6189619 
Figure A5.5 HPLC analysis of nucleotide mixture 2 following boronate 
chromatography. Peak identities are: Peak No. 1, dUDP; and 2, dGDP. 181 
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Date: Sun, Mar 22, 1998 5:21 PM 
Data: sph.03-22MAR98-006 
Sample:  Method Validation: 
500 picomoles of dADP and ADP injected 
Processing File: steve's process 
Method: sph.03 
Inject Vol: 500 
Sampling Int: 0.3 Seconds 
Chromatogram: 
1 
12 
0.0  45.0 
Analysis:  Channel A 
Peak No.  Time  Type  Height(Au)  Area(pV-sec) 
1  13.630  *N1  0.100594  1641971 
2  14.435  *N2  0.089252  1612548 
Figure A5.6 HPLC chromatogram showing partial resolution of ADP and 
dADP. Under the HPLC conditions used in the four-substrate assay, ADP elutes just 
prior to dADP. 